Amedeo Smart

Free Medical Literature Service


 

Amedeo

Liver Diseases

  Free Subscription

Articles published in
Hepatology
    August 2022
  1. LIANG B, Wang H, Qiao Y, Wang X, et al
    Differential requirement of Hippo cascade during CTNNB1 or AXIN1 mutation driven hepatocarcinogenesis.
    Hepatology. 2022 Aug 3. doi: 10.1002/hep.32693.
    >> Share

  2. VIZZUTTI F, Celsa C, Calvaruso V, Enea M, et al
    Mortality after transjugular intrahepatic portosystemic shunt in older adult cirrhotic patients: a validated prediction model.
    Hepatology. 2022 Aug 3. doi: 10.1002/hep.32704.
    >> Share

  3. PENUELAS-HARO I, Espinosa-Sotelo R, Crosas-Molist E, Herranz-Iturbide M, et al
    The NADPH oxidase NOX4 regulates redox and metabolic homeostasis preventing hepatocellular carcinoma progression.
    Hepatology. 2022 Aug 3. doi: 10.1002/hep.32702.
    >> Share

  4. PATTOU F, Lasailly G, Raverdy V, Caiazzo R, et al
    Letter to the editor: Regression of liver fibrosis after bariatric operations: A glass two-third full rather than half empty.
    Hepatology. 2022;76:E51-E52.
    >> Share

  5. JIANG ST, Zhang JW, Lu X, Xu YY, et al
    Letter to the editor: Discussion on application scenario of cell-free DNA fragmentomics in primary liver cancer.
    Hepatology. 2022;76:E44.
    >> Share

  6. JINDAL A
    Letter to the editor: Liver outcomes after bariatric surgery in patients with NASH and advanced fibrosis.
    Hepatology. 2022;76:E42.
    >> Share

  7. GUIDOTTI LG, La Vecchia C, Colombo M
    Low-dose aspirin reduces the risk of HBV-associated HCC even when administered short-term: Too good to be true?
    Hepatology. 2022;76:300-302.
    >> Share

  8. PANIGRAHI MK, Anirvan P
    Letter to the editor: Using angiotensin-converting enzyme inhibitors to prevent liver-related events in NAFLD-Revisiting the renin-angiotensin-aldosterone system pathways.
    Hepatology. 2022;76:E32-E33.
    >> Share

  9. MAYO MJ
    Mechanisms and molecules: What are the treatment targets for primary biliary cholangitis?
    Hepatology. 2022;76:518-531.
    >> Share

  10. VOS MB, Van Natta ML, Blondet NM, Dasarathy S, et al
    Randomized placebo-controlled trial of losartan for pediatric NAFLD.
    Hepatology. 2022;76:429-444.
    >> Share

  11. AGOPIAN VG, Yang JD, Zhu Y, You S, et al
    Early detection of primary liver cancer using plasma cell-free DNA fragmentomics: Do all the pieces come together?
    Hepatology. 2022;76:289-291.
    >> Share

  12. MAO Y, Han CY, Hao L, Lee Y, et al
    p21-activated kinase 4 inhibition protects against liver ischemia/reperfusion injury: Role of nuclear factor erythroid 2-related factor 2 phosphorylation.
    Hepatology. 2022;76:345-356.
    >> Share

  13. VALAINATHAN SR, Sartoris R, Elkrief L, Magaz M, et al
    Contrast-enhanced CT and liver surface nodularity for the diagnosis of porto-sinusoidal vascular disorder: A case-control study.
    Hepatology. 2022;76:418-428.
    >> Share

  14. PAIS R, Aron-Wisnewsky J, Bedossa P, Ponnaiah M, et al
    Persistence of severe liver fibrosis despite substantial weight loss with bariatric surgery.
    Hepatology. 2022;76:456-468.
    >> Share

  15. GUNEWARDENA S, Huck I, Walesky C, Robarts D, et al
    Progressive loss of hepatocyte nuclear factor 4 alpha activity in chronic liver diseases in humans.
    Hepatology. 2022;76:372-386.
    >> Share

  16. SOFTIC S, Kohli R
    Pediatric NASH therapies: A speedbump on the road to success.
    Hepatology. 2022;76:292-294.
    >> Share

  17. ZHANG X, Wang Z, Tang W, Wang X, et al
    Ultrasensitive and affordable assay for early detection of primary liver cancer using plasma cell-free DNA fragmentomics.
    Hepatology. 2022;76:317-329.
    >> Share

  18. ZHANG X, Wong GL, Yip TC, Tse YK, et al
    Angiotensin-converting enzyme inhibitors prevent liver-related events in nonalcoholic fatty liver disease.
    Hepatology. 2022;76:469-482.
    >> Share

  19. HAN B, Francipane MG, Cheikhi A, Johnson J, et al
    Fat-associated lymphoid clusters as expandable niches for ectopic liver development.
    Hepatology. 2022;76:357-371.
    >> Share

  20. XIONG H, Zhang C, Han L, Xu T, et al
    Suppressed farnesoid X receptor by iron overload in mice and humans potentiates iron-induced hepatotoxicity.
    Hepatology. 2022;76:387-403.
    >> Share

    July 2022
  21. SUN N, Zhang C, Lee YT, Tran BV, et al
    HCC EV ECG Score: An Extracellular Vesicle-based Protein Assay for Detection of Early-Stage Hepatocellular Carcinoma.
    Hepatology. 2022 Jul 31. doi: 10.1002/hep.32692.
    >> Share

  22. BAI Y, Yang Z, Xu X, Ding W, et al
    Direct chemical induction of hepatocyte-like cells with capacity for liver repopulation.
    Hepatology. 2022 Jul 26. doi: 10.1002/hep.32686.
    >> Share

  23. QUECK A, Schwierz L, Gu W, Ferstl PG, et al
    Targeted decrease of portal hepatic pressure gradient improves ascites control after TIPS.
    Hepatology. 2022 Jul 23. doi: 10.1002/hep.32676.
    >> Share

  24. HU S, Cao C, Poddar M, Delgado E, et al
    Hepatocyte beta-Catenin Loss is Compensated by Insulin-mTORC1 Activation to Promote Liver Regeneration.
    Hepatology. 2022 Jul 21. doi: 10.1002/hep.32680.
    >> Share

  25. PAPATHEODORIDI M, Lok AS, Papatheodoridis GV
    Letter to the Editor: Hepatitis B virus reactivation in immune checkpoint inhibitor-based combination therapies for hepatocellular carcinoma - Authors' reply.
    Hepatology. 2022 Jul 20. doi: 10.1002/hep.32673.
    >> Share

  26. LIU X, Tan S, Liu H, Jiang J, et al
    Hepatocyte-derived MASP1-enriched small extracellular vesicles activate hepatic stellate cells to promote liver fibrosis.
    Hepatology. 2022 Jul 18. doi: 10.1002/hep.32662.
    >> Share

  27. LAI SW
    Aspirin use and the risk of hepatocellular carcinoma.
    Hepatology. 2022 Jul 17. doi: 10.1002/hep.32674.
    >> Share

  28. ZHONG D, Cai J, Hu C, Chen J, et al
    Inhibition of mPGES-2 ameliorates non-alcoholic steatohepatitis by activating NR1D1 via heme.
    Hepatology. 2022 Jul 15. doi: 10.1002/hep.32671.
    >> Share

  29. JIN ZC, Chen JJ, Luo B, Zhang WH, et al
    Letter to the Editor: Hepatitis B virus reactivation in immune checkpoint inhibitor-based combination therapies for hepatocellular carcinoma.
    Hepatology. 2022 Jul 15. doi: 10.1002/hep.32672.
    >> Share

  30. POZO-MORALES M, Garteizgogeascoa I, Perazzolo C, So J, et al
    In vivo imaging of calcium dynamics in zebrafish hepatocytes.
    Hepatology. 2022 Jul 13. doi: 10.1002/hep.32663.
    >> Share

  31. YANG F, Jiang ST, Lu X, Xu Y, et al
    Letter to the editor: Several issues to consider in the study of hepatocellular carcinoma progression mechanism.
    Hepatology. 2022 Jul 11. doi: 10.1002/hep.32659.
    >> Share

  32. BITTERMANN T, Lewis JD, Levy C, Goldberg DS, et al
    Sociodemographic and geographic differences in the U.S. epidemiology of autoimmune hepatitis with and without cirrhosis.
    Hepatology. 2022 Jul 10. doi: 10.1002/hep.32653.
    >> Share

  33. CHANG D, Truong E, Mena EA, Pacheco F, et al
    Machine Learning Models Are Superior to Non-Invasive Tests in Identifying Clinically Significant Stages of NAFLD and NAFLD-Related Cirrhosis.
    Hepatology. 2022 Jul 9. doi: 10.1002/hep.32655.
    >> Share

  34. ZHANG Y, Ye S, Lu W, Zhong J, et al
    RNA helicase DEAD-box protein 5 alleviates nonalcoholic steatohepatitis progression via tethering TSC complex and suppressing mTORC1 signaling.
    Hepatology. 2022 Jul 7. doi: 10.1002/hep.32651.
    >> Share

  35. KOVALIC AJ, Lee TP, Da BL
    Letter to the editor: L-ornithine L-aspartate in acute treatment of severe hepatic encephalopathy: A double-blind randomized controlled trial.
    Hepatology. 2022 Jul 5. doi: 10.1002/hep.32643.
    >> Share

  36. RYDELL GE, Ringlander J, Larsson SB, Hellstrand K, et al
    Letter to the editor: Alu-PCR design may have compromised detection of integrated core HBV DNA.
    Hepatology. 2022;76:E23.
    >> Share

  37. DANAN G, Teschke R
    Letter to the editor: Electronic RUCAM: Major pitfalls call for caution and proper validation.
    Hepatology. 2022;76:E27.
    >> Share

  38. RASCHI E, Caraceni P
    Letter to the editor: RECAM for the diagnosis of DILI-Is it time to incorporate additional pharmacological criteria?
    Hepatology. 2022;76:E25-E26.
    >> Share

  39. KIVLIGHN S, Schuur E, Gish RG, Cryer D, et al
    Letter to the editor: Beneath the surface of the pandemic: Persons with alcohol-associated liver disease need our attention.
    Hepatology. 2022;76:E7-E8.
    >> Share

  40. TAO X, Zhao Y, Chen L, Zeng M, et al
    Letter to the editor: Prediction of biochemical nonresolution in patients with chronic drug-induced liver injury: A large multicenter study.
    Hepatology. 2022;76:E13-E14.
    >> Share

  41. KAPPUS MR, Patel YA, Duarte-Rojo A
    Improving the fitness of the NASH clinical trial: Standardizing the standard-of-care intervention.
    Hepatology. 2022;76:12-14.
    >> Share

  42. PISCAGLIA F
    Microwave ablation in skilled hands. A treatment opportunity gaining room in the field of single HCC 3-5 cm.
    Hepatology. 2022;76:6-8.
    >> Share

  43. HAYASHI PH, Lucena MI, Fontana RJ, Bjornsson ES, et al
    A revised electronic version of RUCAM for the diagnosis of DILI.
    Hepatology. 2022;76:18-31.
    >> Share

  44. SERPER M, Parikh ND, Thiele G, Ovchinsky N, et al
    Patient-reported outcomes in HCC: A scoping review by the Practice Metrics Committee of the American Association for the Study of Liver Diseases.
    Hepatology. 2022;76:251-274.
    >> Share

  45. LEWIS JH
    Digitizing DILI: Who can? RUCAM? RECAM?
    Hepatology. 2022;76:3-5.
    >> Share

  46. KAWAMURA N, Imajo K, Kalutkiewicz KJ, Nagai K, et al
    Influence of liver stiffness heterogeneity on staging fibrosis in patients with nonalcoholic fatty liver disease.
    Hepatology. 2022;76:186-195.
    >> Share

  47. STINE JG, Schreibman IR, Faust AJ, Dahmus J, et al
    NASHFit: A randomized controlled trial of an exercise training program to reduce clotting risk in patients with NASH.
    Hepatology. 2022;76:172-185.
    >> Share

  48. DEVARAJ E, Perumal E, Subramaniyan R, Mustapha N, et al
    Liver fibrosis: Extracellular vesicles mediated intercellular communication in perisinusoidal space.
    Hepatology. 2022;76:275-285.
    >> Share

  49. POVERO D, Ahn JC, Arnold J, Udompap P, et al
    Hepatology Highlights.
    Hepatology. 2022;76:1-2.
    >> Share

  50. FAN Y, Jiang ST, Yong-Chang Z
    Letter to the Editor: Some reflection on the research related to METTL1 promoting radiotherapy resistance in hepatocellular carcinoma.
    Hepatology. 2022 Jul 1. doi: 10.1002/hep.32644.
    >> Share

  51. SCHMID CD, Olsavszky V, Reinhart M, Weyer V, et al
    ALK1 controls hepatic vessel formation, angiodiversity, and angiocrine functions in hereditary hemorrhagic telangiectasia of the liver.
    Hepatology. 2022 Jul 1. doi: 10.1002/hep.32641.
    >> Share

    June 2022
  52. TRAN NH, Munoz S, Thompson S, Hallemeier CL, et al
    Hepatocellular Carcinoma Down-Staging for Liver Transplantation in the Era of Systemic Combined Therapy with Anti-VEGF/TKI and Immunotherapy.
    Hepatology. 2022 Jun 28. doi: 10.1002/hep.32613.
    >> Share

  53. MALHI H, Gores GJ
    What is Hepatology looking for Version 2.0?
    Hepatology. 2022 Jun 26. doi: 10.1002/hep.32637.
    >> Share

  54. JIANG ST, Xu YY, Lu X
    Letter to the Editor: Using intratumoral steatosis to predict the efficacy of combination therapy in nonviral hepatocellular carcinoma.
    Hepatology. 2022 Jun 25. doi: 10.1002/hep.32628.
    >> Share

  55. ZHAO K, Guo F, Wang J, Zhong Y, et al
    Limited disassembly of cytoplasmic hepatitis B virus nucleocapsids restricts viral infection in murine hepatic cells.
    Hepatology. 2022 Jun 19. doi: 10.1002/hep.32622.
    >> Share

  56. YUAN T, Zhou T, Qian M, Du J, et al
    SDHA/B reduction promotes hepatocellular carcinoma by facilitating the deNEDDylation of cullin1 and stabilizing YAP/TAZ.
    Hepatology. 2022 Jun 17. doi: 10.1002/hep.32621.
    >> Share

  57. JOHN BV, Doshi A, Ferreira RD, Taddei TH, et al
    Comparison of Infection-induced and Vaccine-induced Immunity Against Coronavirus 2019 in Patients with Cirrhosis.
    Hepatology. 2022 Jun 16. doi: 10.1002/hep.32619.
    >> Share

  58. LI B, Yu D
    Is the intratumor steatosis a novel biomarker for predicting the efficacy of immunotherapy in hepatocellular carcinoma?
    Hepatology. 2022 Jun 15. doi: 10.1002/hep.32616.
    >> Share

  59. XU C, Fan J, Liu D, Tuerdi A, et al
    Alpha-kinase 1 (ALPK1) Agonist, DF-006 Demonstrates Potent Efficacy in Murine and Primary Human Hepatocyte Models of Hepatitis B.
    Hepatology. 2022 Jun 14. doi: 10.1002/hep.32614.
    >> Share

  60. LIAO J, Yi Y, Yue X, Wu X, et al
    METTL1 is required for non-homologous end joining repair and renders hepatocellular carcinoma resistant to radiotherapy.
    Hepatology. 2022 Jun 14. doi: 10.1002/hep.32615.
    >> Share

  61. MA X, Chen A, Melo L, Clemente-Sanchez A, et al
    Loss of hepatic DRP1 exacerbates alcoholic hepatitis by inducing megamitochondria and mitochondrial maladaptation.
    Hepatology. 2022 Jun 13. doi: 10.1002/hep.32604.
    >> Share

  62. HOLMAN A, Parikh N, Clauw DJ, Williams DA, et al
    Rethinking the management of pain in cirrhosis: toward precision therapy for pain.
    Hepatology. 2022 Jun 5. doi: 10.1002/hep.32598.
    >> Share

  63. DELTENRE P, Zanetto A, Saltini D, Moreno C, et al
    The role of TIPS in patients with cirrhosis and ascites: recent evolution and open questions.
    Hepatology. 2022 Jun 4. doi: 10.1002/hep.32596.
    >> Share

  64. TESTINO G
    Letter to the editor: Chronic liver disease among adolescents and young adults: Alcohol use disorder identification.
    Hepatology. 2022;75:1662-1663.
    >> Share

  65. JULIEN J, Ayer T, Tapper EB, Barbosa C, et al
    Effect of increased alcohol consumption during COVID-19 pandemic on alcohol-associated liver disease: A modeling study.
    Hepatology. 2022;75:1480-1490.
    >> Share

  66. SANDAHL TD, Gormsen LC, Kjaergaard K, Vendelbo MH, et al
    The pathophysiology of Wilson's disease visualized: A human (64) Cu PET study.
    Hepatology. 2022;75:1461-1470.
    >> Share

  67. QIAN Q, Li Y, Fu J, Leng D, et al
    Switch-associated protein 70 protects against nonalcoholic fatty liver disease through suppression of TAK1.
    Hepatology. 2022;75:1507-1522.
    >> Share

  68. VILAR-GOMEZ E, Nephew LD, Vuppalanchi R, Gawrieh S, et al
    High-quality diet, physical activity, and college education are associated with low risk of NAFLD among the US population.
    Hepatology. 2022;75:1491-1506.
    >> Share

  69. PSARAKI A, Ntari L, Karakostas C, Korrou-Karava D, et al
    Extracellular vesicles derived from mesenchymal stem/stromal cells: The regenerative impact in liver diseases.
    Hepatology. 2022;75:1590-1603.
    >> Share

  70. ALVA-RUIZ R, Wu T, Idalsoaga F, Ramkissoon R, et al
    Hepatology highlights.
    Hepatology. 2022;75:1363-1364.
    >> Share

    May 2022
  71. ZHANG JW, Fang J, Xun Z, Xu Y, et al
    Letter to the Editor: Atezolizumab plus Bevacizumab for Hepatocellular Carcinoma in the Real World.
    Hepatology. 2022 May 23. doi: 10.1002/hep.32588.
    >> Share

  72. KIMURA Y, Koyama Y, Taura K, Kudoh A, et al
    Characterization and role of collagen gene expressing hepatic cells following partial hepatectomy in mice.
    Hepatology. 2022 May 23. doi: 10.1002/hep.32586.
    >> Share

  73. JALAN-SAKRIKAR N, Brevini T, Huebert RC, Sampaziotis F, et al
    Organoids and Regenerative Hepatology.
    Hepatology. 2022 May 21. doi: 10.1002/hep.32583.
    >> Share

  74. LI L, Zhang Y, Zhou Y, Hu H, et al
    Quaternary Nanoparticles Enable Sustained Release of Bortezomib for Hepatocellular Carcinoma.
    Hepatology. 2022 May 21. doi: 10.1002/hep.32584.
    >> Share

  75. XU W, Cui C, Cui C, Chen Z, et al
    Hepatocellular Cystathionine gamma lyase/Hydrogen sulfide Attenuates Non-Alcoholic Fatty Liver Disease by Activating Farnesoid X Receptor.
    Hepatology. 2022 May 19. doi: 10.1002/hep.32577.
    >> Share

  76. PILLING LC, Atkins JL, Melzer D
    Genetic modifiers of penetrance to liver endpoints in HFE hemochromatosis: associations in a large community cohort.
    Hepatology. 2022 May 14. doi: 10.1002/hep.32575.
    >> Share

  77. MURAI H, Kodama T, Maesaka K, Tange S, et al
    Multiomics identifies the link between intratumor steatosis and the exhausted tumor immune microenvironment in hepatocellular carcinoma.
    Hepatology. 2022 May 14. doi: 10.1002/hep.32573.
    >> Share

  78. BAJAJ JS, Rodriguez MP, Fagan A, McGeorge S, et al
    Impact of Bacterial Infections and SBP Prophylaxis on Phage-Bacterial Dynamics in Cirrhosis.
    Hepatology. 2022 May 13. doi: 10.1002/hep.32571.
    >> Share

  79. KIM KE, Lee J, Shin HJ, Jeong EA, et al
    Lipocalin-2 Activates Hepatic stellate cells and Promotes Non-alcoholic Steatohepatitis in High-Fat Diet-Fed ob/ob mice.
    Hepatology. 2022 May 13. doi: 10.1002/hep.32569.
    >> Share

  80. MEHTA S, Asrani SK
    The computer will see you now: Prediction of long-term survival in patients with cirrhosis.
    Hepatology. 2022 May 5. doi: 10.1002/hep.32559.
    >> Share

  81. ANDERSEN JB
    Stromal yin-yang of myofibroblasts and endothelial cells in the progression of intrahepatic cholangiocarcinoma.
    Hepatology. 2022 May 3. doi: 10.1002/hep.32558.
    >> Share

  82. GULATI P, Taneja S, Duseja A, Singh V, et al
    Letter to Editor-Preliminary evidence of safety and tolerability of atezolizumab plus bevacizumab in patients with hepatocellular carcinoma and Child-Pugh A and B cirrhosis: a real-world study- Should we extend the boundaries?
    Hepatology. 2022 May 3. doi: 10.1002/hep.32554.
    >> Share

  83. LIU JJ, Xin B, Du L, Chen L, et al
    Pharmaceutical Shp2 inhibition suppresses primary and metastasized liver tumors by provoking hepatic innate immunity.
    Hepatology. 2022 May 3. doi: 10.1002/hep.32555.
    >> Share

  84. HILSCHER MB, Wells ML, Venkatesh SK, Cetta F, et al
    Fontan-associated liver disease.
    Hepatology. 2022;75:1300-1321.
    >> Share

  85. LEE CH, Lui DTW, Lam KSL
    Letter to the editor: Circulating thrombospondin-2 as a biomarker in patients with NAFLD with and without diabetes-Are we convinced yet?
    Hepatology. 2022;75:1340.
    >> Share

  86. CHUNG HH
    Letter to the editor: The multiple mechanisms of fructose disrupt gut-liver axis and metabolic regulation.
    Hepatology. 2022;75:1338-1339.
    >> Share

  87. ASRANI SK, Ghabril MS, Kuo A, Merriman RB, et al
    Quality measures in HCC care by the Practice Metrics Committee of the American Association for the Study of Liver Diseases.
    Hepatology. 2022;75:1289-1299.
    >> Share

  88. PAIK JM, Kabbara K, Eberly KE, Younossi Y, et al
    Global burden of NAFLD and chronic liver disease among adolescents and young adults.
    Hepatology. 2022;75:1204-1217.
    >> Share

  89. KUREBAYASHI Y, Matsuda K, Ueno A, Tsujikawa H, et al
    Immunovascular classification of HCC reflects reciprocal interaction between immune and angiogenic tumor microenvironments.
    Hepatology. 2022;75:1139-1153.
    >> Share

  90. ZHANG JL, Du BB, Zhang DH, Li H, et al
    OTUB1 alleviates NASH through inhibition of the TRAF6-ASK1 signaling pathways.
    Hepatology. 2022;75:1218-1234.
    >> Share

  91. SONG J, Song H, Wei H, Sun R, et al
    Requirement of RORalpha for maintenance and antitumor immunity of liver-resident natural killer cells/ILC1s.
    Hepatology. 2022;75:1181-1193.
    >> Share

  92. REN QN, Zhang H, Sun CY, Zhou YF, et al
    Phosphorylation of androgen receptor by mTORC1 promotes liver steatosis and tumorigenesis.
    Hepatology. 2022;75:1123-1138.
    >> Share

  93. CONBOY CB, Penrice DD, Watkins R, Diaz LA, et al
    Hepatology highlights.
    Hepatology. 2022;75:1071-1072.
    >> Share

  94. QIN Y, Li A, Liu B, Gao M, et al
    Comment on "Compromised hepatic mitochondrial fatty acid oxidation and reduced markers of mitochondrial turnover in human NAFLD".
    Hepatology. 2022 May 1. doi: 10.1002/hep.32551.
    >> Share

  95. SANGRO B, Argemi J
    Immunotherapy in hepatocellular carcinoma - No rush despite the hype.
    Hepatology. 2022 May 1. doi: 10.1002/hep.32550.
    >> Share

    April 2022
  96. SHAH PA, Patil R, Harrison SA
    NAFLD-related hepatocellular carcinoma: The growing challenge.
    Hepatology. 2022 Apr 28. doi: 10.1002/hep.32542.
    >> Share

  97. KUMAR A, Rajani D, Kumar S
    Letter to the editor: HBV genotype: a significant risk factor in determining which patients with chronic HBV infection should undergo surveillance for HCC: The hepatitis B Alaska study.
    Hepatology. 2022 Apr 28. doi: 10.1002/hep.32544.
    >> Share

  98. YAN T, Luo Y, Yan N, Hamada K, et al
    Intestinal Peroxisome Proliferator-Activated Receptor alpha-Fatty Acid Binding Protein 1 Axis Modulates Nonalcoholic Steatohepatitis.
    Hepatology. 2022 Apr 23. doi: 10.1002/hep.32538.
    >> Share

  99. CHEN L, Dong J, Meng Q, Song Z, et al
    Reply to the comment on "Loss of Sam50 in hepatocytes induces cardiolipin-dependent mitochondrial membrane remodeling to trigger mtDNA release and liver injury".
    Hepatology. 2022 Apr 19. doi: 10.1002/hep.32530.
    >> Share

  100. IVANICS T, Claasen MP, Patel MS, Hansen BE, et al
    Reply to: Letter to the editor: Cautious use of multistate modeling in prognosis analysis of hepatocellular carcinoma.
    Hepatology. 2022 Apr 18. doi: 10.1002/hep.32532.
    >> Share

  101. JIANG ST, Zhang JW, Lu X, Xu YY, et al
    Letter to the editor: Cautious use of multistate modeling in prognosis analysis of hepatocellular carcinoma.
    Hepatology. 2022 Apr 17. doi: 10.1002/hep.32533.
    >> Share

  102. RAO Z, Li F, Guan Z, Zhou H, et al
    Comment on "Loss of Sam50 in hepatocytes induces cardiolipin-dependent mitochondrial membrane remodeling to trigger mtDNA release and liver injury".
    Hepatology. 2022 Apr 16. doi: 10.1002/hep.32529.
    >> Share

  103. XU MX, Tan J, Ge CX, Dong W, et al
    TRIM31 confers protection against nonalcoholic steatohepatitis by deactivating MAP3K7.
    Hepatology. 2022 Apr 16. doi: 10.1002/hep.32526.
    >> Share

  104. AHN JC, Lauzon M, Luu M, Noureddin M, et al
    Racial and ethnic disparities in early treatment with immunotherapy for advanced hepatocellular carcinoma in the United States.
    Hepatology. 2022 Apr 16. doi: 10.1002/hep.32527.
    >> Share

  105. TRIPATHI D, Bureau C
    Prophylactic embolization of large spontaneous portosystemic shunts with TIPS: A panacea for post TIPS hepatic encephalopathy?
    Hepatology. 2022 Apr 16. doi: 10.1002/hep.32525.
    >> Share

  106. ZHU Y, Gu L, Lin X, Zhou X, et al
    P53 deficiency affects cholesterol esterification to exacerbate hepatocarcinogenesis.
    Hepatology. 2022 Apr 10. doi: 10.1002/hep.32518.
    >> Share

  107. DEFFIEU MS, Clement CMH, Dorobantu CM, Partiot E, et al
    Occludin stalls HCV particle dynamics apart from hepatocyte tight junctions, promoting virion internalization.
    Hepatology. 2022 Apr 7. doi: 10.1002/hep.32514.
    >> Share

  108. KHADERI S, Kanwal F
    Changing Epidemiology of Hepatocellular Cancer in the United States: winning the battle but it is not over yet.
    Hepatology. 2022 Apr 7. doi: 10.1002/hep.32512.
    >> Share

  109. TCHORZ JS
    Re-tuning hepatocytes improves their functional engraftment.
    Hepatology. 2022 Apr 7. doi: 10.1002/hep.32513.
    >> Share

  110. GOEPPERT B, Roessler S
    New kid on the block: Netrin-1 as a novel player in the delicate molecular network of hepatic inflammation.
    Hepatology. 2022 Apr 6. doi: 10.1002/hep.32509.
    >> Share

  111. MANDATO C, Vajro P
    Letter to the Editor: The burgeoning field of Progressive Familial Intrahepatic Cholestasis.
    Hepatology. 2022 Apr 5. doi: 10.1002/hep.32489.
    >> Share

  112. KRAMER JR, Natarajan Y, Dai J, Yu X, et al
    Response to letter to the editor from Zhou et al (Effect of diabetes medications and glycemic control on risk of hepatocellular cancer in patients with nonalcoholic fatty liver disease).
    Hepatology. 2022 Apr 2. doi: 10.1002/hep.32503.
    >> Share

  113. ZHOU Y, Chu W, Wu X, Zhou H, et al
    Effect of diabetes medications and glycemic control on risk of hepatocellular cancer in patients with nonalcoholic fatty liver disease.
    Hepatology. 2022 Apr 2. doi: 10.1002/hep.32504.
    >> Share

  114. TOMLINSON JL, Ahn JC, Povero D, Ramkissoon R, et al
    Hepatology Highlights.
    Hepatology. 2022;75:775-776.
    >> Share

  115. AHUJA P, Bi X, Ng CF, Tse MCL, et al
    Src homology 3 domain binding kinase 1 protects against hepatic steatosis and insulin resistance through the Nur77- fibroblast growth factor 21 pathway.
    Hepatology. 2022 Apr 1. doi: 10.1002/hep.32501.
    >> Share

  116. SINGAL AK, Kwo P, Kwong A, Liangpunsakul S, et al
    Research methodologies to address clinical unmet needs and challenges in alcohol-associated liver disease.
    Hepatology. 2022;75:1026-1037.
    >> Share

  117. SINGH SA, Madan K, Gupta S, Indrayan A, et al
    Letter to the editor: Relevance of population-based cutoffs to define frailty in clinical studies.
    Hepatology. 2022;75:1067-1068.
    >> Share

  118. WANG S, Whitlock R, Lai JC, Taneja S, et al
    Reply.
    Hepatology. 2022;75:1068-1069.
    >> Share

  119. JAIN A, Sharma BC
    Reply.
    Hepatology. 2022;75:1066-1067.
    >> Share

  120. COLASANTI T, Di Giamberardino A, Grimaldi A, Cardinale V, et al
    Letter to the editor: Serum thrombospondin-2 as biomarker in liver diseases, a look beyond NASH.
    Hepatology. 2022;75:1056-1057.
    >> Share

  121. PAILHORIES H, Boursier J, Diehl AM
    Determinants of the severity of fatty liver diseases: Need all the pieces to solve the puzzle.
    Hepatology. 2022;75:782-784.
    >> Share

  122. NEIL DAH, Minervini M, Smith ML, Hubscher SG, et al
    Banff consensus recommendations for steatosis assessment in donor livers.
    Hepatology. 2022;75:1014-1025.
    >> Share

  123. KWAN SY, Jiao J, Joon A, Wei P, et al
    Gut microbiome features associated with liver fibrosis in Hispanics, a population at high risk for fatty liver disease.
    Hepatology. 2022;75:955-967.
    >> Share

  124. ZHOU HZ, Li F, Cheng ST, Xu Y, et al
    DDX17-regulated alternative splicing that produced an oncogenic isoform of PXN-AS1 to promote HCC metastasis.
    Hepatology. 2022;75:847-865.
    >> Share

  125. SUBRAMANIAN P, Gargani S, Palladini A, Chatzimike M, et al
    The RNA binding protein human antigen R is a gatekeeper of liver homeostasis.
    Hepatology. 2022;75:881-897.
    >> Share

    March 2022
  126. CULLARO G, Hsu CY, Lai JC
    Variability in Serum Creatinine is Associated with Waitlist and Post-Liver Transplant Mortality in Cirrhosis Patients.
    Hepatology. 2022 Mar 31. doi: 10.1002/hep.32497.
    >> Share

  127. LEE SH, Yim SY, Jeong YS, Li QX, et al
    Consensus subtypes of hepatocellular carcinoma associated with clinical outcomes and genomic phenotypes.
    Hepatology. 2022 Mar 29. doi: 10.1002/hep.32490.
    >> Share

  128. JAVITT NB
    Letter to the Editor: Hyperosmolarity during hepatic bile formation:Overlooked significance.
    Hepatology. 2022 Mar 29. doi: 10.1002/hep.32482.
    >> Share

  129. CAI HX, Xin C, Wang XP
    ATP7B gene therapy of autologous reprogrammed hepatocytes alleviates copper accumulation in a murine model of Wilson's disease.
    Hepatology. 2022 Mar 27. doi: 10.1002/hep.32484.
    >> Share

  130. WANG T, Xu C, Zhang Z, Wu H, et al
    Cellular heterogeneity and transcriptomic profiles during intrahepatic cholangiocarcinoma initiation and progression.
    Hepatology. 2022 Mar 27. doi: 10.1002/hep.32483.
    >> Share

  131. D'ALESSIO A, Fulgenzi CAM, Nishida N, Schonlein M, et al
    Preliminary evidence of safety and tolerability of atezolizumab plus bevacizumab in patients with hepatocellular carcinoma and Child-Pugh A and B cirrhosis: a real-world study.
    Hepatology. 2022 Mar 21. doi: 10.1002/hep.32468.
    >> Share

  132. CHEN L, Dong J, Liao S, Wang S, et al
    Loss of Sam50 in hepatocytes induces cardiolipin-dependent mitochondrial membrane remodeling to trigger mtDNA release and liver injury.
    Hepatology. 2022 Mar 21. doi: 10.1002/hep.32471.
    >> Share

  133. FLEMMING JA, Muaddi H, Djerboua M, Neves P, et al
    Association between social determinants of health and rates of liver transplantation in individuals with cirrhosis.
    Hepatology. 2022 Mar 21. doi: 10.1002/hep.32469.
    >> Share

  134. CREEDEN JF, Kipp ZA, Xu M, Flight RM, et al
    Hepatic Kinome Atlas: An In-Depth Identification of Kinase Pathways in Liver Fibrosis of Humans and Rodents.
    Hepatology. 2022 Mar 21. doi: 10.1002/hep.32467.
    >> Share

  135. HOU J
    Drinking vinegar, a potential adjuvant for immunotherapy of hepatocellular carcinoma?
    Hepatology. 2022 Mar 18. doi: 10.1002/hep.32463.
    >> Share

  136. GOLDBERG D, Mantero A, Kaplan D, Delgado C, et al
    Accurate Long-Term Prediction of Death for Patients with Cirrhosis.
    Hepatology. 2022 Mar 12. doi: 10.1002/hep.32457.
    >> Share

  137. LV Y, Chen H, Luo B, Bai W, et al
    Concurrent large spontaneous portosystemic shunt embolization for the prevention of overt hepatic encephalopathy after transjugular intrahepatic portosystemic shunt: A randomized controlled trial.
    Hepatology. 2022 Mar 10. doi: 10.1002/hep.32453.
    >> Share

  138. HU C, Xu B, Wang X, Wan WH, et al
    Gut microbiota-derived short-chain fatty acids regulates group 3 innate lymphoid cells in hepatocellular carcinoma.
    Hepatology. 2022 Mar 9. doi: 10.1002/hep.32449.
    >> Share

  139. FOERSTER F, Gairing SJ, Ilyas SI, Galle PR, et al
    Emerging Immunotherapy for Hepatocellular Carcinoma: A Guide for Hepatologists.
    Hepatology. 2022 Mar 7. doi: 10.1002/hep.32447.
    >> Share

  140. BARNAULT R, Verzeroli C, Fournier C, Michelet M, et al
    Hepatic inflammation elicits production of proinflammatory netrin-1 through exclusive activation of translation.
    Hepatology. 2022 Mar 7. doi: 10.1002/hep.32446.
    >> Share

  141. HE Y, Luo J, Zhang G, Jin Y, et al
    Single-cell profiling of human CD127(+) innate lymphoid cells reveals diverse immune phenotypes in hepatocellular carcinoma.
    Hepatology. 2022 Mar 4. doi: 10.1002/hep.32444.
    >> Share

  142. NIE YZ, Zheng YW, Taniguchi H
    Improving the repopulation capacity of elderly human hepatocytes by decoding aging-associated hepatocyte plasticity.
    Hepatology. 2022 Mar 4. doi: 10.1002/hep.32443.
    >> Share

  143. LU Z, Liu R, Wang Y, Jiao M, et al
    TET2 Inactivation Restrains IL-10-producing Regulatory B cells to Enable Anti-tumor Immunity in Hepatocellular Carcinoma.
    Hepatology. 2022 Mar 4. doi: 10.1002/hep.32442.
    >> Share

  144. PLAZ TORRES MC, Jaffe A, Perry R, Marabotto E, et al
    Diabetes Medications and Risk of Hepatocellular Carcinoma.
    Hepatology. 2022 Mar 3. doi: 10.1002/hep.32439.
    >> Share


  145. Hepato Liver Cancer logy highlights.
    Hepatology. 2022;75:503-504.
    >> Share

  146. HILSCHER MB, Shah VH
    A NET gain in our understanding of acute liver failure.
    Hepatology. 2022;75:511-513.
    >> Share

  147. LUO MS, Huang GJ
    Letter to the editor: The addition of C-reactive protein and von Willebrand factor to Model for End-Stage Liver Disease-Sodium.
    Hepatology. 2022;75:763-764.
    >> Share

  148. WU JW, Tseng TC, Kao JH
    Letter to the editor: New kid in the playground: HBcrAg and risk of HCC.
    Hepatology. 2022;75:760-761.
    >> Share

  149. BEKKI Y, Fenig Y
    Letter to the editor: The impact of donor liver fibrosis on early allograft dysfunction and ischemia-reperfusion injury.
    Hepatology. 2022;75:754.
    >> Share


  150. Seeking Editor for Clinical Liver Disease.
    Hepatology. 2022;75:i.
    >> Share

  151. VON MEIJENFELDT FA, Stravitz RT, Zhang J, Adelmeijer J, et al
    Generation of neutrophil extracellular traps in patients with acute liver failure is associated with poor outcome.
    Hepatology. 2022;75:623-633.
    >> Share

  152. GOIKOETXEA-USANDIZAGA N, Serrano-Macia M, Delgado TC, Simon J, et al
    Mitochondrial bioenergetics boost macrophage activation, promoting liver regeneration in metabolically compromised animals.
    Hepatology. 2022;75:550-566.
    >> Share

  153. REN R, He Y, Ding D, Cui A, et al
    Aging exaggerates acute-on-chronic alcohol-induced liver injury in mice and humans by inhibiting neutrophilic sirtuin 1-C/EBPalpha-miRNA-223 axis.
    Hepatology. 2022;75:646-660.
    >> Share

  154. TAMAKI N, Imajo K, Sharpton S, Jung J, et al
    Magnetic resonance elastography plus Fibrosis-4 versus FibroScan-aspartate aminotransferase in detection of candidates for pharmacological treatment of NASH-related fibrosis.
    Hepatology. 2022;75:661-672.
    >> Share

  155. WANG C, Zhang L, Sun Z, Yuan X, et al
    Dedifferentiation-associated inflammatory factors of long-term expanded human hepatocytes exacerbate their elimination by macrophages during liver engraftment.
    Hepatology. 2022 Mar 1. doi: 10.1002/hep.32436.
    >> Share

  156. KANWAL F, Khaderi S, Singal AG, Marrero JA, et al
    Risk Factors for Hepatocellular Cancer in Contemporary Cohorts of Patients with Cirrhosis.
    Hepatology. 2022 Mar 1. doi: 10.1002/hep.32434.
    >> Share

  157. IBRAHIM SH, Kamath BM, Loomes KM, Karpen SJ, et al
    Cholestatic Liver Diseases of Genetic Etiology: Advances and Controversies.
    Hepatology. 2022 Mar 1. doi: 10.1002/hep.32437.
    >> Share

    February 2022
  158. ROBERTS SB, Hirschfield GM, Worobetz LJ, Vincent C, et al
    Ethnicity, disease severity and survival in Canadian patients with Primary Biliary Cholangitis.
    Hepatology. 2022 Feb 26. doi: 10.1002/hep.32426.
    >> Share

  159. SUTHEN SD, Lim CJ, Nguyen PHD, Dutertre CA, et al
    Hypoxia-driven immunosuppression by Treg and type-2 conventional dendritic cells in hepatocellular carcinoma.
    Hepatology. 2022 Feb 20. doi: 10.1002/hep.32419.
    >> Share

  160. FAN L, Pan Q, Yang W, Koo SC, et al
    A Developmentally Prometastatic Niche to Hepatoblastoma in Neonatal Liver mediated by the Cxcl1/Cxcr2 Axis.
    Hepatology. 2022 Feb 18. doi: 10.1002/hep.32412.
    >> Share

  161. IVANICS T, Murillo Perez CF, Claasen MP, Patel MS, et al
    Dynamic risk profiling of hepatocellular carcinoma recurrence after curative intent liver resection.
    Hepatology. 2022 Feb 18. doi: 10.1002/hep.32411.
    >> Share

  162. EFE C, Harputluoglu M, Karadag Soylu N, Yilmaz S, et al
    Liver transplantation following SARS-CoV-2 vaccination-induced liver failure.
    Hepatology. 2022 Feb 17. doi: 10.1002/hep.32409.
    >> Share

  163. WANG Z, Yu J, Liang P
    Reply to "Treatment options for 3-5 cm solitary hepatocellular carcinoma-Need a closer look!"
    Hepatology. 2022 Feb 9. doi: 10.1002/hep.32402.
    >> Share

  164. JINDAL A, Mukund A
    Treatment options for 3-5 cm solitary hepatocellular carcinoma-Need a closer look!
    Hepatology. 2022 Feb 9. doi: 10.1002/hep.32401.
    >> Share

  165. NOUREDDIN M, Abdelmalek MF
    ACE inhibitors: The Secret to Prevent Cirrhosis Complications and Hepatocellular Carcinoma in NAFLD?
    Hepatology. 2022 Feb 6. doi: 10.1002/hep.32399.
    >> Share

  166. YAKOVCHENKO V, Morgan TR, Miech EJ, Neely B, et al
    Core implementation strategies for improving cirrhosis care in the Veterans Health Administration.
    Hepatology. 2022 Feb 6. doi: 10.1002/hep.32395.
    >> Share

  167. ALVAREZ CS, Petrick JL, Parisi D, McMahon BJ, et al
    Racial/ethnic disparities in hepatocellular carcinoma incidence and mortality rates in the United States, 1992-2018.
    Hepatology. 2022 Feb 5. doi: 10.1002/hep.32394.
    >> Share

  168. JEON Y, Kwon SM, Rhee H, Yoo JE, et al
    Molecular and radio-pathologic spectrum between hepatocellular carcinoma and intrahepatic cholangiocarcinoma.
    Hepatology. 2022 Feb 5. doi: 10.1002/hep.32397.
    >> Share

  169. ZANETTO A, Campello E, Spiezia L, Burra P, et al
    Letter to the Editor: is PAI-1 a thrombotic biomarker in NASH cirrhosis?
    Hepatology. 2022 Feb 3. doi: 10.1002/hep.32392.
    >> Share

  170. LEMOINE CP, Superina R
    Letter to the Editor: Is TIPS the best treatment for non-cirrhotic adults with EPHVO and portal hypertension?
    Hepatology. 2022 Feb 2. doi: 10.1002/hep.32386.
    >> Share

  171. LUO C, Xin H, Zhou Z, Hu Z, et al
    Tumor-Derived Exosomes Induce Immunosuppressive Macrophages to Foster Intrahepatic Cholangiocarcinoma Progression.
    Hepatology. 2022 Feb 2. doi: 10.1002/hep.32387.
    >> Share

  172. LEE V, Wong TC
    Reply to "prospective study of stereotactic body radiation therapy for hepatocellular carcinoma on waitlist for liver transplant".
    Hepatology. 2022 Feb 2. doi: 10.1002/hep.32379.
    >> Share

  173. WATKINS R, Ilyas SI, Penrice DD, Conboy CB, et al
    Hepatology Highlights.
    Hepatology. 2022;75:241-242.
    >> Share

  174. ROGAL S, Hansen L, Patel A, Ufere NN, et al
    AASLD Practice Guidance: Palliative care and symptom-based management in decompensated cirrhosis.
    Hepatology. 2022 Feb 1. doi: 10.1002/hep.32378.
    >> Share

  175. KARATAYLI E, Lammert F
    Vulnerability to alcohol-associated liver disease: A tale of two systems.
    Hepatology. 2022;75:246-247.
    >> Share

  176. HEY P, Gow P
    Letter to the Editor: Rethinking public health measures to reduce liver injury from therapeutic acetaminophen ingestion.
    Hepatology. 2022;75:495-496.
    >> Share

  177. GIDENER T, Yin M, Dierkhising RA, Allen AM, et al
    Magnetic resonance elastography for prediction of long-term progression and outcome in chronic liver disease: A retrospective study.
    Hepatology. 2022;75:379-390.
    >> Share

  178. VAN KLEEF LA, Ayada I, Alferink LJM, Pan Q, et al
    Metabolic dysfunction-associated fatty liver disease improves detection of high liver stiffness: The Rotterdam Study.
    Hepatology. 2022;75:419-429.
    >> Share

  179. RAMANI K, Robinson AE, Berlind J, Fan W, et al
    S-adenosylmethionine inhibits la ribonucleoprotein domain family member 1 in murine liver and human liver cancer cells.
    Hepatology. 2022;75:280-296.
    >> Share

  180. LIN T, Wang S, Munker S, Jung K, et al
    Follistatin-controlled activin-HNF4alpha-coagulation factor axis in liver progenitor cells determines outcome of acute liver failure.
    Hepatology. 2022;75:322-337.
    >> Share

  181. KIM KY, Kim JO, Kim YS, Choi JE, et al
    Genome-wide association of individual vulnerability with alcohol-associated liver disease: A Korean genome and epidemiology study.
    Hepatology. 2022;75:391-402.
    >> Share

    January 2022
  182. JIANG SY, Yang X, Yang Z, Li JW, et al
    Discovery of a INSIG binding compound that ameliorates nonalcoholic steatohepatitis by inhibiting SREBP-mediated lipogenesis.
    Hepatology. 2022 Jan 31. doi: 10.1002/hep.32381.
    >> Share

  183. DE A, Keisham A, Duseja A
    Spontaneous regression of cirrhosis: a paradigm shift in our understanding of the natural history of non-alcoholic steatohepatitis (NASH).
    Hepatology. 2022 Jan 31. doi: 10.1002/hep.32374.
    >> Share

  184. JANG H, Lee YB, Moon H, Chung JW, et al
    Aspirin Use and Risk of Hepatocellular Carcinoma in Patients With Chronic Hepatitis B With or Without Cirrhosis.
    Hepatology. 2022 Jan 31. doi: 10.1002/hep.32380.
    >> Share

  185. KUMAR A, Sharma P, Arora A
    Letter to the Editor: In patients with established NASH cirrhosis, is there no role of weight reduction in reversing fibrosis?
    Hepatology. 2022 Jan 29. doi: 10.1002/hep.32375.
    >> Share

  186. LIU F, Zhang W, Liu H
    Letter to the Editor: Hepatocyte Proliferation Peak and beta-Oxidation in Liver Regeneration after Partial Hepatectomy.
    Hepatology. 2022 Jan 26. doi: 10.1002/hep.32357.
    >> Share

  187. PAIK JM, Henry L, Younossi ZM
    Response to: Chronic Liver Disease Among Adolescent and Young Adult: Alcohol Use Disorder Identification- Letter to the Editor. Hepatology 2022.
    Hepatology. 2022 Jan 25. doi: 10.1002/hep.32362.
    >> Share

  188. SAHAI P, Jindal A, Mukund A
    Letter to the Editor: Prospective study of stereotactic body radiation therapy for hepatocellular carcinoma on waitlist for liver transplant.
    Hepatology. 2022 Jan 25. doi: 10.1002/hep.32354.
    >> Share

  189. LI YT, Liu CJ, Kao JH, Lin LF, et al
    Metastatic Tumor Antigen 1 Contributes to Hepatocarcinogenesis Posttranscriptionally Through Novel RNA Binding Function.
    Hepatology. 2022 Jan 24. doi: 10.1002/hep.32356.
    >> Share

  190. HAN J, Wang B, Liu W, Wang S, et al
    Declining disease burden of hepatocellular carcinoma in the US, 1992-2017: A population-based analysis.
    Hepatology. 2022 Jan 24. doi: 10.1002/hep.32355.
    >> Share

  191. FANG Y, Liu W, Tang Z, Ji X, et al
    MCT4 inhibition potentiates hepatocellular carcinoma immunotherapy via enhancing T cell infiltration and immune attack.
    Hepatology. 2022 Jan 19. doi: 10.1002/hep.32348.
    >> Share

  192. KHATIB SA, Ma L, Dang H, Forgues M, et al
    Single-cell biology uncovers apoptotic cell death and its spatial organization as a potential modifier of tumor diversity in hepatocellular carcinoma.
    Hepatology. 2022 Jan 16. doi: 10.1002/hep.32345.
    >> Share

  193. LOCKART I, Yeo MGH, Hajarizadeh B, Dore GJ, et al
    Hepatocellular carcinoma incidence after hepatitis C cure among patients with advanced fibrosis or cirrhosis: a meta-analysis.
    Hepatology. 2022 Jan 14. doi: 10.1002/hep.32341.
    >> Share

  194. WU T, Simonetto DA, Halamka JD, Shah VH, et al
    The Digital Transformation of Hepatology: The Patient is Logged In.
    Hepatology. 2022 Jan 13. doi: 10.1002/hep.32329.
    >> Share

  195. JOHN BV, Deng Y, Schwartz KB, Taddei TH, et al
    Post-Vaccination COVID-19 Infection is Associated with Reduced Mortality in Patients With Cirrhosis.
    Hepatology. 2022 Jan 12. doi: 10.1002/hep.32337.
    >> Share

  196. RAMADORI P, Kam S, Heikenwalder M
    T Cells: Friends and Foes in NASH Pathogenesis and Hepatocarcinogenesis.
    Hepatology. 2022 Jan 12. doi: 10.1002/hep.32336.
    >> Share

  197. SANDMANN L, Cornberg M
    Hepatocellular carcinoma and hepatitis B virus reactivation - a preventable condition not to be missed.
    Hepatology. 2022 Jan 10. doi: 10.1002/hep.32333.
    >> Share

  198. WANG Z, Liu M, Zhang DZ, Wu SS, et al
    Microwave Ablation versus Laparoscopic Resection as First-line Therapy for Solitary 3-5 cm Hepatocellular Carcinoma.
    Hepatology. 2022 Jan 10. doi: 10.1002/hep.32323.
    >> Share

  199. FANG ZQ, Ruan B, Liu JJ, Duan JL, et al
    Notch-triggered maladaptation of liver sinusoidal endothelium aggravates nonalcoholic steatohepatitis through eNOS.
    Hepatology. 2022 Jan 10. doi: 10.1002/hep.32332.
    >> Share

  200. MA H, Kang Z, Foo TK, Shen Z, et al
    Disrupted BRCA1-PALB2 Interaction Induces Tumor Immunosuppression and T-Lymphocyte Infiltration in Hepatocellular Carcinoma Through cGAS-STING Pathway.
    Hepatology. 2022 Jan 10. doi: 10.1002/hep.32335.
    >> Share

  201. ANDERSSON ER
    Outside influence: the extrahepatic duct as a source for bile duct regeneration.
    Hepatology. 2022 Jan 10. doi: 10.1002/hep.32334.
    >> Share

  202. MOORE MP, Cunningham RP, Meers GM, Johnson SA, et al
    Compromised hepatic mitochondrial fatty acid oxidation and reduced markers of mitochondrial turnover in human NAFLD.
    Hepatology. 2022 Jan 9. doi: 10.1002/hep.32324.
    >> Share

  203. TRANAH TH, Shawcross DL
    The rise and fall and rise again of ammonia as a therapeutic target in hepatic encephalopathy.
    Hepatology. 2022 Jan 7. doi: 10.1002/hep.32319.
    >> Share

  204. SHIODE Y, Kodama T, Shigeno S, Murai K, et al
    Traf3 inactivation promotes the development of intrahepatic cholangiocarcinoma via NIK-mediated hepatocyte transdifferentiation.
    Hepatology. 2022 Jan 7. doi: 10.1002/hep.32317.
    >> Share

  205. NG CH, Xiao J, Lim WH, Chin YH, et al
    Placebo Effect on Progression and Regression in Non-Alcoholic Steatohepatitis. Evidence from a Meta-Analysis.
    Hepatology. 2022 Jan 6. doi: 10.1002/hep.32315.
    >> Share

  206. WU H, Li Y, Shi G, Du S, et al
    Hepatic IRF8 expression suppresses hepatocellular carcinoma progression and enhances the response to anti-PD-1 therapy.
    Hepatology. 2022 Jan 6. doi: 10.1002/hep.32316.
    >> Share


  207. Hepatology Highlights.
    Hepatology. 2022;75:1-2.
    >> Share

  208. PHAM L, Kennedy L, Baiocchi L, Meadows V, et al
    Mast cells in liver disease progression: An update on current studies and implications.
    Hepatology. 2022;75:213-218.
    >> Share

    December 2021
  209. LABENZ C, Labenz J, Galle PR
    Letter to the Editor: Evidence on the use of L-ornithine L-aspartate in overt hepatic encephalopathy - but does it really improve prognosis?
    Hepatology. 2021 Dec 27. doi: 10.1002/hep.32309.
    >> Share

  210. RIDOLA L, Nardelli S, Gioia S, Faccioli J, et al
    Letter to the editor: Episodic-precipitant induced hepatic encephalopathy treatment: look at new and old precipitants!
    Hepatology. 2021 Dec 24. doi: 10.1002/hep.32306.
    >> Share

  211. MASYUK AI, Masyuk TV, Trussoni CE, Pirius NE, et al
    Autophagy Promotes Hepatic Cystogenesis in Polycystic Liver Disease via Depletion of Cholangiocyte Ciliogenic Proteins.
    Hepatology. 2021 Dec 23. doi: 10.1002/hep.32298.
    >> Share

  212. LAEMMLE A, Haberle J, Willenbring H
    Reply to "The Role of Aquaporin 9 in Modeling of Ornithine Transcarbamylase Deficiency".
    Hepatology. 2021 Dec 21. doi: 10.1002/hep.32290.
    >> Share

  213. KODAMA T, Takehara T
    Reply; Transcriptomics identify thrombospondin-2 as a biomarker for nonalcoholic steatohepatitis and advanced liver fibrosis.
    Hepatology. 2021 Dec 20. doi: 10.1002/hep.32292.
    >> Share

  214. REMETIC J, Ghallab A, Hobloss Z, Brackhagen L, et al
    Loss of bile salt export pump aggravates lipopolysaccharide-induced liver injury in mice due to impaired hepatic endotoxin clearance.
    Hepatology. 2021 Dec 20. doi: 10.1002/hep.32289.
    >> Share

  215. RICH NE, Singal AG
    Overdiagnosis of hepatocellular carcinoma: Prevented by guidelines?
    Hepatology. 2021 Dec 19. doi: 10.1002/hep.32284.
    >> Share

  216. FRIEDMAN SL, Pinzani M
    Hepatic Fibrosis 2022: Unmet Needs and a Blueprint for the Future.
    Hepatology. 2021 Dec 19. doi: 10.1002/hep.32285.
    >> Share

  217. CARABALLO GALVA LD, Jiang X, Hussein MS, Zhang H, et al
    Novel low-avidity glypican-3 specific CARTs resist exhaustion and mediate durable antitumor effects against hepatocellular carcinoma.
    Hepatology. 2021 Dec 12. doi: 10.1002/hep.32279.
    >> Share

  218. LIBRERO JIMENEZ M, Lopez Garrido MA, Fernandez Cano MC
    Letter to the editor: Reactivation of HBV triggered by SARS-CoV-2 in a patient with cirrhosis.
    Hepatology. 2021 Dec 8. doi: 10.1002/hep.32271.
    >> Share

  219. LAI JC, Shui AM, Duarte-Rojo A, Ganger DR, et al
    Frailty, Mortality, and Healthcare Utilization after Liver Transplantation: From the Multi-Center Functional Assessment in Liver Transplantation (FrAILT) Study.
    Hepatology. 2021 Dec 4. doi: 10.1002/hep.32268.
    >> Share

  220. XIN B, Yang M, Wu P, Du L, et al
    Enhancing the Therapeutic Efficacy of PD-L1 Antibody for Metastasized Liver Cancer by Overcoming Hepatic Immunotolerance.
    Hepatology. 2021 Dec 3. doi: 10.1002/hep.32266.
    >> Share

  221. SAPISOCHIN G, Ivanics T, Heimbach J
    Liver Transplantation for intrahepatic cholangiocarcinoma: ready for prime time?
    Hepatology. 2021 Dec 3. doi: 10.1002/hep.32258.
    >> Share

  222. KAWAI H, Osawa Y, Matsuda M, Tsunoda T, et al
    Sphingosine-1-phosphate promotes tumor development and liver fibrosis in mouse model of congestive hepatopathy.
    Hepatology. 2021 Dec 2. doi: 10.1002/hep.32256.
    >> Share


  223. 2021 Hepatology Referees (Volumes 73 and 74).
    Hepatology. 2021;74:3565-3569.
    >> Share

  224. CODISPODO G, Brown RS Jr, Hans A, Roccaro G, et al
    Hepatology Highlights.
    Hepatology. 2021;74:2931-2934.
    >> Share

  225. KUMAR K, Kulkarni A, Jagdish RK
    Letter to the Editor: Saroglitazar for Treatment of NAFLD and NASH.
    Hepatology. 2021;74:3559-3560.
    >> Share

  226. AGARWAL A, Sharma S, Saraya A
    Letter to the Editor: Defining the Futility for Rescue Transjugular Intrahepatic Portosystemic Shunt Using the Model for End-Stage Liver Disease Score and Lactate in Variceal Bleed.
    Hepatology. 2021;74:3556-3557.
    >> Share

  227. JINDAL A, Sarin SK, Mukund A
    Letter to the Editor: Salvage TIPS for Refractory Variceal Bleed-More Questions Than Answers!
    Hepatology. 2021;74:3557-3558.
    >> Share

  228. VALENTI LVC, Cherubini A
    To Be or Not to Be: The Quest for Patatin-Like Phospholipase Domain Containing 3 p.I148M Function.
    Hepatology. 2021;74:2942-2944.
    >> Share

  229. GOH GB, Chan WK, Wong VW
    Breastfeeding to Prevent NAFLD.
    Hepatology. 2021;74:2939-2941.
    >> Share

  230. SONG J, Liu Y, Wan J, Zhao GN, et al
    SIMPLE Is an Endosomal Regulator That Protects Against NAFLD by Targeting the Lysosomal Degradation of EGFR.
    Hepatology. 2021;74:3091-3109.
    >> Share

  231. WAN J, Zhang Y, Yang D, Liang Y, et al
    Gastrodin Improves Nonalcoholic Fatty Liver Disease Through Activation of the Adenosine Monophosphate-Activated Protein Kinase Signaling Pathway.
    Hepatology. 2021;74:3074-3090.
    >> Share

  232. TILSON SG, Morell CM, Lenaerts AS, Park SB, et al
    Modeling PNPLA3-Associated NAFLD Using Human-Induced Pluripotent Stem Cells.
    Hepatology. 2021;74:2998-3017.
    >> Share

  233. SHAH NL, Miller JB, Kalman RS, Kumar S, et al
    AASLD Educating and Engaging in the Digital Age: Editorial from Communications and Technology Committee.
    Hepatology. 2021;74:2935-2938.
    >> Share

  234. PARK Y, Sinn DH, Oh JH, Goh MJ, et al
    The Association Between Breastfeeding and Nonalcoholic Fatty Liver Disease in Parous Women: A Nation-wide Cohort Study.
    Hepatology. 2021;74:2988-2997.
    >> Share

  235. WU T, Luo G, Lian Q, Sui C, et al
    Discovery of a Carbamoyl Phosphate Synthetase 1-Deficient HCC Subtype With Therapeutic Potential Through Integrative Genomic and Experimental Analysis.
    Hepatology. 2021;74:3249-3268.
    >> Share

  236. KUMAR S, Wong R, Newberry C, Yeung M, et al
    Multidisciplinary Clinic Models: A Paradigm of Care for Management of NAFLD.
    Hepatology. 2021;74:3472-3478.
    >> Share

  237. OTT P, Ala A, Askari FK, Czlonkowska A, et al
    Designing Clinical Trials in Wilson's Disease.
    Hepatology. 2021;74:3460-3471.
    >> Share

  238. GARCIA-MACIA M, Santos-Ledo A, Leslie J, Paish HL, et al
    A Mammalian Target of Rapamycin-Perilipin 3 (mTORC1-Plin3) Pathway is essential to Activate Lipophagy and Protects Against Hepatosteatosis.
    Hepatology. 2021;74:3441-3459.
    >> Share

  239. LANGE AP, Usmani AA, Wald C, Gordon FD, et al
    Sinusoidal Obstruction Syndrome in a Young Woman With Antiphospholipid Syndrome on Oral Contraceptives.
    Hepatology. 2021;74:3539-3541.
    >> Share

  240. HAKIM A, Moll M, Brancale J, Liu J, et al
    Genetic Variation in the Mitochondrial Glycerol-3-Phosphate Acyltransferase Is Associated With Liver Injury.
    Hepatology. 2021;74:3394-3408.
    >> Share

  241. BAI W, Al-Karaghouli M, Stach J, Sung S, et al
    Test-Retest Reliability and Consistency of HVPG and Impact on Trial Design: A Study in 289 Patients from 20 Randomized Controlled Trials.
    Hepatology. 2021;74:3301-3315.
    >> Share

  242. RUSYN I, Arzuaga X, Cattley RC, Corton JC, et al
    Key Characteristics of Human Hepatotoxicants as a Basis for Identification and Characterization of the Causes of Liver Toxicity.
    Hepatology. 2021;74:3486-3496.
    >> Share

    November 2021
  243. JAIN A, Sharma BC, Mahajan B, Srivastava S, et al
    "L-ornithine L-aspartate in acute treatment of severe hepatic encephalopathy: A double-blind randomized controlled trial".
    Hepatology. 2021 Nov 25. doi: 10.1002/hep.32255.
    >> Share

  244. GHANY MG, King WC, Lisker-Melman M, Sf Lok A, et al
    Letter to the Editor: HBcrAg and Prediction of Hepatocellular Carcinoma Risk.
    Hepatology. 2021 Nov 20. doi: 10.1002/hep.32251.
    >> Share

  245. LAEMMLE A, Poms M, Hsu B, Borsuk M, et al
    Aquaporin 9 Induction in Human iPSC-derived Hepatocytes Facilitates Modeling of Ornithine Transcarbamylase Deficiency.
    Hepatology. 2021 Nov 16. doi: 10.1002/hep.32247.
    >> Share

  246. KRAMER JR, Natarajan Y, Dai J, Yu X, et al
    Effect of diabetes medications and glycemic control on risk of hepatocellular cancer in patients with non-alcoholic fatty liver disease.
    Hepatology. 2021 Nov 15. doi: 10.1002/hep.32244.
    >> Share

  247. KIM ER, Park JS, Kim JH, Oh JY, et al
    A GLP-1/GLP-2 receptor dual agonist to treat non-alcoholic steatohepatitis: targeting the gut-liver axis and microbiome.
    Hepatology. 2021 Nov 12. doi: 10.1002/hep.32235.
    >> Share

  248. TIAN L, Zhao L, Sze KM, Kam CS, et al
    Dysregulation of RalA signaling through dual regulatory mechanisms exerts its oncogenic functions in hepatocellular carcinoma.
    Hepatology. 2021 Nov 12. doi: 10.1002/hep.32236.
    >> Share

  249. YANG J, Ye J, Ma T, Tang F, et al
    TRIM11 promotes hepatocellular carcinogenesis through ubiquitin-proteasome mediated degradation of PHLPP1.
    Hepatology. 2021 Nov 12. doi: 10.1002/hep.32234.
    >> Share

  250. LI H, Lan T, Liu H, Liu C, et al
    IL-6 induced cGGNBP2 encodes a novel protein to promote cell growth and metastasis in intrahepatic cholangiocarcinoma.
    Hepatology. 2021 Nov 10. doi: 10.1002/hep.32232.
    >> Share

  251. WU N, Carpino G, Ceci L, Baiocchi L, et al
    MT1 but not MT2 melatonin receptor knockout decreases biliary damage and liver fibrosis during cholestatic liver injury.
    Hepatology. 2021 Nov 7. doi: 10.1002/hep.32233.
    >> Share

  252. DING MJ, Fang HR, Zhang JK, Shi JH, et al
    E3 ubiquitin ligase RNF5 protects against hepatic ischemia reperfusion injury by mediating PGAM5 ubiquitination.
    Hepatology. 2021 Nov 4. doi: 10.1002/hep.32226.
    >> Share

  253. KAPLAN A, Brown RS Jr, Buckholz A, Hang TP, et al
    Hepatology Highlights.
    Hepatology. 2021;74:2329-2332.
    >> Share

  254. BERNUAU J, Cazals-Hatem D, Vigrain V, Durand F, et al
    Letter to the Editor: Serum Aminotransferase Activity Beyond 100 Times the Upper Limit of Normal Value Does Not Suggest Acute Fatty Liver of Pregnancy Alone.
    Hepatology. 2021;74:2922.
    >> Share

  255. JINDAL A
    Letter to the Editor: Infections in Severe Forms of Alcohol-Associated Liver Disease: Need a Closer Look!
    Hepatology. 2021;74:2926-2927.
    >> Share

  256. BAZARBASHI AN, Li M, Ryou M
    Letter to the Editor: Endoscopic Ultrasound-Guided Coil Therapy for Secondary Prevention After Gastric Variceal Bleeding: A Promising Alternative.
    Hepatology. 2021;74:2914.
    >> Share

  257. LOU L, Li X
    Letter to the Editor: Liver Stiffness by Transient Elastography to Detect Porto-sinusoidal Vascular Liver Disease.
    Hepatology. 2021;74:2910-2911.
    >> Share

  258. CHINNADURAI KK, De A, Duseja A, Singh V, et al
    Letter to the Editor: Is Balloon-Occluded Retrograde Transvenous Obliteration Superior to Endoscopic Cyanoacrylate in Gastric Varices?
    Hepatology. 2021;74:2907-2908.
    >> Share

  259. VOJJALA N, Mehtani R, Singh V
    Letter to the Editor: Acute Liver Injury Due to Therapeutic Doses of Acetaminophen-Confounders Must Be Ruled Out!
    Hepatology. 2021;74:2904.
    >> Share

  260. ZHOU J, Bai L, Zhang XJ, Li H, et al
    Nonalcoholic Fatty Liver Disease and Cardiac Remodeling Risk: Pathophysiological Mechanisms and Clinical Implications.
    Hepatology. 2021;74:2839-2847.
    >> Share

  261. INARRAIRAEGUI M, Sangro B
    Selective Internal Radiation Therapy Approval for Early HCC: What Comes Next?
    Hepatology. 2021;74:2333-2335.
    >> Share

  262. HU Y, He W, Huang Y, Xiang H, et al
    Fatty Acid Synthase-Suppressor Screening Identifies Sorting Nexin 8 as a Therapeutic Target for NAFLD.
    Hepatology. 2021;74:2508-2525.
    >> Share

  263. DIAZ LA, Idalsoaga F, Fuentes-Lopez E, Marquez-Lomas A, et al
    Impact of Public Health Policies on Alcohol-Associated Liver Disease in Latin America: An Ecological Multinational Study.
    Hepatology. 2021;74:2478-2490.
    >> Share

  264. PAISANT A, Bellal S, Lebigot J, Canivet CM, et al
    Imaging Features of Hepatic Small Vessel Neoplasm: Case Series.
    Hepatology. 2021;74:2894-2896.
    >> Share

  265. VAN DALEM J, Driessen JHM, Burden AM, Stehouwer CDA, et al
    Thiazolidinediones and Glucagon-Like Peptide-1 Receptor Agonists and the Risk of Nonalcoholic Fatty Liver Disease: A Cohort Study.
    Hepatology. 2021;74:2467-2477.
    >> Share

  266. SUN H, Meng Q, Shi C, Yang H, et al
    Hypoxia-Inducible Exosomes Facilitate Liver-Tropic Premetastatic Niche in Colorectal Cancer.
    Hepatology. 2021;74:2633-2651.
    >> Share

  267. BURYSKA S, Ahn JC, Allen AM, Simha V, et al
    Familial Hypobetalipoproteinemia: An Underrecognized Cause of Lean NASH.
    Hepatology. 2021;74:2897-2898.
    >> Share

  268. BARCENA-VARELA M, Lujambio A
    Dissecting Early Relapse in Liver Cancer, One Cell at a Time.
    Hepatology. 2021;74:2891-2893.
    >> Share

  269. DRISCOLL J, Wehrkamp C, Ota Y, Thomas JN, et al
    Biological Nanotherapeutics for Liver Disease.
    Hepatology. 2021;74:2863-2875.
    >> Share

  270. SIMON TG, Roelstraete B, Sharma R, Khalili H, et al
    Cancer Risk in Patients With Biopsy-Confirmed Nonalcoholic Fatty Liver Disease: A Population-Based Cohort Study.
    Hepatology. 2021;74:2410-2423.
    >> Share

  271. JAGDISH RK, Maras JS, Sarin SK
    Albumin in Advanced Liver Diseases: The Good and Bad of a Drug!
    Hepatology. 2021;74:2848-2862.
    >> Share

    October 2021
  272. LAN T, Jiang S, Zhang J, Weng Q, et al
    Breviscapine Alleviates Nonalcoholic Steatohepatitis by Inhibiting TGF-beta-activated Kinase 1-dependent Signaling.
    Hepatology. 2021 Oct 30. doi: 10.1002/hep.32221.
    >> Share

  273. KONIGSHOFER P, Hofer BS, Brusilovskaya K, Simbrunner B, et al
    Distinct structural and dynamic components of portal hypertension in different animal models and human liver disease etiologies.
    Hepatology. 2021 Oct 30. doi: 10.1002/hep.32220.
    >> Share

  274. MANCUSO A
    Portal vein thrombosis in cirrhosis: the issue of treatment.
    Hepatology. 2021 Oct 28. doi: 10.1002/hep.32216.
    >> Share

  275. LI M, Wong D, Vogel AS, Sack JS, et al
    Effect of corticosteroid dosing on outcomes in high-grade immune checkpoint inhibitor hepatitis.
    Hepatology. 2021 Oct 28. doi: 10.1002/hep.32215.
    >> Share

  276. LUCE E, Steichen C, Allouche M, Messina A, et al
    In vitro recovery of FIX clotting activity as a marker of highly functional hepatocytes in a hemophilia B iPSC model.
    Hepatology. 2021 Oct 23. doi: 10.1002/hep.32211.
    >> Share

  277. SANYAL AJ, Anstee QM, Trauner M, Lawitz EJ, et al
    Cirrhosis Regression is Associated with Improved Clinical Outcomes in Patients with Nonalcoholic Steatohepatitis.
    Hepatology. 2021 Oct 18. doi: 10.1002/hep.32204.
    >> Share

  278. ZHOU J, Guo L, Ma T, Qiu T, et al
    N-Acetylgalactosaminyltransferase-4 protects against hepatic ischaemia/reperfusion injury via blocking ASK1 N-terminal dimerization.
    Hepatology. 2021 Oct 18. doi: 10.1002/hep.32202.
    >> Share


  279. Correction of HEPATOLOGY 2020;71:259-274.
    Hepatology. 2021 Oct 12. doi: 10.1002/hep.32036.
    >> Share

  280. GRAHAM JJ, Mukherjee S, Yuksel M, Sanabria Mateos R, et al
    Aberrant hepatic trafficking of gut-derived T-cells is not specific to primary sclerosing cholangitis.
    Hepatology. 2021 Oct 11. doi: 10.1002/hep.32193.
    >> Share

  281. SINGAL AG, Nabihah T, Mehta A, Marrero JA, et al
    GALAD Demonstrates High Sensitivity for HCC Surveillance in a Cohort of Patients with Cirrhosis.
    Hepatology. 2021 Oct 7. doi: 10.1002/hep.32185.
    >> Share

  282. LIU N, Steer CJ, Song G
    MicroRNA-206 Enhances Antitumor Immunity by Disrupting the Communication between Malignant Hepatocytes and Tregs in c-Myc Mice.
    Hepatology. 2021 Oct 4. doi: 10.1002/hep.32182.
    >> Share

  283. LAWITZ EJ, Shevell DE, Tirucherai GS, Du S, et al
    BMS-986263 in Patients with Advanced Hepatic Fibrosis: 36-Week Results from a Randomized, Placebo-Controlled Phase 2 Trial.
    Hepatology. 2021 Oct 4. doi: 10.1002/hep.32181.
    >> Share

  284. ALLAMNENI C, Vora RS, Bamidele AO, Schwartz RE, et al
    Hepatology Highlights.
    Hepatology. 2021;74:1727-1729.
    >> Share

  285. MCCARRON S, Bathon B, Conlon DM, Abbey D, et al
    Functional Characterization of Organoids Derived From Irreversibly Damaged Liver of Patients With NASH.
    Hepatology. 2021;74:1825-1844.
    >> Share

  286. EDELSON JC, Rockey DC
    Letter to the Editor: Complications Associated With Anesthesia Services in Endoscopic Procedures Among Patients With Cirrhosis.
    Hepatology. 2021;74:2313-2314.
    >> Share

  287. LLEO A, Hirschfield GM
    Letter to the Editor: Are We Confident That Primary Biliary Cholangitis Liver-Related Mortality Is Higher in Males?
    Hepatology. 2021;74:2307.
    >> Share

  288. VILARINHO S, Ajmera V, Zheng M, Loomba R, et al
    Emerging Role of Genomic Analysis in Clinical Evaluation of Lean Individuals With NAFLD.
    Hepatology. 2021;74:2241-2250.
    >> Share

  289. FRANCQUE S
    Saroglitazar for the Treatment of NASH: The Peroxisome Proliferator-Activated Receptor Story Goes On!
    Hepatology. 2021;74:1730-1733.
    >> Share

  290. ZHOU J, Hu M, He M, Wang X, et al
    TNFAIP3 Interacting Protein 3 Is an Activator of Hippo-YAP Signaling Protecting Against Hepatic Ischemia/Reperfusion Injury.
    Hepatology. 2021;74:2133-2153.
    >> Share

  291. MALESPIN M, May EJ, Nephew LD, Paul S, et al
    AASLD Deepens Commitment to Diversity, Equity, and Inclusion.
    Hepatology. 2021;74:2216-2225.
    >> Share

  292. WALTER A, Rudler M, Olivas P, Moga L, et al
    Combination of Model for End-Stage Liver Disease and Lactate Predicts Death in Patients Treated With Salvage Transjugular Intrahepatic Portosystemic Shunt for Refractory Variceal Bleeding.
    Hepatology. 2021;74:2085-2101.
    >> Share

  293. GEURTSEN ML, Wahab RJ, Felix JF, Gaillard R, et al
    Maternal Early-Pregnancy Glucose Concentrations and Liver Fat Among School-Age Children.
    Hepatology. 2021;74:1902-1913.
    >> Share

  294. NI M, Zhang J, Sosa R, Zhang H, et al
    T-Cell Immunoglobulin and Mucin Domain-Containing Protein-4 Is Critical for Kupffer Cell Homeostatic Function in the Activation and Resolution of Liver Ischemia Reperfusion Injury.
    Hepatology. 2021;74:2118-2132.
    >> Share

  295. COLUCCI S, Altamura S, Marques O, Dropmann A, et al
    Liver Sinusoidal Endothelial Cells Suppress Bone Morphogenetic Protein 2 Production in Response to TGFbeta Pathway Activation.
    Hepatology. 2021;74:2186-2200.
    >> Share

  296. IM YR, Hunter H, de Gracia Hahn D, Duret A, et al
    A Systematic Review of Animal Models of NAFLD Finds High-Fat, High-Fructose Diets Most Closely Resemble Human NAFLD.
    Hepatology. 2021;74:1884-1901.
    >> Share

  297. BARROW F, Khan S, Wang H, Revelo XS, et al
    The Emerging Role of B Cells in the Pathogenesis of NAFLD.
    Hepatology. 2021;74:2277-2286.
    >> Share

  298. CHOI WM, Ryu T, Lee JH, Shim YR, et al
    Metabotropic Glutamate Receptor 5 in Natural Killer Cells Attenuates Liver Fibrosis by Exerting Cytotoxicity to Activated Stellate Cells.
    Hepatology. 2021;74:2170-2185.
    >> Share

  299. CHEN L, Wu N, Kennedy L, Francis H, et al
    Inhibition of Secretin/Secretin Receptor Axis Ameliorates NAFLD Phenotypes.
    Hepatology. 2021;74:1845-1863.
    >> Share

  300. DINANI AM, Kowdley KV, Noureddin M
    Application of Artificial Intelligence for Diagnosis and Risk Stratification in NAFLD and NASH: The State of the Art.
    Hepatology. 2021;74:2233-2240.
    >> Share

  301. YU H, He J, Liu W, Feng S, et al
    The Transcriptional Coactivator, ALL1-Fused Gene From Chromosome 9, Simultaneously Sustains Hypoxia Tolerance and Metabolic Advantages in Liver Cancer.
    Hepatology. 2021;74:1952-1970.
    >> Share

  302. GAWRIEH S, Noureddin M, Loo N, Mohseni R, et al
    Saroglitazar, a PPAR-alpha/gamma Agonist, for Treatment of NAFLD: A Randomized Controlled Double-Blind Phase 2 Trial.
    Hepatology. 2021;74:1809-1824.
    >> Share

  303. LUO X, Xiang T, Wu J, Wang X, et al
    Endoscopic Cyanoacrylate Injection Versus Balloon-Occluded Retrograde Transvenous Obliteration for Prevention of Gastric Variceal Bleeding: A Randomized Controlled Trial.
    Hepatology. 2021;74:2074-2084.
    >> Share

    September 2021
  304. FANG Y, Zhan Y, Xie Y, Du S, et al
    Integration of Glucose and Cardiolipin Anabolism Confers Radiation Resistance of Hepatocellular Carcinoma.
    Hepatology. 2021 Sep 28. doi: 10.1002/hep.32177.
    >> Share

  305. LI H, Liu G, Wan X, Zhou L, et al
    ZBTB20 regulates plasma triglyceride metabolism by repressing lipoprotein lipase gene transcription in hepatocytes.
    Hepatology. 2021 Sep 28. doi: 10.1002/hep.32176.
    >> Share

  306. GARCIA-TSAO G
    Can we rely on changes in HVPG in patients with cirrhosis?
    Hepatology. 2021 Sep 27. doi: 10.1002/hep.32159.
    >> Share

  307. ZHAO C, Lancman JJ, Yang Y, Gates KP, et al
    Intrahepatic cholangiocyte regeneration from an Fgf-dependent extrahepatic progenitor niche in a zebrafish model of Alagille Syndrome.
    Hepatology. 2021 Sep 27. doi: 10.1002/hep.32173.
    >> Share

  308. DRIEVER EG, von Meijenfeldt FA, Adelmeijer J, de Haas RJ, et al
    Non-malignant portal vein thrombi in patients with cirrhosis consist of intimal fibrosis with or without a fibrin-rich thrombus.
    Hepatology. 2021 Sep 24. doi: 10.1002/hep.32169.
    >> Share

  309. ZHAO Y, Gao L, Jiang C, Chen J, et al
    The Transcription Factor ZHX2 Alleviates Nonalcoholic Steatohepatitis by Transcriptional Activation of PTEN.
    Hepatology. 2021 Sep 21. doi: 10.1002/hep.32165.
    >> Share

  310. ZHOU SL, Luo CB, Song CL, Zhou ZJ, et al
    Genomic evolution and the impact of SLIT2 mutation in relapsed intrahepatic cholangiocarcinoma.
    Hepatology. 2021 Sep 20. doi: 10.1002/hep.32164.
    >> Share

  311. ZHAI LL, Zhen SH, Tang ZG
    Letter to the Editor: Serum bioavailable 25-hydroxyvitamin D levels correlate with hepatocellular carcinoma survival.
    Hepatology. 2021 Sep 18. doi: 10.1002/hep.32158.
    >> Share

  312. FANG AP, Zhang YJ, Chen MS, Zhu HL, et al
    Response to "Serum bioavailable 25-hydroxyvitamin D levels correlate with hepatocellular carcinoma survival".
    Hepatology. 2021 Sep 18. doi: 10.1002/hep.32160.
    >> Share

  313. WANG S, Whitlock R, Xu C, Taneja S, et al
    Frailty is associated with increased risk of cirrhosis disease progression and death.
    Hepatology. 2021 Sep 15. doi: 10.1002/hep.32157.
    >> Share

  314. HUANG R, Liu J, Wang J, Li J, et al
    Letter to the Editor: Is hepatitis B virus genotype strongly associated with hepatocellular carcinoma risk in patients with chronic hepatitis B?
    Hepatology. 2021 Sep 14. doi: 10.1002/hep.32155.
    >> Share

  315. DUAN J, Wang Z, Duan R, Yang C, et al
    Therapeutic Targeting of Hepatic ACSL4 Ameliorates Non-alcoholic Steatohepatitis in Mice.
    Hepatology. 2021 Sep 12. doi: 10.1002/hep.32148.
    >> Share

  316. CARAPETO F, Bozorgui B, Shroff RT, Chagani S, et al
    The Immunogenomic Landscape of Resected Intrahepatic Cholangiocarcinoma.
    Hepatology. 2021 Sep 12. doi: 10.1002/hep.32150.
    >> Share

  317. BLOOM PP, Fontana RJ
    With Alcohol as the fuel, COVID is the match: Liver Transplantation for Alcoholic liver disease is increasing in the United States.
    Hepatology. 2021 Sep 8. doi: 10.1002/hep.32141.
    >> Share

  318. SHAH BJ, Onken JE, Edgar L, Jou JH, et al
    Development of Gastroenterology and Transplant Hepatology Milestones 2.0: A Guide For Programs, Faculty, and Fellows.
    Hepatology. 2021 Sep 7. doi: 10.1002/hep.32097.
    >> Share

  319. COLL M, Arino S, Martinez-Sanchez C, Garcia-Pras E, et al
    Ductular Reaction Promotes Intrahepatic Angiogenesis Via Slit2-Robo1 Signaling.
    Hepatology. 2021 Sep 7. doi: 10.1002/hep.32140.
    >> Share

  320. ZHANG X, Yang H, Zeng S, Tian S, et al
    Melanoma-Differentiation-Associated gene 5 protects against nonalcoholic steatohepatitis in mice.
    Hepatology. 2021 Sep 5. doi: 10.1002/hep.32139.
    >> Share

  321. AN J, Kim D, Oh B, Oh YJ, et al
    Comprehensive characterization of viral integrations and genomic aberrations in HBV-infected intrahepatic cholangiocarcinomas.
    Hepatology. 2021 Sep 3. doi: 10.1002/hep.32135.
    >> Share

  322. GORES GJ, Malhi H
    Presenting the New Incoming Editorial Team for HEPATOLOGY: Team Members and Perspectives.
    Hepatology. 2021 Sep 2. doi: 10.1002/hep.32137.
    >> Share

  323. KHAN IW, Ali MA, Lau DTY, Hang TP, et al
    Hepatology Highlights.
    Hepatology. 2021;74:1137-1140.
    >> Share

  324. RAEVENS S, Boret M, De Pauw M, Fallon MB, et al
    Pulmonary Abnormalities in Liver Disease: Relevance to Transplantation and Outcome.
    Hepatology. 2021;74:1674-1686.
    >> Share

  325. SHARMA S, Gunjan D, Saraya A
    Letter to the Editor: Balloon-Occluded Retrograde Transvenous Obliteration for Prevention of Gastric Variceal Rebleeding: A Paradigm Shift?
    Hepatology. 2021;74:1721-1722.
    >> Share

  326. ZHANG XP, Zhao GD, Liu Q, Liu R, et al
    Letter to the Editor: Recognizing Significant Role of Neoadjuvant Radiotherapy for HCC With Vascular Invasion.
    Hepatology. 2021;74:1719.
    >> Share

  327. SEKAR D, K AP
    Letter to the Editor: H19 Promotes HCC Bone Metastasis by Reducing Osteoprotegerin Expression in a PPP1CA/p38MAPK-Dependent Manner and Sponging miR-200b-3p.
    Hepatology. 2021;74:1713.
    >> Share

  328. CRAXI L
    Letter to the Editor: Comment on "The Application of Artificial Intelligence for the Diagnosis and Treatment of Liver Diseases".
    Hepatology. 2021;74:1710.
    >> Share

  329. ALLEN AM, Neuschwander-Tetri BA
    The Importance of Glycemic Equipoise in NASH.
    Hepatology. 2021;74:1145-1147.
    >> Share

  330. JIANG X, Qian H, Ding WX
    New Glance at the Role of TM6SF2 in Lipid Metabolism and Liver Cancer.
    Hepatology. 2021;74:1141-1144.
    >> Share

  331. WANG SS, Tang XT, Lin M, Yuan J, et al
    Perivenous Stellate Cells Are the Main Source of Myofibroblasts and Cancer-Associated Fibroblasts Formed After Chronic Liver Injuries.
    Hepatology. 2021;74:1578-1594.
    >> Share

  332. NIU Y, Lin Z, Wan A, Sun L, et al
    Loss-of-Function Genetic Screening Identifies Aldolase A as an Essential Driver for Liver Cancer Cell Growth Under Hypoxia.
    Hepatology. 2021;74:1461-1479.
    >> Share

  333. STARLINGER P, Ahn JC, Mullan A, Gyoeri GP, et al
    The Addition of C-Reactive Protein and von Willebrand Factor to Model for End-Stage Liver Disease-Sodium Improves Prediction of Waitlist Mortality.
    Hepatology. 2021;74:1533-1545.
    >> Share

  334. LAGO-HERNANDEZ C, Nguyen NH, Khera R, Loomba R, et al
    Financial Hardship From Medical Bills Among Adults With Chronic Liver Diseases: National Estimates From the United States.
    Hepatology. 2021;74:1509-1522.
    >> Share

  335. LIU Y, Song J, Yang J, Zheng J, et al
    Tumor Necrosis Factor alpha-Induced Protein 8-Like 2 Alleviates Nonalcoholic Fatty Liver Disease Through Suppressing Transforming Growth Factor Beta-Activated Kinase 1 Activation.
    Hepatology. 2021;74:1300-1318.
    >> Share

  336. BEALS JW, Smith GI, Shankaran M, Fuchs A, et al
    Increased Adipose Tissue Fibrogenesis, Not Impaired Expandability, Is Associated With Nonalcoholic Fatty Liver Disease.
    Hepatology. 2021;74:1287-1299.
    >> Share

  337. ANDREWS TS, MacParland SA
    A Spotlight on the Drivers of Inflammation in Acute Liver Failure.
    Hepatology. 2021;74:1687-1689.
    >> Share

  338. STRATAKIS N, Golden-Mason L, Margetaki K, Zhao Y, et al
    In Utero Exposure to Mercury Is Associated With Increased Susceptibility to Liver Injury and Inflammation in Childhood.
    Hepatology. 2021;74:1546-1559.
    >> Share

  339. KUSUMANCHI P, Liang T, Zhang T, Ross RA, et al
    Stress-Responsive Gene FK506-Binding Protein 51 Mediates Alcohol-Induced Liver Injury Through the Hippo Pathway and Chemokine (C-X-C Motif) Ligand 1 Signaling.
    Hepatology. 2021;74:1234-1250.
    >> Share

  340. WANG Y, Hylemon PB, Zhou H
    Long Noncoding RNA H19: A Key Player in Liver Diseases.
    Hepatology. 2021;74:1652-1659.
    >> Share

    August 2021
  341. INNES H, Crooks CJ, Aspinall E, Card TR, et al
    Characterising the risk interplay between alcohol intake and body mass index on cirrhosis morbidity.
    Hepatology. 2021 Aug 28. doi: 10.1002/hep.32123.
    >> Share

  342. VARGHESE J, Malleswaran S, Mouleeswaran K
    Letter to the Editor: Toxin-induced Graft Injury following Liver Transplantation for Yellow Phosphorus Poisoning.
    Hepatology. 2021 Aug 28. doi: 10.1002/hep.32124.
    >> Share

  343. PLUMMER MD, Regenstein F
    Light chain deposition disease: an unusual cause of portal hypertension.
    Hepatology. 2021 Aug 27. doi: 10.1002/hep.32118.
    >> Share

  344. FU J, Hu F, Ma T, Zhao WJ, et al
    A conventional immune regulator MAVS blocks hepatic steatosis via maintaining mitochondrial homeostasis.
    Hepatology. 2021 Aug 26. doi: 10.1002/hep.32126.
    >> Share

  345. IMAI N, Nicholls HT, Alves-Bezerra M, Li Y, et al
    Upregulation of Thioesterase Superfamily Member 2 in Skeletal Muscle Promotes Hepatic Steatosis and Insulin Resistance.
    Hepatology. 2021 Aug 25. doi: 10.1002/hep.32122.
    >> Share

  346. LINDOR KD, Bowlus CL, Boyer J, Levy C, et al
    Primary Biliary Cholangitis: 2021 Practice Guidance Update from the American Association for the Study of Liver Diseases.
    Hepatology. 2021 Aug 24. doi: 10.1002/hep.32117.
    >> Share

  347. FAN S, Gao Y, Qu A, Jiang Y, et al
    YAP-TEAD mediates peroxisome proliferator-activated receptor alpha-induced hepatomegaly and liver regeneration in mice.
    Hepatology. 2021 Aug 13. doi: 10.1002/hep.32105.
    >> Share

  348. FUCHS CD, Radun R, Dixon ED, Mlitz V, et al
    Hepatocyte-specific deletion of adipose triglyceride lipase (ATGL/PNPLA2) ameliorates dietary induced steatohepatitis in mice.
    Hepatology. 2021 Aug 13. doi: 10.1002/hep.32112.
    >> Share

  349. EL KASMI KC, Ghosh S, Anderson AL, Devereaux MW, et al
    Pharmacologic Activation of Hepatic Farnesoid X Receptor Prevents Parenteral Nutrition Associated Cholestasis in Mice.
    Hepatology. 2021 Aug 13. doi: 10.1002/hep.32101.
    >> Share

  350. LIN Y, Cai Q, Chen Y, Shi T, et al
    CAFs shape myeloid-derived suppressor cells to promote stemness of intrahepatic cholangiocarcinoma via 5-lipoxygenase.
    Hepatology. 2021 Aug 13. doi: 10.1002/hep.32099.
    >> Share

  351. WADHWANI SI, Ge J, Gottlieb L, Lyles C, et al
    Racial/Ethnic Disparities in Wait List Outcomes Are Only Partly Explained by Socioeconomic Deprivation Among Children Awaiting Liver Transplantation.
    Hepatology. 2021 Aug 13. doi: 10.1002/hep.32106.
    >> Share

  352. ALLAIRE M, Garcia-Pagan JC, Walter A, Bureau C, et al
    Salvage TIPS in cirrhotic patients with variceal bleeding: MELD, lactates and << a la carte >> decision.
    Hepatology. 2021 Aug 5. doi: 10.1002/hep.32091.
    >> Share

  353. BOSCH J, Chung C, Carrasco-Zevallos OM, Harrison SA, et al
    A Machine Learning Approach to Liver Histological Evaluation Predicts Clinically Significant Portal Hypertension in NASH Cirrhosis.
    Hepatology. 2021 Aug 1. doi: 10.1002/hep.32087.
    >> Share

  354. WAHID N, Jesudian A, Buckholz A, Brown RS Jr, et al
    Hepatology Highlights.
    Hepatology. 2021;74:539-542.
    >> Share

  355. FIX OK, Blumberg EA, Chang KM, Chu J, et al
    American Association for the Study of Liver Diseases Expert Panel Consensus Statement: Vaccines to Prevent Coronavirus Disease 2019 Infection in Patients With Liver Disease.
    Hepatology. 2021;74:1049-1064.
    >> Share

  356. SAVIANO A, Wrensch F, Ghany MG, Baumert TF, et al
    Liver Disease and Coronavirus Disease 2019: From Pathogenesis to Clinical Care.
    Hepatology. 2021;74:1088-1100.
    >> Share

  357. TROVATO FM, Zia R, Napoli S, Wolfer K, et al
    Dysregulation of the Lysophosphatidylcholine/Autotaxin/Lysophosphatidic Acid Axis in Acute-on-Chronic Liver Failure Is Associated With Mortality and Systemic Inflammation by Lysophosphatidic Acid-Dependent Monocyte Activation.
    Hepatology. 2021;74:907-925.
    >> Share

  358. CARTER J, Wang S, Friedman SL
    Ten Thousand Points of Light: Heterogeneity Among the Stars of NASH Fibrosis.
    Hepatology. 2021;74:543-546.
    >> Share

  359. FONTANA RJ, Stravitz RT, Durkalski V, Hanje J, et al
    Prognostic Value of the (13) C-Methacetin Breath Test in Adults with Acute Liver Failure and Non-acetaminophen Acute Liver Injury.
    Hepatology. 2021;74:961-972.
    >> Share

  360. REN H, Hu F, Wang D, Kang X, et al
    Sirtuin 2 Prevents Liver Steatosis and Metabolic Disorders by Deacetylation of Hepatocyte Nuclear Factor 4alpha.
    Hepatology. 2021;74:723-740.
    >> Share

  361. STRAVITZ RT, Fontana RJ, Meinzer C, Durkalski-Mauldin V, et al
    Coagulopathy, Bleeding Events, and Outcome According to Rotational Thromboelastometry in Patients With Acute Liver Injury/Failure.
    Hepatology. 2021;74:937-949.
    >> Share

  362. LEE D, Zhang MS, Tsang FH, Bao MH, et al
    Adaptive and Constitutive Activations of Malic Enzymes Confer Liver Cancer Multilayered Protection Against Reactive Oxygen Species.
    Hepatology. 2021;74:776-796.
    >> Share

  363. VEERAMACHANENI H, Subramanian RM
    Combined High-Dose Continuous Renal Replacement Therapy and Plasma Exchange in the Management of Severe Multiorgan System Dysfunction Associated With Acute Liver Failure.
    Hepatology. 2021;74:1124-1126.
    >> Share

  364. TRIANTOS C, Aggeletopoulou I, Thomopoulos K, Mouzaki A, et al
    Vitamin D-Liver Disease Association: Biological Basis and Mechanisms of Action.
    Hepatology. 2021;74:1065-1073.
    >> Share

    July 2021
  365. WIN S, Min RWM, Zhang J, Kanel G, et al
    Hepatic mitochondrial SAB deletion or knockdown alleviates diet induced metabolic syndrome, steatohepatitis and hepatic fibrosis.
    Hepatology. 2021 Jul 31. doi: 10.1002/hep.32083.
    >> Share

  366. ZHANG Z, Ji Z, He J, Lu Y, et al
    GNAI2 exacerbates non-alcoholic steatohepatitis progression via regulating PRDX1-related inflammation and lipophagy.
    Hepatology. 2021 Jul 29. doi: 10.1002/hep.32078.
    >> Share

  367. SUDA T, Yoshikawa S, Kanefuji T, Abe S, et al
    Suppression of Noncoding RNAs as Shared Early Genetic Events in Multistep Hepatocarcinogenesis.
    Hepatology. 2021 Jul 29. doi: 10.1002/hep.32077.
    >> Share

  368. MA L, Xu A, Kang L, Cong R, et al
    LSD1-Demethylated LINC01134 Confers Oxaliplatin Resistance via SP1-induced p62 Transcription in Hepatocellular Carcinoma.
    Hepatology. 2021 Jul 29. doi: 10.1002/hep.32079.
    >> Share

  369. LIU G, Wang N, Zhang C, Li M, et al
    ALDOB depletion promotes hepatocellular carcinogenesis through activating insulin receptor signaling and lipogenesis.
    Hepatology. 2021 Jul 22. doi: 10.1002/hep.32064.
    >> Share

  370. MCMAHON BJ, Nolen S, Snowball M, Homan C, et al
    Hepatitis B Virus (HBV) Genotype: A Significant Risk Factor in Determining which Patients with Chronic HBV Infection should Undergo Surveillance for Hepatocellular Carcinoma: The Hepatitis B Alaska (HEP-B-AK) Study.
    Hepatology. 2021 Jul 22. doi: 10.1002/hep.32065.
    >> Share

  371. HU M, Zhang D, Xu H, Zhang Y, et al
    Salidroside activates the AMP-activated protein kinase pathway to suppress non-alcoholic steatohepatitis.
    Hepatology. 2021 Jul 22. doi: 10.1002/hep.32066.
    >> Share

  372. HE Q, Liu M, Huang W, Chen X, et al
    IL-1beta-induced Elevation of SLC7A11 Promotes Hepatocellular Carcinoma Metastasis through Upregulating PD-L1 and CSF1.
    Hepatology. 2021 Jul 20. doi: 10.1002/hep.32062.
    >> Share

  373. YANG Q, Chen X, Zhang Y, Hu S, et al
    The E3 ubiquitin ligase RNF5 ameliorates nonalcoholic steatohepatitis via ubiquitin-mediated degradation of HRD1.
    Hepatology. 2021 Jul 17. doi: 10.1002/hep.32061.
    >> Share

  374. PIANO S, Cardenas A
    Metabolomics to predict acute kidney injury in cirrhosis.
    Hepatology. 2021 Jul 16. doi: 10.1002/hep.32060.
    >> Share

  375. MILLER BM, Oderberg IM, Goessling W
    The Hepatic Nervous System in Development, Regeneration, and Disease.
    Hepatology. 2021 Jul 13. doi: 10.1002/hep.32055.
    >> Share

  376. ZHENG J, Daniel CR, Hatia RI, Stuff J, et al
    Dietary N-Nitroso Compounds and Risk of Hepatocellular Carcinoma: A US-Based Study.
    Hepatology. 2021 Jul 7. doi: 10.1002/hep.32046.
    >> Share

  377. LAI JC, Tandon P, Bernal W, Tapper EB, et al
    Malnutrition, Frailty, and Sarcopenia in Patients With Cirrhosis: 2021 Practice Guidance by the American Association for the Study of Liver Diseases.
    Hepatology. 2021 Jul 7. doi: 10.1002/hep.32049.
    >> Share

  378. KIM OK, Nam DE, Hahn YS
    The Panx1/P2X4 pathway controls the secretion of miRNA-containing exosomes by HCV-infected hepatocytes.
    Hepatology. 2021 Jul 4. doi: 10.1002/hep.32042.
    >> Share

  379. CAPORALI C, Turco L, Prampolini F, Quaretti P, et al
    Proximal splenic artery embolization to treat refractory ascites in a cirrhotic patient.
    Hepatology. 2021 Jul 4. doi: 10.1002/hep.32037.
    >> Share

  380. BUCKHOLZ A, Lucero C, Yang LM, Lau DTY, et al
    Hepatology Highlights.
    Hepatology. 2021;74:1-4.
    >> Share

  381. WILSON A, Beaton M, Brahmania M
    Letter to the Editor: Nonalcoholic Fatty Liver Disease-One Size May Not Fit All.
    Hepatology. 2021;74:528.
    >> Share

  382. DIENSTAG JL
    Introducing Raymond T. Chung, M.D., Our 2021 AASLD President.
    Hepatology. 2021;74:12-18.
    >> Share

  383. SZABO G
    Exosomes and MicroRNA-223 at the Intersection of Inflammation and Fibrosis in NAFLD.
    Hepatology. 2021;74:5-8.
    >> Share

  384. PARTHASARATHY G, Malhi H
    Macrophage Heterogeneity in NASH: More Than Just Nomenclature.
    Hepatology. 2021;74:515-518.
    >> Share

  385. NOUREDDIN M
    Artificial Intelligence in NASH Histology: Human Teaches a Machine for the Machine to Help Humans.
    Hepatology. 2021;74:9-11.
    >> Share

  386. HUANG Z, Chu L, Liang J, Tan X, et al
    H19 Promotes HCC Bone Metastasis Through Reducing Osteoprotegerin Expression in a Protein Phosphatase 1 Catalytic Subunit Alpha/p38 Mitogen-Activated Protein Kinase-Dependent Manner and Sponging microRNA 200b-3p.
    Hepatology. 2021;74:214-232.
    >> Share

  387. TAYLOR-WEINER A, Pokkalla H, Han L, Jia C, et al
    A Machine Learning Approach Enables Quantitative Measurement of Liver Histology and Disease Monitoring in NASH.
    Hepatology. 2021;74:133-147.
    >> Share

  388. COPPLE IM, Park BK, Goldring CE
    Gene Signatures Reduce the Stress of Preclinical Drug Hepatotoxicity Screening.
    Hepatology. 2021;74:513-515.
    >> Share

  389. HAGSTROM H, Adams LA, Allen AM, Byrne CD, et al
    Administrative Coding in Electronic Health Care Record-Based Research of NAFLD: An Expert Panel Consensus Statement.
    Hepatology. 2021;74:474-482.
    >> Share

  390. HE Y, Shi M, Wu X, Ma J, et al
    Mutational Signature Analysis Reveals Widespread Contribution of Pyrrolizidine Alkaloid Exposure to Human Liver Cancer.
    Hepatology. 2021;74:264-280.
    >> Share

  391. KENNEDY L, Meadows V, Sybenga A, Demieville J, et al
    Mast Cells Promote Nonalcoholic Fatty Liver Disease Phenotypes and Microvesicular Steatosis in Mice Fed a Western Diet.
    Hepatology. 2021;74:164-182.
    >> Share

  392. WANG H, Song X, Liao H, Wang P, et al
    Overexpression of Mothers Against Decapentaplegic Homolog 7 Activates the Yes-Associated Protein/NOTCH Cascade and Promotes Liver Carcinogenesis in Mice and Humans.
    Hepatology. 2021;74:248-263.
    >> Share

  393. JIANG T, Sanchez-Rivera FJ, Soto-Feliciano YM, Yang Q, et al
    Targeting the De Novo Purine Synthesis Pathway Through Adenylosuccinate Lyase Depletion Impairs Liver Cancer Growth by Perturbing Mitochondrial Function.
    Hepatology. 2021;74:233-247.
    >> Share

  394. GOUDSMIT BFJ, Putter H, Tushuizen ME, Vogelaar S, et al
    Refitting the Model for End-Stage Liver Disease for the Eurotransplant Region.
    Hepatology. 2021;74:351-363.
    >> Share

  395. BERNARDO-SEISDEDOS G, Bilbao J, Fernandez-Ramos D, Lopitz-Otsoa F, et al
    Metabolic Landscape of the Mouse Liver by Quantitative (31) P Nuclear Magnetic Resonance Analysis of the Phosphorome.
    Hepatology. 2021;74:148-163.
    >> Share

  396. HOU X, Yin S, Ren R, Liu S, et al
    Myeloid-Cell-Specific IL-6 Signaling Promotes MicroRNA-223-Enriched Exosome Production to Attenuate NAFLD-Associated Fibrosis.
    Hepatology. 2021;74:116-132.
    >> Share

  397. WOOD NL, Kernodle AB, Hartley AJ, Segev DL, et al
    Heterogeneous Circles for Liver Allocation.
    Hepatology. 2021;74:312-321.
    >> Share

  398. POSE E, Coll M, Martinez-Sanchez C, Zeng Z, et al
    Programmed Death Ligand 1 Is Overexpressed in Liver Macrophages in Chronic Liver Diseases, and Its Blockade Improves the Antibacterial Activity Against Infections.
    Hepatology. 2021;74:296-311.
    >> Share

    June 2021
  399. FLEMMING JA, Djerboua M, Groome PA, Booth CM, et al
    NAFLD and alcohol-related liver disease will be responsible for almost all new diagnoses of cirrhosis in Canada by 2040.
    Hepatology. 2021 Jun 26. doi: 10.1002/hep.32032.
    >> Share

  400. GARATE-RASCON M, Recalde M, Jimenez M, Elizalde M, et al
    SLU7 prevents oxidative stress-mediated HNF4alpha degradation preserving hepatic differentiation and protecting from liver damage.
    Hepatology. 2021 Jun 25. doi: 10.1002/hep.32029.
    >> Share

  401. HIRAO H, Ito T, Kadono K, Kojima H, et al
    Donor Hepatic Occult Collagen Deposition Predisposes to Peri-transplant Stress and Impacts Human Liver Transplantation.
    Hepatology. 2021 Jun 25. doi: 10.1002/hep.32030.
    >> Share

  402. KRIEGERMEIER A, Hyon A, Sommars M, Hubchak S, et al
    Hepatic X-box binding protein 1 and unfolded protein response is impaired in weanling mice with resultant hepatic injury.
    Hepatology. 2021 Jun 25. doi: 10.1002/hep.32031.
    >> Share

  403. CHOLANKERIL G, Kanwal F
    Nonalcoholic fatty liver disease and Hepatocellular Carcinoma: Time to Bridge the Gap.
    Hepatology. 2021 Jun 23. doi: 10.1002/hep.32025.
    >> Share

  404. TORRENS L, Montironi C, Puigvehi M, Mesropian A, et al
    Immunomodulatory effects of lenvatinib plus anti-PD1 in mice and rationale for patient enrichment in hepatocellular carcinoma.
    Hepatology. 2021 Jun 22. doi: 10.1002/hep.32023.
    >> Share

  405. LIU H, Lee SS
    Diagnostic criteria of cirrhotic cardiomyopathy: out with the old, in with the new?
    Hepatology. 2021 Jun 21. doi: 10.1002/hep.32021.
    >> Share

  406. JEPSEN P, Tapper EB, Deleuran T, Kazankov K, et al
    Risk and outcome of venous and arterial thrombosis in patients with cirrhosis: a Danish nationwide cohort study.
    Hepatology. 2021 Jun 16. doi: 10.1002/hep.32019.
    >> Share

  407. SHI YF, Xie WZ
    Letter to the Editor: Risk Stratification in Patients With Child-Pugh B Cirrhosis and Acute Variceal Bleeding.
    Hepatology. 2021 Jun 15. doi: 10.1002/hep.32013.
    >> Share

  408. MAZUMDER NR, Simpson D, Atiemo K, Jackson K, et al
    Black Patients With Cirrhosis Have Higher Mortality and Lower Transplant Rates: Results From a Metropolitan Cohort Study.
    Hepatology. 2021 Jun 15. doi: 10.1002/hep.31742.
    >> Share

  409. BARRON-MILLAR B, Ogle L, Mells G, Flack S, et al
    The Serum Proteome and Ursodeoxycholic Acid Response in Primary Biliary Cholangitis.
    Hepatology. 2021 Jun 15. doi: 10.1002/hep.32011.
    >> Share

  410. LEE YT, Wang JJ, Luu M, Noureddin M, et al
    Comparison of Clinical Features and Outcomes between Intrahepatic Cholangiocarcinoma and Hepatocellular Carcinoma in the United States.
    Hepatology. 2021 Jun 11. doi: 10.1002/hep.32007.
    >> Share

  411. JINDAL A, Sharma S
    Biomarkers for predicting renal outcomes in decompensated cirrhosis - Need a closer look!
    Hepatology. 2021 Jun 9. doi: 10.1002/hep.32005.
    >> Share

  412. SOLIPURAM V, Baretti M, Kim AY, Chen LX, et al
    Surgical Debulking for Refractory Hyperammonemic Encephalopathy in Fibrolamellar Hepatocellular Carcinoma.
    Hepatology. 2021 Jun 9. doi: 10.1002/hep.31998.
    >> Share

  413. SHAH V, Iwakiri Y, Boyer JL
    Obituary for Roberto J. Groszmann - the Father of Portal Hypertension.
    Hepatology. 2021 Jun 9. doi: 10.1002/hep.31996.
    >> Share

  414. KOZUMI K, Kodama T, Murai H, Sakane S, et al
    Transcriptomics Identify Thrombospondin-2 as a Biomarker for Nonalcoholic Steatohepatitis and Advanced Liver Fibrosis.
    Hepatology. 2021 Jun 9. doi: 10.1002/hep.31995.
    >> Share

  415. CHO K, Ro SW, Lee HW, Moon H, et al
    YAP/TAZ suppress drug penetration into hepatocellular carcinoma via stromal activation.
    Hepatology. 2021 Jun 8. doi: 10.1002/hep.32000.
    >> Share

  416. CHEN B, Wu JX, Cheng SH, Wang LM, et al
    Phase II study of adjuvant radiotherapy following narrow-margin hepatectomy in patients with hepatocellular carcinoma.
    Hepatology. 2021 Jun 7. doi: 10.1002/hep.31993.
    >> Share

  417. JINDAL A, Jagdish RK
    Response to terlipressin plus albumin in Hepatorenal syndrome - Need a closer look!
    Hepatology. 2021 Jun 6. doi: 10.1002/hep.31990.
    >> Share

  418. WONG TC, Lee VH, Law AL, Pang HH, et al
    Prospective study of stereotactic body radiation therapy for hepatocellular carcinoma on waitlist for liver transplant.
    Hepatology. 2021 Jun 6. doi: 10.1002/hep.31992.
    >> Share

  419. YANG W, He H, Wang T, Su N, et al
    Single-cell transcriptomic analysis reveals a hepatic stellate cell-activation roadmap and myofibroblast origin during liver fibrosis.
    Hepatology. 2021 Jun 5. doi: 10.1002/hep.31987.
    >> Share

  420. MUHAMMAD KHAN M, Alejandra Luna-Cuadros M, Lau DTY, Sehrawat TS, et al
    Hepatology Highlights.
    Hepatology. 2021;73:2085-2088.
    >> Share

  421. ROSENBLATT R, Lee H, Liapakis A, Lunsford KE, et al
    Equitable access to liver transplant: Bridging the gaps in the social determinants of health.
    Hepatology. 2021 Jun 1. doi: 10.1002/hep.31986.
    >> Share

  422. KULKARNI AV, Kumar P, Sharma M, Menon B, et al
    Letter to the Editor: Living Donor Liver Transplantation or Deceased Donor Liver Transplantation in High Model for End-Stage Liver Disease Score-Which Is Better?
    Hepatology. 2021;73:2619-2620.
    >> Share

  423. VUPPALANCHI R, Loomba R
    Noninvasive Tests to Phenotype Nonalcoholic Fatty Liver Disease: Sequence and Consequences of Arranging the Tools in the Tool Box.
    Hepatology. 2021;73:2095-2098.
    >> Share

  424. CASSINOTTO C, Boursier J, Paisant A, Guiu B, et al
    Transient Versus Two-Dimensional Shear-Wave Elastography in a Multistep Strategy to Detect Advanced Fibrosis in NAFLD.
    Hepatology. 2021;73:2196-2205.
    >> Share

  425. LIN Q, Huang Z, Cai G, Fan X, et al
    Activating Adenosine Monophosphate-Activated Protein Kinase Mediates Fibroblast Growth Factor 1 Protection From Nonalcoholic Fatty Liver Disease in Mice.
    Hepatology. 2021;73:2206-2222.
    >> Share

  426. KENNEDY L, Francis H, Alpini G
    Fructose Promotion of Intestinal and Liver Injury: A Sugar by Any Other Name That Isn't So Sweet.
    Hepatology. 2021;73:2092-2094.
    >> Share

  427. CHO YE, Kim DK, Seo W, Gao B, et al
    Fructose Promotes Leaky Gut, Endotoxemia, and Liver Fibrosis Through Ethanol-Inducible Cytochrome P450-2E1-Mediated Oxidative and Nitrative Stress.
    Hepatology. 2021;73:2180-2195.
    >> Share

  428. MARTINS PN, Clavien PA, Jalan R, Ghinolfi D, et al
    A Call for Randomization in Clinical Trials of Liver Machine Perfusion Preservation.
    Hepatology. 2021;73:2586-2591.
    >> Share

  429. MOON JH, Stormon MO
    Sucrose Toxicity in Infants.
    Hepatology. 2021;73:2607-2609.
    >> Share

  430. AHN JC, Connell A, Simonetto DA, Hughes C, et al
    Application of Artificial Intelligence for the Diagnosis and Treatment of Liver Diseases.
    Hepatology. 2021;73:2546-2563.
    >> Share

  431. HOOFNAGLE JH, Bonkovsky HL, Phillips EJ, Li YJ, et al
    HLA-B*35:01 and Green Tea-Induced Liver Injury.
    Hepatology. 2021;73:2484-2493.
    >> Share

  432. KYRITSI K, Kennedy L, Meadows V, Hargrove L, et al
    Mast Cells Induce Ductular Reaction Mimicking Liver Injury in Mice Through Mast Cell-Derived Transforming Growth Factor Beta 1 Signaling.
    Hepatology. 2021;73:2397-2410.
    >> Share

    May 2021
  433. VIVEIROS A, Schaefer B, Panzer M, Henninger B, et al
    MRI-based Iron Phenotyping and Patient Selection for Next-Generation Sequencing of non-HFE Hemochromatosis Genes.
    Hepatology. 2021 May 28. doi: 10.1002/hep.31982.
    >> Share

  434. LEPORE A, Choy PM, Lee NC, Carella MA, et al
    Phosphorylation and stabilization of PIN1 by JNK promote intrahepatic cholangiocarcinoma growth.
    Hepatology. 2021 May 28. doi: 10.1002/hep.31983.
    >> Share

  435. JOHNSTON ME 2ND, Rivas MP, Nicolle D, Gorse A, et al
    Olaparib Inhibits Tumor Growth of Hepatoblastoma in Patient Derived Xenograft Models.
    Hepatology. 2021 May 26. doi: 10.1002/hep.31919.
    >> Share

  436. YI C, Chen L, Ling Z, Liu L, et al
    Lenvatinib Targets FGFR4 to Enhance Antitumor Immune Response of Anti-PD-1 in Hepatocellular Carcinoma.
    Hepatology. 2021 May 26. doi: 10.1002/hep.31921.
    >> Share

  437. SUN LY, Hu JY, Liang L, Tong XM, et al
    Letter to the Editor: Is Male Gender Associated with Increased Liver-related Mortality in Primary Biliary Cholangitis and Cirrhosis?
    Hepatology. 2021 May 22. doi: 10.1002/hep.31916.
    >> Share

  438. JOHN BV, Deng Y, Martin P, Levy C, et al
    Response to "Is Male Gender Associated with Increased Liver-related Mortality in Primary Biliary Cholangitis and Cirrhosis?"
    Hepatology. 2021 May 22. doi: 10.1002/hep.31917.
    >> Share

  439. MEHTA G, Jalan R
    The 'Alter Ego' of Albumin in Cirrhosis.
    Hepatology. 2021 May 18. doi: 10.1002/hep.31908.
    >> Share

  440. BAJAJ JS, Garcia-Tsao G, Reddy KR, O'Leary JG, et al
    Admission urinary and serum metabolites predict renal outcomes in hospitalized patients with cirrhosis.
    Hepatology. 2021 May 18. doi: 10.1002/hep.31907.
    >> Share

  441. JANSSON H, Sparrelid E
    Letter to the Editor: The role of surgery in multiple intrahepatic cholangiocarcinoma should not be dismissed without further analysis.
    Hepatology. 2021 May 18. doi: 10.1002/hep.31905.
    >> Share

  442. MARTINEZ M, Perito ER, Valentino P, Mack CL, et al
    Recurrence of primary sclerosing cholangitis after liver transplant in children: an international observational study.
    Hepatology. 2021 May 18. doi: 10.1002/hep.31911.
    >> Share

  443. LAMARCA A, Santos-Laso A, Utpatel K, La Casta A, et al
    Reply to (20-1119.R1) Surgery for advanced intrahepatic cholangiocarcinoma warrants further investigation.
    Hepatology. 2021 May 17. doi: 10.1002/hep.31904.
    >> Share

  444. PEISELER M, Tacke F
    An unexpected line of defense: hepatoprotective eosinophils in ischemia-reperfusion injury.
    Hepatology. 2021 May 11. doi: 10.1002/hep.31895.
    >> Share

  445. VALSAN A, Verma N, Singh V
    Non-invasive differentiation of porto-sinusoidal vascular disease and cirrhosis: The Devil is in the details!
    Hepatology. 2021 May 11. doi: 10.1002/hep.31896.
    >> Share

  446. ELKRIEF L, Lazareth M, Rautou PE
    Reply to: "Non-invasive differentiation of porto-sinusoidal vascular disease and cirrhosis: The Devil is in the details!"
    Hepatology. 2021 May 11. doi: 10.1002/hep.31894.
    >> Share

  447. DICHTEL LE
    The GLP-1 Receptor Agonist Semaglutide for the Treatment of Nonalcoholic Steatohepatitis.
    Hepatology. 2021 May 6. doi: 10.1002/hep.31886.
    >> Share

  448. BIGGINS SW, Angeli P, Garcia-Tsao G, Gines P, et al
    Diagnosis, evaluation, and management of ascites and hepatorenal syndrome.
    Hepatology. 2021 May 3. doi: 10.1002/hep.31884.
    >> Share

  449. LIU Y, Dou X, Zhou WY, Ding M, et al
    Hepatic SENP2 Controls Systemic Metabolism via SUMOylation-dependent Regulation of Liver-Adipose Tissue Crosstalk.
    Hepatology. 2021 May 2. doi: 10.1002/hep.31881.
    >> Share

  450. BUCKHOLZ A, Jesudian A, Sehrawat TS, Sehrawat O, et al
    Hepatology Highlights.
    Hepatology. 2021;73:1627-1630.
    >> Share


  451. Seeking Editor for Hepatology Communications.
    Hepatology. 2021;73:i.
    >> Share

  452. LEI MML, Lee TKW
    Cancer-Associated Fibroblasts: Orchestrating the Crosstalk Between Liver Cancer Cells and Neutrophils Through the Cardiotrophin-Like Cytokine Factor 1-Mediated Chemokine (C-X-C motif) Ligand 6/TGF-beta Axis.
    Hepatology. 2021;73:1631-1633.
    >> Share

  453. LEE WM, Kaplowitz N
    Alcohol, Fasting, and Therapeutic Dosing of Acetaminophen: A Perfect Storm.
    Hepatology. 2021;73:1634-1636.
    >> Share

  454. LOUVET A, Ntandja Wandji LC, Lemaitre E, Khaldi M, et al
    Acute Liver Injury With Therapeutic Doses of Acetaminophen: A Prospective Study.
    Hepatology. 2021;73:1945-1955.
    >> Share

  455. ASRANI SK, Mellinger J, Arab JP, Shah VH, et al
    Reducing the Global Burden of Alcohol-Associated Liver Disease: A Blueprint for Action.
    Hepatology. 2021;73:2039-2050.
    >> Share

  456. SUNDARAM V, Jalan R, Shah P, Singal AK, et al
    Acute on Chronic Liver Failure From Nonalcoholic Fatty Liver Disease: A Growing and Aging Cohort With Rising Mortality.
    Hepatology. 2021;73:1932-1944.
    >> Share

  457. HAFNER S, Seufferlein T, Kleger A, Muller M, et al
    Aseptic Liver Abscesses as an Exceptional Finding in Cogan's Syndrome.
    Hepatology. 2021;73:2067-2070.
    >> Share

  458. LI Z, Lu X, Liu Y, Zhao J, et al
    Gain of LINC00624 Enhances Liver Cancer Progression by Disrupting the Histone Deacetylase 6/Tripartite Motif Containing 28/Zinc Finger Protein 354C Corepressor Complex.
    Hepatology. 2021;73:1764-1782.
    >> Share

  459. DAVULURI G, Welch N, Sekar J, Gangadhariah M, et al
    Activated Protein Phosphatase 2A Disrupts Nutrient Sensing Balance Between Mechanistic Target of Rapamycin Complex 1 and Adenosine Monophosphate-Activated Protein Kinase, Causing Sarcopenia in Alcohol-Associated Liver Disease.
    Hepatology. 2021;73:1892-1908.
    >> Share

  460. MA Y, Brown PM, Lin DD, Ma J, et al
    17-Beta Hydroxysteroid Dehydrogenase 13 Deficiency Does Not Protect Mice From Obesogenic Diet Injury.
    Hepatology. 2021;73:1701-1716.
    >> Share

  461. DRIEVER EG, Stravitz RT, Zhang J, Adelmeijer J, et al
    VWF/ADAMTS13 Imbalance, But Not Global Coagulation or Fibrinolysis, Is Associated With Outcome and Bleeding in Acute Liver Failure.
    Hepatology. 2021;73:1882-1891.
    >> Share

    April 2021
  462. SHENG J, Kohno S, Okada N, Okahashi N, et al
    Treatment of RB1-intact hepatocellular carcinoma with CDK4/6 inhibitor combination therapy.
    Hepatology. 2021 Apr 30. doi: 10.1002/hep.31872.
    >> Share

  463. BUCKARMA E, Smoot R
    Hepatocytes Induce Change in Their Neighbors by YAP-ing at Them.
    Hepatology. 2021 Apr 30. doi: 10.1002/hep.31874.
    >> Share

  464. ISHIKAWA T, Sasaki R, Matsuda T, Saeki I, et al
    Successful Management with Dual Therapy of Lenvatinib and Macitentan for Hepatocellular Carcinoma with Portopulmonary Hypertension.
    Hepatology. 2021 Apr 26. doi: 10.1002/hep.31865.
    >> Share

  465. LUO Y, Gao Y, Liu W, Yang Y, et al
    MYC-Protein Arginine Methyltransferase 5 Axis Defines the Tumorigenesis and Immune Response in Hepatocellular Carcinoma.
    Hepatology. 2021 Apr 25. doi: 10.1002/hep.31864.
    >> Share

  466. YANG X, Sun D, Xiang H, Wang S, et al
    Hepatocyte SH3RF2 Deficiency is a Key Aggravator for Nonalcoholic Fatty Liver Disease.
    Hepatology. 2021 Apr 24. doi: 10.1002/hep.31863.
    >> Share

  467. LIU D, Pang J, Shao W, Gu J, et al
    Hepatic fibroblast growth factor 21 is involved in mediating functions of liraglutide in mice with dietary challenge.
    Hepatology. 2021 Apr 13. doi: 10.1002/hep.31856.
    >> Share

  468. XU X, Ye L, Zhang Q, Shen H, et al
    Group-2 Innate Lymphoid Cells Promote Hepatocellular Carcinoma Progression via CXCL2-Neutrophil Induced Immunosuppression.
    Hepatology. 2021 Apr 8. doi: 10.1002/hep.31855.
    >> Share

  469. SUN D, Yang X, Wu B, Zhang XJ, et al
    Therapeutic Potential of G Protein-Coupled Receptors against Nonalcoholic Steatohepatitis.
    Hepatology. 2021 Apr 7. doi: 10.1002/hep.31852.
    >> Share

  470. WING-SUM CHEU J, Chak-Lui Wong C
    Mechanistic Rationales guiding Combination Hepatocellular Carcinoma Therapies involving Immune Checkpoint Inhibitors.
    Hepatology. 2021 Apr 3. doi: 10.1002/hep.31840.
    >> Share

  471. KOVALIC AJ, Huang G, Thuluvath PJ, Satapathy SK, et al
    Elevated Liver Biochemistries in Hospitalized Chinese Patients With Severe COVID-19: Systematic Review and Meta-analysis.
    Hepatology. 2021;73:1521-1530.
    >> Share

  472. FU Y, Zhu R, Bai T, Han P, et al
    Clinical Features of Patients Infected With Coronavirus Disease 2019 With Elevated Liver Biochemistries: A Multicenter, Retrospective Study.
    Hepatology. 2021;73:1509-1520.
    >> Share

  473. KAUR SP, Trivedi H, Lau DTY, Bamidele AO, et al
    Hepatology Highlights.
    Hepatology. 2021;73:1245-1247.
    >> Share


  474. Seeking Editor for Hepatology Communications.
    Hepatology. 2021;73:i.
    >> Share

  475. DE ZEGHER F, Ibanez L
    Letter to the Editor: Tackling NAFLD in Adolescent Polycystic Ovary Syndrome: Reducing Liver Fat to Mimic Weight Loss.
    Hepatology. 2021;73:1623-1624.
    >> Share

  476. GOLRIZ M, Ramouz A, Mehrabi A
    Letter to the Editor: Surgical Method for Establishing Posthepatectomy Liver Failure.
    Hepatology. 2021;73:1621.
    >> Share

  477. DHAR D, Loomba R
    Emerging Metabolic and Transcriptomic Signature of PNPLA3-Associated NASH.
    Hepatology. 2021;73:1248-1250.
    >> Share

  478. XU H, Tian Y, Tang D, Zou S, et al
    An Endoplasmic Reticulum Stress-MicroRNA-26a Feedback Circuit in NAFLD.
    Hepatology. 2021;73:1327-1345.
    >> Share

  479. SONG Z, Chen W, Athavale D, Ge X, et al
    Osteopontin Takes Center Stage in Chronic Liver Disease.
    Hepatology. 2021;73:1594-1608.
    >> Share

  480. ALKHOURI N, Reddy GK, Lawitz E
    Oligonucleotide-Based Therapeutics: An Emerging Strategy for the Treatment of Chronic Liver Diseases.
    Hepatology. 2021;73:1581-1593.
    >> Share

  481. ARJUNAN V, Hansen A, Deutzmann A, Sze DY, et al
    Spontaneous Regression of Hepatocellular Carcinoma: When the Immune System Stands Up to Cancer.
    Hepatology. 2021;73:1611-1614.
    >> Share

  482. OSTROUMOV D, Duong S, Wingerath J, Woller N, et al
    Transcriptome Profiling Identifies TIGIT as a Marker of T-Cell Exhaustion in Liver Cancer.
    Hepatology. 2021;73:1399-1418.
    >> Share

  483. CHEN L, Guo P, Li W, Fang F, et al
    Perturbation of Specific Signaling Pathways Is Involved in Initiation of Mouse Liver Fibrosis.
    Hepatology. 2021;73:1551-1569.
    >> Share

    March 2021
  484. NINA KIM H, Newcomb CW, Carbonari DM, Roy JA, et al
    Risk of Hepatocellular Carcinoma with Hepatitis B Viremia among HIV/Hepatitis B Virus-Coinfected Persons in North America.
    Hepatology. 2021 Mar 29. doi: 10.1002/hep.31839.
    >> Share

  485. ROSENBLATT R, Wahid N, Halazun KJ, Kaplan A, et al
    Black Patients Have Unequal Access to Listing for Liver Transplantation in the United States.
    Hepatology. 2021 Mar 29. doi: 10.1002/hep.31837.
    >> Share

  486. DI-LUOFFO M, Pirenne S, Saandi T, Loriot A, et al
    A novel mouse model of cholangiocarcinoma uncovers a role for Tensin-4 in tumor progression.
    Hepatology. 2021 Mar 26. doi: 10.1002/hep.31834.
    >> Share

  487. BOERNER T, Drill E, Pak LM, Nguyen B, et al
    Genetic Determinants of Outcome in Intrahepatic Cholangiocarcinoma.
    Hepatology. 2021 Mar 25. doi: 10.1002/hep.31829.
    >> Share

  488. DOURTHE C, Julien C, Di Tommaso S, Dupuy JW, et al
    Proteomic profiling of hepatocellular adenomas paves the way to new diagnostic and prognostic approaches.
    Hepatology. 2021 Mar 23. doi: 10.1002/hep.31826.
    >> Share

  489. BLOOM PP, Matherly S, Kumar S, Koh C, et al
    Professional Use of Social Media by Hepatology Providers.
    Hepatology. 2021 Mar 20. doi: 10.1002/hep.31824.
    >> Share

  490. SALEM R, Johnson GE, Kim E, Riaz A, et al
    Yttrium-90 Radioembolization for the Treatment of Solitary, Unresectable Hepatocellular Carcinoma: The LEGACY Study.
    Hepatology. 2021 Mar 19. doi: 10.1002/hep.31819.
    >> Share

  491. YASUDO H, Ando T, Maehara A, Ando T, et al
    A possible association between a novel NLRP1 mutation and an autoinflammatory disease involving liver cirrhosis.
    Hepatology. 2021 Mar 19. doi: 10.1002/hep.31818.
    >> Share

  492. ZHAO Y, Wang J, Liu WN, Fong SY, et al
    Analysis and validation of human targets and treatments using a hepatocellular carcinoma-immune humanized mouse model.
    Hepatology. 2021 Mar 18. doi: 10.1002/hep.31812.
    >> Share

  493. LEE YT, Wang JJ, Luu M, Tseng HR, et al
    State-Level Hepatocellular Carcinoma Incidence and Association with Obesity and Physical Activity in the United States.
    Hepatology. 2021 Mar 17. doi: 10.1002/hep.31811.
    >> Share

  494. WADA Y, Shimada M, Yamamura K, Toshima T, et al
    A transcriptomic signature for risk-stratification and recurrence prediction in intrahepatic cholangiocarcinoma.
    Hepatology. 2021 Mar 16. doi: 10.1002/hep.31803.
    >> Share

  495. SANO A, Kakazu E, Hamada S, Inoue J, et al
    Steatotic hepatocytes release mature VLDL via methionine and tyrosine metabolism in a Keap1-Nrf2 dependent manner.
    Hepatology. 2021 Mar 16. doi: 10.1002/hep.31808.
    >> Share

  496. ALEXOPOULOS AS, Crowley MJ, Wang Y, Moylan CA, et al
    Glycemic Control Predicts Severity of Hepatocyte Ballooning and Hepatic Fibrosis in Nonalcoholic Fatty Liver Disease.
    Hepatology. 2021 Mar 16. doi: 10.1002/hep.31806.
    >> Share

  497. CRISTOFERI L, Calvaruso V, Overi D, Vigano M, et al
    Accuracy of Transient Elastography in assessing fibrosis at diagnosis in naive patients with Primary Biliary Cholangitis: a dual cut-off approach.
    Hepatology. 2021 Mar 16. doi: 10.1002/hep.31810.
    >> Share

  498. MEUNIER L, Hirsch TZ, Caruso S, Imbeaud S, et al
    DNA Methylation Signatures Reveal the Diversity of Processes Remodeling Hepatocellular Carcinoma Methylomes.
    Hepatology. 2021 Mar 13. doi: 10.1002/hep.31796.
    >> Share

  499. WU H, Xu X, Zheng A, Wang W, et al
    TIPE1 Inhibits Hepatic Steatosis, Inflammation, and Fibrosis by Suppressing Polyubiquitination of ASK1.
    Hepatology. 2021 Mar 13. doi: 10.1002/hep.31801.
    >> Share

  500. BALDASSARRE M, Naldi M, Zaccherini G, Bartoletti M, et al
    Determination of effective albumin in patients with decompensated cirrhosis: clinical and prognostic implications.
    Hepatology. 2021 Mar 12. doi: 10.1002/hep.31798.
    >> Share

  501. SATHIYAPALAN A, Legault K, van der Pol CB, Meyers BM, et al
    Paraneoplastic Polyarthritis in Hepatocellular Carcinoma Treated with Lenvatinib.
    Hepatology. 2021 Mar 11. doi: 10.1002/hep.31794.
    >> Share

  502. KENDRE G, Marhenke S, Lorz G, Becker D, et al
    The co-mutational spectrum determines the therapeutic response in murine FGFR2 fusion - driven cholangiocarcinoma.
    Hepatology. 2021 Mar 11. doi: 10.1002/hep.31799.
    >> Share

  503. SONG M, He J, Pan QZ, Yang J, et al
    Cancer-associated fibroblast-mediated cellular crosstalk supports hepatocellular carcinoma progression.
    Hepatology. 2021 Mar 8. doi: 10.1002/hep.31792.
    >> Share

  504. PONZIANI FR, Gasbarrini A, Pompili M
    Letter to the Editor. Restructuring the Gut Microbiota of Cirrhotic Patients after HCV Eradication: a Matter of Time?
    Hepatology. 2021 Mar 5. doi: 10.1002/hep.31784.
    >> Share

  505. VAN WESSEL DBE, Thompson RJ, Gonzales E, Jankowska I, et al
    Impact of Genotype, Serum Bile Acids, and Surgical Biliary Diversion on Native Liver Survival in FIC1 Deficiency.
    Hepatology. 2021 Mar 5. doi: 10.1002/hep.31787.
    >> Share

  506. VANDERWERKEN D, Wood NL, Segev D, Gentry S, et al
    The Precise Relationship Between MELD and Survival Without a Liver Transplant.
    Hepatology. 2021 Mar 2. doi: 10.1002/hep.31781.
    >> Share

  507. ZHOU Y, Chen Y, Zhang X, Xu Q, et al
    Brg1 Inhibition Prevents Liver Fibrosis and Cholangiocarcinoma by Attenuating Progenitor Expansion.
    Hepatology. 2021 Mar 2. doi: 10.1002/hep.31780.
    >> Share


  508. Seeking Editor for Hepatology Communications.
    Hepatology. 2021;73:i.
    >> Share

  509. HANIF H, Ali MJ, Chen HW, Lau DTY, et al
    Hepatology Highlights.
    Hepatology. 2021;73:877-880.
    >> Share

  510. BLOOM PP, Meyerowitz EA, Reinus Z, Daidone M, et al
    Liver Biochemistries in Hospitalized Patients With COVID-19.
    Hepatology. 2021;73:890-900.
    >> Share

  511. MCHENRY SA, Davidson NO
    Ceramide Salvage, Gut Mucosal Immunoglobulin A Signaling, and Diet-Induced NASH.
    Hepatology. 2021;73:884-886.
    >> Share

  512. MELLINGER J, Winder GS, Fernandez AC
    Measuring the Alcohol in Alcohol-Associated Liver Disease: Choices and Challenges for Clinical Research.
    Hepatology. 2021;73:1207-1212.
    >> Share

  513. WEGERMANN K, Suzuki A, Mavis AM, Abdelmalek MF, et al
    Tackling Nonalcoholic Fatty Liver Disease: Three Targeted Populations.
    Hepatology. 2021;73:1199-1206.
    >> Share

  514. PAPAROUPA M, Schrader J, Jung C, Boenisch O, et al
    Bilateral Hematothorax Without Hematemesis-An Unusual Presentation of Variceal Bleeding.
    Hepatology. 2021;73:1233-1235.
    >> Share

  515. GODBEE M, Jakate S, Eswaran S
    A Case of Electronic Nicotine Delivery Systems (ENDS) Liver Injury.
    Hepatology. 2021;73:1230-1232.
    >> Share

  516. YOUNOSSI ZM, Rinella ME, Sanyal AJ, Harrison SA, et al
    From NAFLD to MAFLD: Implications of a Premature Change in Terminology.
    Hepatology. 2021;73:1194-1198.
    >> Share

  517. PROTCHENKO O, Baratz E, Jadhav S, Li F, et al
    Iron Chaperone Poly rC Binding Protein 1 Protects Mouse Liver From Lipid Peroxidation and Steatosis.
    Hepatology. 2021;73:1176-1193.
    >> Share

    February 2021
  518. NEWBERRY EP, Hall Z, Xie Y, Molitor EA, et al
    Liver specific deletion of mouse Tm6sf2 promotes steatosis, fibrosis and hepatocellular cancer.
    Hepatology. 2021 Feb 27. doi: 10.1002/hep.31771.
    >> Share

  519. CHIU M, Garabon J, Chen L, Karp N, et al
    Mevalonic Aciduria Associated with Intrahepatic Bile Duct Paucity.
    Hepatology. 2021 Feb 27. doi: 10.1002/hep.31778.
    >> Share

  520. HERCUN J, Parikh E, Kleiner DE, Fuss I, et al
    Recurrent nodular regenerative hyperplasia post-liver transplantation in common variable immunodeficiency.
    Hepatology. 2021 Feb 27. doi: 10.1002/hep.31775.
    >> Share

  521. SHIOTA J, Samuelson LC, Razumilava N
    Hepatobiliary organoids and their applications for studies of liver health and disease: are we there yet?
    Hepatology. 2021 Feb 26. doi: 10.1002/hep.31772.
    >> Share

  522. SU T, Huang M, Liao J, Lin S, et al
    Insufficient Radiofrequency Ablation Promotes Hepatocellular Carcinoma Metastasis through m(6) A mRNA Methylation Dependent Mechanism.
    Hepatology. 2021 Feb 26. doi: 10.1002/hep.31766.
    >> Share

  523. JOHN BV, Aitcheson G, Schwartz KB, Shabbir Khakoo N, et al
    Male Gender is Associated with Higher Rates of Liver-related Mortality in Primary Biliary Cholangitis and Cirrhosis.
    Hepatology. 2021 Feb 26. doi: 10.1002/hep.31776.
    >> Share

  524. HUANG DQ, Yeo YH, Nguyen MH
    Letter to the Editor: HCC surveillance in cirrhosis patients: Is the real-world situation even worse than reported?
    Hepatology. 2021 Feb 22. doi: 10.1002/hep.31760.
    >> Share

  525. RICH NE, Parikh ND, Singal AG
    HCC Surveillance in Cirrhosis Patients: Room for Improvement.
    Hepatology. 2021 Feb 22. doi: 10.1002/hep.31762.
    >> Share

  526. YAMASHITA T, Koshikawa N, Shimakami T, Terashima T, et al
    Serum laminin gamma2 monomer as a novel diagnostic and predictive biomarker for hepatocellular carcinoma.
    Hepatology. 2021 Feb 20. doi: 10.1002/hep.31758.
    >> Share

  527. BARROW F, Khan S, Fredrickson G, Wang H, et al
    Microbiota-Driven Activation of Intrahepatic B Cells Aggravates Nonalcoholic Steatohepatitis through Innate and Adaptive Signaling.
    Hepatology. 2021 Feb 20. doi: 10.1002/hep.31755.
    >> Share

  528. QU C, He L, Yao N, Li J, et al
    Myofibroblast-specific Msi2 knockout inhibits hepatocellular carcinoma progression in a mouse model.
    Hepatology. 2021 Feb 20. doi: 10.1002/hep.31754.
    >> Share

  529. LAN T, Yu Y, Zhang J, Li H, et al
    Cordycepin Ameliorates Nonalcoholic Steatohepatitis via Activation of AMP-Activated Protein Kinase Signaling Pathway.
    Hepatology. 2021 Feb 12. doi: 10.1002/hep.31749.
    >> Share

  530. DAT NQ, Thuy LTT, Hieu VN, Hai H, et al
    6His-tagged Recombinant Human Cytoglobin Deactivates Hepatic Stellate Cells and Inhibits Liver Fibrosis by Scavenging Reactive Oxygen Species.
    Hepatology. 2021 Feb 11. doi: 10.1002/hep.31752.
    >> Share

  531. YOU Z, Li Y, Wang Q, Zhao Z, et al
    The Clinical Significance of Hepatic CD69(+) CD103(+) CD8(+) Resident Memory T Cells in Autoimmune Hepatitis.
    Hepatology. 2021 Feb 8. doi: 10.1002/hep.31739.
    >> Share

  532. MOHANTY SK, Donnelly B, Temple H, Ortiz-Perez A, et al
    HMGB1 release by cholangiocytes governs biliary atresia pathogenesis and correlates with increases in afflicted infants.
    Hepatology. 2021 Feb 8. doi: 10.1002/hep.31745.
    >> Share

  533. LAMARCA A, Santos-Laso A, Utpatel K, La Casta A, et al
    Reply to "Does multiple intrahepatic cholangiocarcinoma worsen prognosis as "M1" stage?"; multiple primaries vs liver metastases.
    Hepatology. 2021 Feb 7. doi: 10.1002/hep.31740.
    >> Share

  534. ROSENTHAL SB, Liu X, Ganguly S, Dhar D, et al
    Heterogeneity of hepatic stellate cells in a mouse model of non-alcoholic steatohepatitis (NASH).
    Hepatology. 2021 Feb 7. doi: 10.1002/hep.31743.
    >> Share

  535. ZHANG XF, Lv Y, Pawlik TM
    Letter to the editor: Does multiple intrahepatic cholangiocarcinoma worsen prognosis as "M1" stage?
    Hepatology. 2021 Feb 6. doi: 10.1002/hep.31741.
    >> Share

  536. KE W, Cai De L, Jian Nan S, Chun Nian W, et al
    Primary Hepatic Squamous Cell Carcinoma With MSI-H Shows Good Response to PD-1 Inhibitor as Adjuvant Therapy.
    Hepatology. 2021 Feb 5. doi: 10.1002/hep.31737.
    >> Share

  537. NASSER-GHODSI N, Mara K, Watt KD
    De novo Colorectal and Pancreatic Cancer in Liver Transplant Recipients: Identifying the Higher Risk Populations.
    Hepatology. 2021 Feb 5. doi: 10.1002/hep.31731.
    >> Share

  538. TAO J, Krutsenko Y, Moghe A, Singh S, et al
    Nrf2 and beta-catenin coactivation in hepatocellular cancer: Biological and therapeutic implications.
    Hepatology. 2021 Feb 2. doi: 10.1002/hep.31730.
    >> Share

  539. SANSOE G, Aragno M, Wong F
    Covid-19 and liver cirrhosis: focus on the non-classical renin-angiotensin system and implications for therapy.
    Hepatology. 2021 Feb 1. doi: 10.1002/hep.31728.
    >> Share


  540. Seeking Editor for Hepatology Communications.
    Hepatology. 2021;73:1.
    >> Share

  541. BUCKHOLZ A, Brown RS Jr, Parthasarathy G, Schwartz RE, et al
    Hepatology Highlights.
    Hepatology. 2021;73:475-478.
    >> Share

  542. KARDASHIAN A, Wilder J, Terrault NA, Price JC, et al
    Addressing Social Determinants of Liver Disease During the COVID-19 Pandemic and Beyond: A Call to Action.
    Hepatology. 2021;73:811-820.
    >> Share

  543. DI GUGLIELMO MD, Perito ER
    To Juice or Not to Juice: Fatty Liver Repercussions for Infants.
    Hepatology. 2021;73:483-485.
    >> Share

  544. PIROLA CJ, Sookoian S
    NAFLD and Cardiometabolic Risk Factors: The Liver Fibrosis Trajectory Through the Lens of Biological Interactions.
    Hepatology. 2021;73:479-482.
    >> Share

  545. GEURTSEN ML, Santos S, Gaillard R, Felix JF, et al
    Associations Between Intake of Sugar-Containing Beverages in Infancy With Liver Fat Accumulation at School Age.
    Hepatology. 2021;73:560-570.
    >> Share

  546. TILG H, Adolph TE, Moschen AR
    Multiple Parallel Hits Hypothesis in Nonalcoholic Fatty Liver Disease: Revisited After a Decade.
    Hepatology. 2021;73:833-842.
    >> Share

  547. AL-NAAMANI N, Krowka MJ, Forde KA, Krok KL, et al
    Estrogen Signaling and Portopulmonary Hypertension: The Pulmonary Vascular Complications of Liver Disease Study (PVCLD2).
    Hepatology. 2021;73:726-737.
    >> Share

  548. JUNG YS, Stratton SA, Lee SH, Kim MJ, et al
    TMEM9-v-ATPase Activates Wnt/beta-Catenin Signaling Via APC Lysosomal Degradation for Liver Regeneration and Tumorigenesis.
    Hepatology. 2021;73:776-794.
    >> Share

  549. HU W, Zheng S, Guo H, Dai B, et al
    PLAGL2-EGFR-HIF-1/2alpha Signaling Loop Promotes HCC Progression and Erlotinib Insensitivity.
    Hepatology. 2021;73:674-691.
    >> Share

  550. ZUO Q, He J, Zhang S, Wang H, et al
    PPARgamma Coactivator-1alpha Suppresses Metastasis of Hepatocellular Carcinoma by Inhibiting Warburg Effect by PPARgamma-Dependent WNT/beta-Catenin/Pyruvate Dehydrogenase Kinase Isozyme 1 Axis.
    Hepatology. 2021;73:644-660.
    >> Share

    January 2021
  551. ITOH A, Adams D, Huang W, Wu Y, et al
    Enoxacin upregulates microRNA biogenesis and downregulates cytotoxic CD8 T cell function in autoimmune cholangitis.
    Hepatology. 2021 Jan 19. doi: 10.1002/hep.31724.
    >> Share

  552. KALASEKAR SM, Garrido-Laguna I, Evason KJ
    Immune Checkpoint Inhibitors in Novel Combinations for Hepatocellular Carcinoma.
    Hepatology. 2021 Jan 12. doi: 10.1002/hep.31706.
    >> Share

  553. CARACENI P, Vargas V, Sola E, Alessandria C, et al
    The use of Rifaximin in Patients with Cirrhosis.
    Hepatology. 2021 Jan 9. doi: 10.1002/hep.31708.
    >> Share

  554. LUCE E, Messina A, Duclos-Vallee JC, Dubart-Kupperschmitt A, et al
    Advanced techniques and awaited clinical applications for human pluripotent stem cell differentiation into hepatocytes.
    Hepatology. 2021 Jan 8. doi: 10.1002/hep.31705.
    >> Share

  555. WELLHONER F, Doscher N, Woelfl F, Vital M, et al
    Eradication of chronic HCV infection: improvement of dysbiosis only in patients without liver cirrhosis.
    Hepatology. 2021 Jan 7. doi: 10.1002/hep.31700.
    >> Share

  556. SATIYA J, Kaur SP, Lau DTY, Hejazifar N, et al
    Hepatology Highlights.
    Hepatology. 2021;73:1-3.
    >> Share

  557. JAESCHKE H, Ramachandran A
    Letter to the Editor: Does c-Jun N-Terminal Kinase Regulate Acetaminophen Hepatotoxicity by Modulating Nuclear Factor Erythroid 2-Related Factor 2-Dependent Genes or Mitochondrial Oxidant Stress?
    Hepatology. 2021;73:467-468.
    >> Share

  558. TANG X, Wang XJ
    REPLY.
    Hepatology. 2021;73:468-469.
    >> Share

  559. CHOI J, Lim YS
    REPLY.
    Hepatology. 2021;73:467.
    >> Share

  560. CASEY L, Aday A, Rule J, Lee WM, et al
    Letter to the Editor: Response to Letter Concerning Our Pregnancy Manuscript.
    Hepatology. 2021;73:465.
    >> Share

  561. NORTHUP PG, Garcia-Pagan JC, Garcia-Tsao G, Intagliata NM, et al
    Vascular Liver Disorders, Portal Vein Thrombosis, and Procedural Bleeding in Patients With Liver Disease: 2020 Practice Guidance by the American Association for the Study of Liver Diseases.
    Hepatology. 2021;73:366-413.
    >> Share

  562. SARKAR M, Brady CW, Fleckenstein J, Forde KA, et al
    Reproductive Health and Liver Disease: Practice Guidance by the American Association for the Study of Liver Diseases.
    Hepatology. 2021;73:318-365.
    >> Share

  563. DE JONGHE S, Weinstock D, Aligo J, Washington K, et al
    Biopsy Pathology and Immunohistochemistry of a Case of Immune-Mediated Drug-Induced Liver Injury With Atabecestat.
    Hepatology. 2021;73:452-455.
    >> Share

  564. LEONIS MA, Miethke AG, Fei L, Maynor S, et al
    Four Biomarkers Linked to Activation of Cluster of Differentiation 8-Positive Lymphocytes Predict Clinical Outcomes in Pediatric Acute Liver Failure.
    Hepatology. 2021;73:233-246.
    >> Share

  565. LI YJ, Phillips EJ, Dellinger A, Nicoletti P, et al
    Human Leukocyte Antigen B*14:01 and B*35:01 Are Associated With Trimethoprim-Sulfamethoxazole Induced Liver Injury.
    Hepatology. 2021;73:268-281.
    >> Share

  566. MORENO E, Toussaint MJM, van Essen SC, Bongiovanni L, et al
    E2F7 Is a Potent Inhibitor of Liver Tumor Growth in Adult Mice.
    Hepatology. 2021;73:303-317.
    >> Share

  567. GU L, Zhu Y, Lin X, Lu B, et al
    The IKKbeta-USP30-ACLY Axis Controls Lipogenesis and Tumorigenesis.
    Hepatology. 2021;73:160-174.
    >> Share

  568. ZHOU B, Liu C, Xu L, Yuan Y, et al
    N(6) -Methyladenosine Reader Protein YT521-B Homology Domain-Containing 2 Suppresses Liver Steatosis by Regulation of mRNA Stability of Lipogenic Genes.
    Hepatology. 2021;73:91-103.
    >> Share

  569. CABALLERO-CAMINO FJ, Rivilla I, Herraez E, Briz O, et al
    Synthetic Conjugates of Ursodeoxycholic Acid Inhibit Cystogenesis in Experimental Models of Polycystic Liver Disease.
    Hepatology. 2021;73:186-203.
    >> Share

  570. FENG GS, Hanley KL, Liang Y, Lin X, et al
    Improving the Efficacy of Liver Cancer Immunotherapy: The Power of Combined Preclinical and Clinical Studies.
    Hepatology. 2021;73 Suppl 1:104-114.
    >> Share

  571. RIZVI S, Wang J, El-Khoueiry AB
    Liver Cancer Immunity.
    Hepatology. 2021;73 Suppl 1:86-103.
    >> Share

  572. CARUSO S, O'Brien DR, Cleary SP, Roberts LR, et al
    Genetics of Hepatocellular Carcinoma: Approaches to Explore Molecular Diversity.
    Hepatology. 2021;73 Suppl 1:14-26.
    >> Share

  573. LU X, Paliogiannis P, Calvisi DF, Chen X, et al
    Role of the Mammalian Target of Rapamycin Pathway in Liver Cancer: From Molecular Genetics to Targeted Therapies.
    Hepatology. 2021;73 Suppl 1:49-61.
    >> Share

  574. PEA A, Jamieson NB, Braconi C
    Biology and Clinical Application of Regulatory RNAs in Hepatocellular Carcinoma.
    Hepatology. 2021;73 Suppl 1:38-48.
    >> Share

    December 2020
  575. PINATO DJ, Fessas P, Sapisochin G, Marron TU, et al
    Perspectives on the neoadjuvant use of immunotherapy in hepatocellular carcinoma.
    Hepatology. 2020 Dec 28. doi: 10.1002/hep.31697.
    >> Share

  576. ELKRIEF L, Lazareth M, Chevret S, Paradis V, et al
    Liver stiffness by transient elastography to detect porto-sinusoidal vascular liver disease with portal hypertension.
    Hepatology. 2020 Dec 21. doi: 10.1002/hep.31688.
    >> Share

  577. ANANIA FA, Dimick-Santos L, Mehta R, Toerner J, et al
    Nonalcoholic Steatohepatitis: Current Thinking from the Division of Hepatology and Nutrition at the Food and Drug Administration.
    Hepatology. 2020 Dec 19. doi: 10.1002/hep.31687.
    >> Share

  578. VIVEIROS A, Beliveau V, Panzer M, Schaefer B, et al
    Neurodegeneration in Hepatic and Neurologic Wilson Disease.
    Hepatology. 2020 Dec 14. doi: 10.1002/hep.31681.
    >> Share

  579. LIOU H, Mody K, Boyle AW, Keaveny AP, et al
    Neoadjuvant Radiation Lobectomy and Immunotherapy for Angioinvasive Hepatocellular Carcinoma Resulting in Complete Pathologic Response.
    Hepatology. 2020 Dec 7. doi: 10.1002/hep.31675.
    >> Share

  580. KOUKOULIOTI E, Ziagaki A, Weber SN, Lammert F, et al
    Long-term colestyramine treatment prevents cholestatic attacks in refractory benign recurrent intrahepatic cholestasis type 1 disease.
    Hepatology. 2020 Dec 5. doi: 10.1002/hep.31671.
    >> Share

  581. KEISHAM A, Taneja S, Roy A, Singh V, et al
    ABIDE in NAFLD: A potential game changer in a select cohort of cirrhosis.
    Hepatology. 2020 Dec 4. doi: 10.1002/hep.31667.
    >> Share

  582. ANAND A, Pathak P, Shalimar
    Letter to the editor: ABIDE model for predicting decompensation in non-alcoholic fatty liver disease-related cirrhosis.
    Hepatology. 2020 Dec 3. doi: 10.1002/hep.31668.
    >> Share

  583. BUCKHOLZ A, Brown RS Jr, Trivedi H, Khan MM, et al
    Hepatology Highlights.
    Hepatology. 2020;72:1893-1896.
    >> Share

  584. NOUREDDIN N, Alkhouri N, Brown KA, Noureddin M, et al
    Driving Nonalcoholic Steatohepatitis Forward Using the FibroScan Aspartate Aminotransferase Score, But Obey the Traffic Lights.
    Hepatology. 2020;72:2228-2230.
    >> Share

  585. MEHTA N, Yao FY
    Reply.
    Hepatology. 2020;72:2243-2244.
    >> Share

  586. SELCK TJ, Bok J, Amintavakoli R
    Letter to the Editor: Do Weather and Sunlight Really Affect Alcohol Consumption?
    Hepatology. 2020;72:2239.
    >> Share

  587. VENTURA-COTS M, Abraldes JG, Bataller R
    Reply.
    Hepatology. 2020;72:2239-2240.
    >> Share

    November 2020
  588. SIMON TG, Chan AT, Huttenhower C
    Microbiome Biomarkers: One Step Closer in NAFLD-Cirrhosis.
    Hepatology. 2020 Nov 29. doi: 10.1002/hep.31660.
    >> Share

  589. KWON HM, Moon YJ, Kim KS, Shin WJ, et al
    Prognostic value of B-type natriuretic peptide in liver transplant patients: Implication in post-transplant mortality.
    Hepatology. 2020 Nov 28. doi: 10.1002/hep.31661.
    >> Share

  590. HERNANDEZ-MEZA G, von Felden J, Gonzalez-Kozlova EE, Garcia-Lezana T, et al
    DNA methylation profiling of human hepatocarcinogenesis.
    Hepatology. 2020 Nov 25. doi: 10.1002/hep.31659.
    >> Share

  591. KHATUN M, Sur S, Steele R, Ray R, et al
    Inhibition of long noncoding RNA Linc-Pint by hepatitis C virus in infected hepatocytes enhances lipogenesis.
    Hepatology. 2020 Nov 24. doi: 10.1002/hep.31656.
    >> Share

  592. MOUSA OY, Juran BD, McCauley BM, Vesterhus MN, et al
    Bile Acid Profiles in Primary Sclerosing Cholangitis and their Ability to Predict Hepatic Decompensation.
    Hepatology. 2020 Nov 23. doi: 10.1002/hep.31652.
    >> Share

  593. SIMONETTO DA, Shah VH, Kamath PS
    Surgery in patients with cirrhosis: as much an art as science.
    Hepatology. 2020 Nov 21. doi: 10.1002/hep.31643.
    >> Share

  594. IOANNOU GN, Liang PS, Locke E, Green P, et al
    Cirrhosis and SARS-CoV-2 infection in US Veterans: risk of infection, hospitalization, ventilation and mortality.
    Hepatology. 2020 Nov 21. doi: 10.1002/hep.31649.
    >> Share

  595. BARMAN PM, VanWagner LB
    Cardiac Risk Assessment in Liver Transplant Candidates: Current Controversies and Future Directions.
    Hepatology. 2020 Nov 20. doi: 10.1002/hep.31647.
    >> Share

  596. LI S, Liu Y, Bai Y, Chen M, et al
    RHOF promotes hepatocellular carcinoma metastasis by altering the metabolic status of cancer cells via RAB3D.
    Hepatology. 2020 Nov 18. doi: 10.1002/hep.31641.
    >> Share

  597. RICH NE, Marrero JA, Singal AG
    Reply: Wang et al, "Should growth pattern of hepatocellular carcinoma be constant and homogenous?"
    Hepatology. 2020 Nov 18. doi: 10.1002/hep.31638.
    >> Share

  598. WANG H, Mao Y, Huang M
    Letter to the Editors: should growth pattern of hepatocellular carcinoma be constant and homogenous?
    Hepatology. 2020 Nov 18. doi: 10.1002/hep.31640.
    >> Share

  599. SETIAWAN VW, Rosen HR
    Stratification of residual risk of hepatocellular carcinoma following HCV clearance with DAA in patients with advanced fibrosis and cirrhosis.
    Hepatology. 2020 Nov 18. doi: 10.1002/hep.31639.
    >> Share

  600. GU X, Sun R, Chen L, Chu S, et al
    Neutral ceramidase mediates nonalcoholic steatohepatitis by regulating monounsaturated fatty acids and gut IgA(+) B cells.
    Hepatology. 2020 Nov 13. doi: 10.1002/hep.31628.
    >> Share

  601. KOKUDO T
    Evaluating Liver Function in Patients With Cirrhosis.
    Hepatology. 2020 Nov 13. doi: 10.1002/hep.31626.
    >> Share

  602. LOUSTAUD-RATTI V, Anneraud A, Carrier P, Debette-Gratien M, et al
    Letter to the Editor: Post-Liver Transplantation Sinusoidal Obstruction Syndrome and immunosuppressive drugs: causality of MMF or tacrolimus?
    Hepatology. 2020 Nov 13. doi: 10.1002/hep.31633.
    >> Share

  603. LOOMBA R
    MRI-PDFF treatment response criteria in nonalcoholic steatohepatitis.
    Hepatology. 2020 Nov 11. doi: 10.1002/hep.31624.
    >> Share

  604. HUO TI, Liu PH, Hsu CY
    Using circulating biomarkers to stage hepatocellular carcinoma: Pitfalls and limitations.
    Hepatology. 2020 Nov 10. doi: 10.1002/hep.31618.
    >> Share

  605. SUN L, Guan A, Liu M, Mao Y, et al
    Letter to the editor: Comment on "HepatoScore-14: Measures of biological heterogeneity significantly improve prediction of hepatocellular carcinoma risk".
    Hepatology. 2020 Nov 10. doi: 10.1002/hep.31621.
    >> Share

  606. LOOMBA R, Noureddin M, Kowdley KV, Kohli A, et al
    Combination therapies including cilofexor and firsocostat for bridging fibrosis and cirrhosis due to NASH.
    Hepatology. 2020 Nov 10. doi: 10.1002/hep.31622.
    >> Share

  607. GAO J, Wei B, Liu M, Hirsova P, et al
    Endothelial p300 promotes portal hypertension and hepatic fibrosis through CCL2-mediated angiocrine signaling.
    Hepatology. 2020 Nov 7. doi: 10.1002/hep.31617.
    >> Share

  608. KURODA H, Abe T, Fujiwara Y, Nagasawa T, et al
    Contrast-enhanced ultrasonography-based hepatic perfusion for early prediction of prognosis in acute liver failure.
    Hepatology. 2020 Nov 5. doi: 10.1002/hep.31615.
    >> Share

  609. KRISHNAN MS, Rajan Kd A, Park J, Arjunan V, et al
    Genomic analysis of Vascular Invasion in Hepatocellular Carcinoma (HCC) Reveals Molecular Drivers and Predictive Biomarkers.
    Hepatology. 2020 Nov 3. doi: 10.1002/hep.31614.
    >> Share

  610. SMETS L, Verbeek J, Korf H, van der Merwe S, et al
    Improved markers of cholestatic liver injury in patients with primary biliary cholangitis treated with obeticholic acid and bezafibrate.
    Hepatology. 2020 Nov 3. doi: 10.1002/hep.31613.
    >> Share

  611. RUSSO NW, Brown RS Jr, Parthasarathy G, Schwartz RE, et al
    Hepatology Highlights.
    Hepatology. 2020;72:1505-1508.
    >> Share

  612. BANINI BA, P Kumar D, Cazanave S, Seneshaw M, et al
    Identification of a metabolic, transcriptomic and molecular signature of PNPLA3-mediated acceleration of steatohepatitis.
    Hepatology. 2020 Nov 1. doi: 10.1002/hep.31609.
    >> Share

  613. ALKHOURI N, Kohli A, Loomba R, Harrison SA, et al
    Maintaining Patient Safety and Data Integrity of Nonalcoholic Steatohepatitis Clinical Trials During the Severe Acute Respiratory Syndrome-Coronavirus 2 Pandemic.
    Hepatology. 2020;72:1509-1513.
    >> Share

  614. BERTOLINI A, van de Peppel IP, Bodewes FAJA, Moshage H, et al
    Abnormal Liver Function Tests in Patients With COVID-19: Relevance and Potential Pathogenesis.
    Hepatology. 2020;72:1864-1872.
    >> Share

  615. CAVE MC
    Environmental Pollution and the Developmental Origins of Childhood Liver Disease.
    Hepatology. 2020;72:1518-1521.
    >> Share

  616. JAESCHKE H, Ramachandran A
    Pleiotropic Roles of Platelets and Neutrophils in Cell Death and Recovery During Acetaminophen Hepatotoxicity.
    Hepatology. 2020;72:1873-1876.
    >> Share

  617. SINGH S, Verma N, Singh V
    Letter to the Editor: MELD-Lactate-the New Kid on the Block.
    Hepatology. 2020;72:1883.
    >> Share

    October 2020
  618. LONG MT, Zhang X, Xu H, Liu CT, et al
    Hepatic fibrosis associates with multiple cardiometabolic disease risk factors: The Framingham Heart Study.
    Hepatology. 2020 Oct 30. doi: 10.1002/hep.31608.
    >> Share

  619. XU Y, Zhu Y, Hu S, Xu Y, et al
    Hepatocyte nuclear factor 4alpha prevents the steatosis-to-NASH progression by regulating p53 and bile acid signaling.
    Hepatology. 2020 Oct 23. doi: 10.1002/hep.31604.
    >> Share

  620. STARLINGER P, Pereyra D, Hackl H, Ortmayr G, et al
    Consequences of Perioperative Serotonin Reuptake Inhibitor Treatment during Hepatic Surgery.
    Hepatology. 2020 Oct 20. doi: 10.1002/hep.31601.
    >> Share

  621. LAMARCA A, Santos-Laso A, Utpatel K, La Casta A, et al
    Liver metastases of intrahepatic cholangiocarcinoma: implications for a potential new staging system.
    Hepatology. 2020 Oct 18. doi: 10.1002/hep.31598.
    >> Share

  622. TAN HY, Wang N, Zhang C, Chan YT, et al
    LOXL4 Fosters an Immunosuppressive Microenvironment During Hepatocarcinogenesis.
    Hepatology. 2020 Oct 17. doi: 10.1002/hep.31600.
    >> Share

  623. LI XJ, Li QL, Ju LG, Zhao C, et al
    Deficiency of histone methyltransferase SETD2 in liver leads to abnormal lipid metabolism and hepatocarcinoma.
    Hepatology. 2020 Oct 15. doi: 10.1002/hep.31594.
    >> Share

  624. BROWN SA, Izzy M, Watt KD
    Pharmacotherapy for Weight Loss in Cirrhosis and Liver Transplantation: Translating the Data and Underutilized Potential.
    Hepatology. 2020 Oct 12. doi: 10.1002/hep.31595.
    >> Share

  625. ALONSO S, Manzano ML, Gea F, Gutierrez ML, et al
    A model based on non-invasive markers predicts very low hepatocellular carcinoma risk after viral response in HCV-advanced fibrosis.
    Hepatology. 2020 Oct 6. doi: 10.1002/hep.31588.
    >> Share

  626. YUAN G, Yao J, Yu J, Xie X, et al
    Letter to the Editors: Tenofovir vs. Entecavir on Recurrence of Hepatitis B Virus-Related Hepatocellular Carcinoma After Surgical Resection.
    Hepatology. 2020 Oct 5. doi: 10.1002/hep.31590.
    >> Share

  627. WONG TC, Yan-Yue Fung J, Pang HH, Leung CK, et al
    Analysis of survival benefits of living vs. deceased donor liver transplant in high MELD and hepatorenal syndrome.
    Hepatology. 2020 Oct 2. doi: 10.1002/hep.31584.
    >> Share

  628. ANTKOWIAK M, Green RM
    Telomeres, p53, Hepatocyte Nuclear Factor 4alpha, and Liver Disease.
    Hepatology. 2020;72:1166-1168.
    >> Share

  629. LA MURA V, Villanueva C, Abraldes JG, Bosch J, et al
    Reply.
    Hepatology. 2020;72:1494-1495.
    >> Share

  630. KUNZMANN LK, Schoknecht T, Poch T, Henze L, et al
    Monocytes as Potential Mediators of Pathogen-Induced T-Helper 17 Differentiation in Patients With Primary Sclerosing Cholangitis (PSC).
    Hepatology. 2020;72:1310-1326.
    >> Share

    September 2020
  631. CALZADILLA-BERTOT L, Vilar-Gomez E, Wong VW, Romero-Gomez M, et al
    ABIDE: an accurate predictive model of liver decompensation in patients with non-alcoholic fatty liver-related cirrhosis.
    Hepatology. 2020 Sep 25. doi: 10.1002/hep.31576.
    >> Share

  632. CHANDLER RJ, Venturoni LE, Liao J, Hubbard BT, et al
    Promoterless, nuclease-free genome editing confers a growth advantage for corrected hepatocytes in mice with methylmalonic acidemia.
    Hepatology. 2020 Sep 25. doi: 10.1002/hep.31570.
    >> Share

  633. OOSHIO T, Yamamoto M, Fujii K, Xin B, et al
    Hepatocyte MKK7 Contributes to Restoration of the Liver Parenchyma Following Injury.
    Hepatology. 2020 Sep 23. doi: 10.1002/hep.31565.
    >> Share

  634. ZHANG BH, Cai YS, Song JL, Lyu T, et al
    Letter to the Editor: Statin Reduces the Risk of Hepatocellular Carcinoma Development in CHB Patients.
    Hepatology. 2020 Sep 23. doi: 10.1002/hep.31563.
    >> Share

  635. GOH MJ, Sinn DH, Woo SY, Kim S, et al
    Statins and reduced risk of hepatocellular carcinoma in patients with chronic hepatitis B: Author's Reply.
    Hepatology. 2020 Sep 22. doi: 10.1002/hep.31567.
    >> Share

  636. CHEN D, Wu H, Feng X, Chen Y, et al
    DNA Methylation of CNRIP1 Promotes Pathogenesis of Intrahepatic Cholangiocarcinoma Through Suppressing Parkin-Dependent PKM2 Ubiquitination.
    Hepatology. 2020 Sep 21. doi: 10.1002/hep.31561.
    >> Share

  637. MAHMUD N, Fricker Z, Hubbard RA, Ioannou GN, et al
    Novel Risk Prediction Models for Post-Operative Mortality in Patients with Cirrhosis.
    Hepatology. 2020 Sep 16. doi: 10.1002/hep.31558.
    >> Share

  638. JASPER S, Hakeem AR, Vij M, Sachan D, et al
    First report of toxin-induced graft injury following liver transplantation for Yellow Phosphorus Poisoning.
    Hepatology. 2020 Sep 16. doi: 10.1002/hep.31553.
    >> Share

  639. MARTIN N, Ziegler DV, Parent R, Bernard D, et al
    Hepatic Stellate Cell Senescence in Liver Tumorigenesis.
    Hepatology. 2020 Sep 15. doi: 10.1002/hep.31556.
    >> Share

  640. MORRIS JS, Hassan MM, Zohner YE, Wang Z, et al
    HepatoScore-14: Measures of biological heterogeneity significantly improve prediction of hepatocellular carcinoma risk.
    Hepatology. 2020 Sep 15. doi: 10.1002/hep.31555.
    >> Share

  641. YAZDANI HO, Kaltenmeier C, Morder K, Moon J, et al
    Exercise training decreases hepatic injury via changes in immune response to liver ischemia/reperfusion in mice.
    Hepatology. 2020 Sep 14. doi: 10.1002/hep.31552.
    >> Share

  642. VERMA M, Younossi Z
    Integrating Patient Reported Outcomes within Routine Hepatology Care: A Prompt to Action.
    Hepatology. 2020 Sep 12. doi: 10.1002/hep.31550.
    >> Share

  643. THOMSON MJ, Lok AS, Tapper EB
    Appropriate and Potentially Inappropriate Medication Use in Decompensated Cirrhosis.
    Hepatology. 2020 Sep 10. doi: 10.1002/hep.31548.
    >> Share

  644. ZHEN S, Cai X
    Letter to Editor: Predicting survival after hepatocellular carcinoma resection using deep-learning on histological slides.
    Hepatology. 2020 Sep 7. doi: 10.1002/hep.31543.
    >> Share

  645. CHEN L, Zhou T, White T, O'Brien A, et al
    The apelin-apelin receptor axis triggers cholangiocyte proliferation and liver fibrosis during mouse models of cholestasis.
    Hepatology. 2020 Sep 7. doi: 10.1002/hep.31545.
    >> Share

  646. PIANO S, Gambino C, Vettore E, Calvino V, et al
    Response to Terlipressin and Albumin Is Associated With Improved Liver Transplant Outcomes in Patients With Hepatorenal Syndrome.
    Hepatology. 2020 Sep 1. doi: 10.1002/hep.31529.
    >> Share

  647. PHIPPS MM, Barraza LH, LaSota ED, Sobieszczyk ME, et al
    Acute Liver Injury in COVID-19: Prevalence and Association with Clinical Outcomes in a Large U.S. Cohort.
    Hepatology. 2020;72:807-817.
    >> Share

  648. DA BL, Im GY, Schiano TD
    Coronavirus Disease 2019 Hangover: A Rising Tide of Alcohol Use Disorder and Alcohol-Associated Liver Disease.
    Hepatology. 2020;72:1102-1108.
    >> Share

  649. KAPLAN A, Rosenblatt R, Buckholz A, Kumar S, et al
    Hepatology Highlights.
    Hepatology. 2020;72:791-793.
    >> Share

  650. JIANG X, Ding WX
    Acyl Coenzyme A Thioesterase 9: A Novel Target for Nonalcoholic Fatty Liver Disease by Shuttling Mitochondrial Short-Chain Fatty Acids?
    Hepatology. 2020;72:797-800.
    >> Share

  651. GUICCIARDI ME, Nakao Y, Gores GJ
    The Metabolic Sensor Adenosine Monophosphate-Activated Protein Kinase Regulates Apoptosis in Nonalcoholic Steatohepatitis.
    Hepatology. 2020;72:1139-1141.
    >> Share

  652. KUMAR M
    Reply.
    Hepatology. 2020;72:1160.
    >> Share

  653. WEISS TS, Melter M, Dayoub R
    Letter to the Editor: Does Augmenter of Liver Regeneration Deficiency Pave the Way for Nonalcoholic Steatohepatitis Progression?
    Hepatology. 2020;72:1156-1157.
    >> Share

  654. VERMA AK, Gandhi CR
    Reply.
    Hepatology. 2020;72:1157-1158.
    >> Share

    August 2020
  655. SCHWANTES-AN TH, Darlay R, Mathurin P, Masson S, et al
    Genome-wide association study and meta-analysis on alcohol-related liver cirrhosis identifies novel genetic risk factors.
    Hepatology. 2020 Aug 27. doi: 10.1002/hep.31535.
    >> Share

  656. LOOMBA R, Ling L, Dinh DM, DePaoli AM, et al
    The Commensal Microbe Veillonella as a Marker for Response to an FGF19 Analog in Nonalcoholic Steatohepatitis.
    Hepatology. 2020 Aug 13. doi: 10.1002/hep.31523.
    >> Share

  657. BHUSHAN B, Molina L, Koral K, Stoops JW, et al
    Yap is crucial for CAR-driven hepatocyte proliferation, but not for induction of drug metabolism genes in mice.
    Hepatology. 2020 Aug 13. doi: 10.1002/hep.31521.
    >> Share

  658. LEUNG KK, James PD, Jaberi A, Hirschfield GM, et al
    Esophageal Stenting as Bridge Therapy to Direct Intrahepatic Portocaval Shunt for Refractory Variceal Bleeding.
    Hepatology. 2020 Aug 11. doi: 10.1002/hep.31519.
    >> Share

  659. KULKARNI AV, Sharma M, Kumar P, Gupta R, et al
    Midodrine for Hepatic Hydrothorax.
    Hepatology. 2020 Aug 8. doi: 10.1002/hep.31513.
    >> Share

  660. BANINI BA, Alwatari Y, Ogden N, Gershman E, et al
    Letter to Editor: Response to Commentary "Midodrine for Hepatic Hydrothorax".
    Hepatology. 2020 Aug 7. doi: 10.1002/hep.31512.
    >> Share

  661. LU L, Jiang J, Zhan M, Zhang H, et al
    Targeting Tumor-Associated Antigens in Hepatocellular Carcinoma for Immunotherapy: Past Pitfalls and Future Strategies.
    Hepatology. 2020 Aug 7. doi: 10.1002/hep.31502.
    >> Share

  662. DEGASPERI E, Galmozzi E, Pelusi S, D'Ambrosio R, et al
    Hepatic fat - genetic risk score predicts hepatocellular carcinoma in HCV cirrhotic patients treated with DAAs.
    Hepatology. 2020 Aug 6. doi: 10.1002/hep.31500.
    >> Share

  663. FRISSEN M, Liao L, Schneider KM, Djudjaj S, et al
    Bidirectional role of NLRP3 during acute and chronic cholestatic liver injury.
    Hepatology. 2020 Aug 4. doi: 10.1002/hep.31494.
    >> Share

  664. GINDIN Y, Chung C, Jiang Z, Zhou JZ, et al
    A Fibrosis-Independent Hepatic Transcriptomic Signature Identifies Novel Drivers of Disease Progression in Primary Sclerosing Cholangitis.
    Hepatology. 2020 Aug 3. doi: 10.1002/hep.31488.
    >> Share

  665. VERNA EC, Serper M, Chu J, Corey K, et al
    Clinical Research in Hepatology in the COVID-19 Pandemic and Post-Pandemic Era: Challenges and the Need for Innovation.
    Hepatology. 2020 Aug 2. doi: 10.1002/hep.31491.
    >> Share

  666. WANGENSTEEN KJ, Chang KM
    Multiple roles for hepatitis B and C viruses and the host in the development of hepatocellular carcinoma.
    Hepatology. 2020 Aug 1. doi: 10.1002/hep.31481.
    >> Share

  667. TALAT A, Shah PA, Lau DTY, Russo NW, et al
    Hepatology Highlights.
    Hepatology. 2020;72:369-370.
    >> Share

  668. SERPER M, Cubell AW, Deleener ME, Casher TK, et al
    Telemedicine in Liver Disease and Beyond: Can the COVID-19 Crisis Lead to Action?
    Hepatology. 2020;72:723-728.
    >> Share

  669. WEN Y, Ju C
    MER Proto-Oncogene Tyrosine Kinase: A Novel Potential Target to Treat Nonalcoholic Steatohepatitis Fibrosis.
    Hepatology. 2020;72:772-774.
    >> Share

  670. SINHA RA, Bruinstroop E, Singh BK, Yen PM, et al
    Thyroid Hormones and Thyromimetics: A New Approach to Nonalcoholic Steatohepatitis?
    Hepatology. 2020;72:770-771.
    >> Share

  671. GAWRIEH S, Kleiner DE, Chalasani N, Vanderbeck S, et al
    Letter to the Editor: Quantitative Histological Assessment in Nonalcoholic Fatty Liver Disease.
    Hepatology. 2020;72:785.
    >> Share

  672. WEI L, Chang PEJ, Anstee QM
    Reply.
    Hepatology. 2020;72:786.
    >> Share

  673. KWON HM, Hwang GS
    Reply.
    Hepatology. 2020;72:784.
    >> Share

  674. HUANG JF, Dai CY, Yu ML, Chuang WL, et al
    Letter to the Editor: Regional Epidemics of Nonalcoholic Fatty Liver Disease: Timing of Westernization and Ethnicity Matter.
    Hepatology. 2020;72:781.
    >> Share

    July 2020
  675. LV Y, Wang Z, Li K, Wang Q, et al
    Risk Stratification based on CLIF Consortium Acute Decompensation score in Patients with Child-Pugh B Cirrhosis and Acute Variceal Bleeding.
    Hepatology. 2020 Jul 24. doi: 10.1002/hep.31478.
    >> Share

  676. AMZAL R, Thebaut A, Lapalus M, Almes M, et al
    Pharmacological premature termination codon readthrough of ABCB11 in bile salt export pump deficiency: an in vitro study.
    Hepatology. 2020 Jul 23. doi: 10.1002/hep.31476.
    >> Share

  677. SABERI B, Naik H, Overbey JR, Erwin AL, et al
    Hepatocellular Carcinoma in Acute Hepatic Porphyrias: Results from the Longitudinal Study of the U.S. Porphyrias Consortium.
    Hepatology. 2020 Jul 18. doi: 10.1002/hep.31460.
    >> Share

  678. LISMAN T
    Hemostatic Changes of Acute Kidney Injury in Patients With Cirrhosis: What Do They Mean?
    Hepatology. 2020 Jul 4. doi: 10.1002/hep.31451.
    >> Share

  679. ZANETTO A, Rinder HM, Campello E, Saggiorato G, et al
    Acute kidney injury in decompensated cirrhosis is associated with both hypo- and hyper-coagulable features.
    Hepatology. 2020 Jul 2. doi: 10.1002/hep.31443.
    >> Share

  680. WEI X, Zhao L, Ren R, Ji F, et al
    MiR-125b Loss Activated HIF1alpha/pAKT Loop, Leading to Trans-Arterial Chemoembolization Resistance in Hepatocellular Carcinoma.
    Hepatology. 2020 Jul 1. doi: 10.1002/hep.31448.
    >> Share

  681. WANG Y
    Letter to the Editor: Issues of Circular RNAs as MicroRNA Sponges.
    Hepatology. 2020;72:365.
    >> Share

  682. LI L, Wei Y, Wang H
    REPLY.
    Hepatology. 2020;72:366.
    >> Share

  683. HOOFNAGLE JH
    FXR Agonists as Therapy for Liver Disease.
    Hepatology. 2020;72:1-3.
    >> Share

  684. MALLAT A, Lotersztajn S
    Glutamate Signaling in Alcohol-associated Fatty Liver: "Pas de Deux".
    Hepatology. 2020;72:350-352.
    >> Share

  685. SU T, Iwakiri Y
    Endothelial Leukocyte Cell-Derived Chemotaxin 2/Tyrosine Kinase With Immunoglobulin-Like and Epidermal Growth Factor-Like Domains 1 Signaling in Liver Fibrosis.
    Hepatology. 2020;72:347-349.
    >> Share

  686. YANG JD, Mara KC, Gores GJ, Roberts LR, et al
    Reply.
    Hepatology. 2020;72:364-365.
    >> Share

  687. YANG JD, Mara KC, Gores GJ, Roberts LR, et al
    REPLY.
    Hepatology. 2020;72:362-363.
    >> Share

  688. ARASE Y, Kagawa T, Tanaka A
    Reply.
    Hepatology. 2020;72:360-361.
    >> Share

  689. LLEO A, Ma X, Gershwin ME, Invernizzi P, et al
    Letter to the Editor: Might Denosumab Fit in Primary Biliary Cholangitis Treatment?
    Hepatology. 2020;72:359-360.
    >> Share

    June 2020
  690. PAPATHEODORIDIS GV, Voulgaris T, Papatheodoridi M, Kim WR, et al
    Risk Scores for Hepatocellular Carcinoma in Chronic Hepatitis B: A Promise for Precision Medicine.
    Hepatology. 2020 Jun 30. doi: 10.1002/hep.31440.
    >> Share

  691. KIM BK, Kim SU
    Re: Tenofovir vs. Entecavir on Recurrence of Hepatitis B Virus-Related Hepatocellular Carcinoma after Surgical Resection.
    Hepatology. 2020 Jun 29. doi: 10.1002/hep.31439.
    >> Share

  692. WU J, Gao W, Tang Q, Yu Y, et al
    M2 macrophage-derived exosomes facilitate hepatocarcinoma metastasis by transferring alphaM beta2 integrin to tumor cells.
    Hepatology. 2020 Jun 28. doi: 10.1002/hep.31432.
    >> Share

  693. XU M, Ge C, Zhu L, Qin Y, et al
    iRhom2 promotes hepatic steatosis by activating MAP3K7-dependent pathway.
    Hepatology. 2020 Jun 26. doi: 10.1002/hep.31436.
    >> Share

  694. BANINI BA, Alwatari Y, Stovall M, Ogden N, et al
    Multidisciplinary Management of Hepatic Hydrothorax in 2020: An Evidence-Based Review and Guidance.
    Hepatology. 2020 Jun 25. doi: 10.1002/hep.31434.
    >> Share

  695. AKBULUT S, Sahin TT, Yilmaz S
    Comment on Alpha-Fetoprotein Decrease from > 1.000 to < 500 ng/mL in Patients with Hepatocellular Carcinoma Leads to Improved Posttransplant Outcomes.
    Hepatology. 2020 Jun 24. doi: 10.1002/hep.31433.
    >> Share

  696. KLOECKNER R, Galle PR, Bruix J
    Local and Regional Therapies for Hepatocellular Carcinoma.
    Hepatology. 2020 Jun 18. doi: 10.1002/hep.31424.
    >> Share

  697. KIM YS, Nam HJ, Han CY, Joo MS, et al
    LXRalpha activation inhibits autophagy and lipophagy in hepatocytes by dysregulating ATG4B and Rab-8B, reducing mitochondrial fuel oxidation.
    Hepatology. 2020 Jun 17. doi: 10.1002/hep.31423.
    >> Share

  698. RUSSO MW, Fix OK, Koteish AA, Duggan K, et al
    Modeling the Hepatology Workforce in the United States: A Predicted Critical Shortage.
    Hepatology. 2020 Jun 17. doi: 10.1002/hep.31425.
    >> Share

  699. ZHANG J, Li Y, Liu Q, Huang Y, et al
    Sirt6 alleviated liver fibrosis by deacetylating conserved lysine 54 on Smad2 in hepatic stellate cells.
    Hepatology. 2020 Jun 14. doi: 10.1002/hep.31418.
    >> Share

  700. ALFERINK LJ, Radjabzadeh D, Erler NS, Vojinovic D, et al
    Microbiomics, metabolomics, predicted metagenomics and hepatic steatosis in a population-based study of 1355 adults.
    Hepatology. 2020 Jun 12. doi: 10.1002/hep.31417.
    >> Share

  701. XIE C, Fang JH, Zhuang SM
    Reply to: Letter to the editor, "PDIA3P1 level could predict recurrence-free survival in hepatocellular carcinoma: reliable?" (HEP-20-0942).
    Hepatology. 2020 Jun 11. doi: 10.1002/hep.31300.
    >> Share

  702. MUNROE M, Niero EL, Fok WC, Vessoni AT, et al
    Telomere dysfunction activates p53 and represses HNF4alpha expression leading to impaired human hepatocyte development and function.
    Hepatology. 2020 Jun 9. doi: 10.1002/hep.31414.
    >> Share

  703. PFEIFFER RM, Rotman Y, O'Brien TR
    Genetic Determinants of Cirrhosis and Hepatocellular Carcinoma Due to Fatty Liver Disease: What's the Score?
    Hepatology. 2020 Jun 7. doi: 10.1002/hep.31413.
    >> Share

  704. ZHAO N, Dang H, Ma L, Martin SP, et al
    Intratumoral gammadelta T-cell infiltrates, CCL4/5 protein expression and survival in patients with hepatocellular carcinoma.
    Hepatology. 2020 Jun 5. doi: 10.1002/hep.31412.
    >> Share

  705. ABUD A, Maddur H, Salem R
    Management of symptomatic portal cavernoma cholangiopathy via transplenic portal vein recanalization and TIPS.
    Hepatology. 2020 Jun 5. doi: 10.1002/hep.31411.
    >> Share

  706. PRABHU A, Cargill T, Roberts N, Ryan JD, et al
    Systematic review of the clinical outcomes of iron reduction in Hereditary Hemochromatosis.
    Hepatology. 2020 Jun 4. doi: 10.1002/hep.31405.
    >> Share

  707. KUMAR K, Kulkarni AV
    Sodium-Glucose Cotransporter-2(SGLT2-I) inhibitor are not the magic pills for control of ascites in cirrhosis and diabetes.
    Hepatology. 2020 Jun 3. doi: 10.1002/hep.31399.
    >> Share

  708. PATEL K, Chung C, Myers RP
    Reply to HEP-20-0871 Letter to the Editors: Cilofexor in patients with non-alcoholic steatohepatitis (NASH): Is it really effective?
    Hepatology. 2020 Jun 3. doi: 10.1002/hep.31402.
    >> Share

  709. PATOULIAS D, Katsimardou A, Papadopoulos C, Doumas M, et al
    Letter to the Editor: Sodium-glucose cotransporter 2 inhibitors (SGLT2-I) ameliorate ascites and peripheral edema in patients with cirrhosis and diabetes.
    Hepatology. 2020 Jun 3. doi: 10.1002/hep.31398.
    >> Share

  710. KARDASHIAN A, Ge J, McCulloch CE, Kappus MR, et al
    Identifying an Optimal Liver Frailty Index Cutoff to Predict Waitlist Mortality in Liver Transplant Candidates.
    Hepatology. 2020 Jun 3. doi: 10.1002/hep.31406.
    >> Share

  711. JINDAL A, Sarin SK
    Letter to the Editors: Cilofexor in Patients With Nonalcoholic Steatohepatitis (NASH): Is It Really Effective?
    Hepatology. 2020 Jun 2. doi: 10.1002/hep.31400.
    >> Share

  712. THALJI L, Thalji NM, Heimbach JK, Ibrahim SH, et al
    Renal Function Parameters and Serum Sodium Enhance Prediction of Waitlist Outcomes in Pediatric Liver Transplantation.
    Hepatology. 2020 Jun 2. doi: 10.1002/hep.31397.
    >> Share

  713. LUCEY MR, Singal AK
    Integrated Treatment of Alcohol Use Disorder in Patients With Alcohol-Associated Liver Disease: An Evolving Story.
    Hepatology. 2020;71:1891-1893.
    >> Share

    May 2020
  714. CALVISI DF
    Schistoma mansoni and Hepatocellular Carcinoma: is it all about c-Jun and STAT3?
    Hepatology. 2020 May 28. doi: 10.1002/hep.31392.
    >> Share

  715. HALL Z, Chiarugi D, Charidemou E, Leslie J, et al
    Lipid remodelling in hepatocyte proliferation and hepatocellular carcinoma.
    Hepatology. 2020 May 27. doi: 10.1002/hep.31391.
    >> Share

  716. SMITH JL, Rodriguez TC, Mou H, Kwan SY, et al
    YAP1 withdrawal in hepatoblastoma drives therapeutic differentiation of tumor cells to functional hepatocyte-like cells.
    Hepatology. 2020 May 26. doi: 10.1002/hep.31389.
    >> Share

  717. GUNASEKARAN G, Bekki Y, Lourdusamy V, Schwartz M, et al
    Surgical Treatments of Hepatobiliary Cancers.
    Hepatology. 2020 May 21. doi: 10.1002/hep.31325.
    >> Share

  718. LLOVET JM, Villanueva A, Marrero JA, Schwartz M, et al
    Trial Design and Endpoints in hepatocellular carcinoma: AASLD Consensus Conference.
    Hepatology. 2020 May 20. doi: 10.1002/hep.31327.
    >> Share

  719. DEVARBHAVI H
    RE: Acute Liver Failure (ALF) in Pregnancy: How Much Is Pregnancy-Related? Casey et al. Hepatology 2020 Jan 28[Online ahead of print DOI: 10.1002/hep.31144.
    Hepatology. 2020 May 17. doi: 10.1002/hep.31323.
    >> Share

  720. CHU S, Sun R, Gu X, Chen L, et al
    Inhibition of sphingosine-1-phosphate-induced Th17 cells ameliorates alcoholic steatohepatitis in mice.
    Hepatology. 2020 May 17. doi: 10.1002/hep.31321.
    >> Share

  721. NEWTON KP, Lavine JE, Wilson L, Behling C, et al
    Alanine Aminotransferase and Gamma Glutamyl Transpeptidase Predict Histologic Improvement in Pediatric Nonalcoholic Steatohepatitis.
    Hepatology. 2020 May 16. doi: 10.1002/hep.31317.
    >> Share

  722. GABR A, Kulik L, Mouli S, Riaz A, et al
    Liver Transplantation Following Yttrium-90 Radioembolization: 15-year Experience in 207-Patient Cohort.
    Hepatology. 2020 May 16. doi: 10.1002/hep.31318.
    >> Share

  723. VANDEL J, Dubois-Chevalier J, Gheeraert C, Derudas B, et al
    Hepatic molecular signatures highlight the sexual dimorphism of Non-Alcoholic SteatoHepatitis (NASH).
    Hepatology. 2020 May 11. doi: 10.1002/hep.31312.
    >> Share

  724. WOLF E, Rich NE, Marrero JA, Parikh N, et al
    Utilization of hepatocellular carcinoma surveillance in patients with cirrhosis: A systematic review and meta-analysis.
    Hepatology. 2020 May 8. doi: 10.1002/hep.31309.
    >> Share

  725. FINN RS, Zhu AX
    Evolution of Systemic Therapy for Hepatocellular Carcinoma.
    Hepatology. 2020 May 7. doi: 10.1002/hep.31306.
    >> Share

  726. LI W
    Letter to the Editor: PDIA3P1 level could predict recurrence-free survival in hepatocellular carcinoma: reliable?
    Hepatology. 2020 May 7. doi: 10.1002/hep.31299.
    >> Share

  727. PISA JF, Brown RS Jr, Hirsova P, Schwartz RE, et al
    Hepatology Highlights.
    Hepatology. 2020;71:1527-1529.
    >> Share

  728. KAPLOWITZ N, Than TA, Win S
    Acetaminophen Hepatotoxicity: Strong Offense and Weakened Defense.
    Hepatology. 2020;71:1530-1532.
    >> Share

  729. RAEVENS S, Fallon MB
    PORTICO: First Randomized Controlled Trial of Vasomodulator Therapy in Portopulmonary Hypertension.
    Hepatology. 2020;71:1870-1872.
    >> Share

  730. HENSON JB, Roden M, Targher G, Corey KE, et al
    Is Nonalcoholic Fatty Liver Disease Not a Risk Factor for Cardiovascular Disease: Not Yet Time for a Change of Heart.
    Hepatology. 2020;71:1867-1869.
    >> Share

  731. ABERG F, Farkkila M, Salomaa V, Jula A, et al
    REPLY.
    Hepatology. 2020;71:1888-1889.
    >> Share

  732. GOW P, Testro AG, Hey P, Sinclair M, et al
    Letter to the Editor: Moderate Alcohol Use in Fatty Liver Disease: Don't Throw the Cabernet Out With the Bathwater.
    Hepatology. 2020;71:1887-1888.
    >> Share

  733. MA Y, Brown PM, Rotman Y
    REPLY.
    Hepatology. 2020;71:1886-1887.
    >> Share

  734. GALMOZZI E
    Letter to the Editor: Does the HSD17B13 rs72613567 Splice Variant Actually Yield a New Type of Alternative Splicing?
    Hepatology. 2020;71:1885-1886.
    >> Share

  735. IZZY M, VanWagner LB, Lin G, Altieri M, et al
    Reply.
    Hepatology. 2020;71:1884-1885.
    >> Share

  736. ZHOU J, Zhou F, Wang W, Zhang XJ, et al
    Epidemiological Features of NAFLD From 1999 to 2018 in China.
    Hepatology. 2020;71:1851-1864.
    >> Share

  737. CHEN Y, Liu K, Zhang J, Hai Y, et al
    c-Jun NH2 -Terminal Protein Kinase Phosphorylates the Nrf2-ECH Homology 6 Domain of Nuclear Factor Erythroid 2-Related Factor 2 and Downregulates Cytoprotective Genes in Acetaminophen-Induced Liver Injury in Mice.
    Hepatology. 2020;71:1787-1801.
    >> Share

  738. GAO W, Jia Z, Tian Y, Yang P, et al
    HBx Protein Contributes to Liver Carcinogenesis by H3K4me3 Modification Through Stabilizing WD Repeat Domain 5 Protein.
    Hepatology. 2020;71:1678-1695.
    >> Share

  739. FLEMING BD, Urban DJ, Hall MD, Longerich T, et al
    Engineered Anti-GPC3 Immunotoxin, HN3-ABD-T20, Produces Regression in Mouse Liver Cancer Xenografts Through Prolonged Serum Retention.
    Hepatology. 2020;71:1696-1711.
    >> Share

  740. XIE C, Zhang LZ, Chen ZL, Zhong WJ, et al
    A hMTR4-PDIA3P1-miR-125/124-TRAF6 Regulatory Axis and Its Function in NF kappa B Signaling and Chemoresistance.
    Hepatology. 2020;71:1660-1677.
    >> Share

    April 2020
  741. BEYLS C, Haustermans K, Deroose CM, Pans S, et al
    Could autoimmune disease contribute to the abscopal effect in metastatic hepatocellular carcinoma?
    Hepatology. 2020 Apr 29. doi: 10.1002/hep.31186.
    >> Share

  742. FONDEVILA MF, Fernandez U, Gonzalez-Rellan MJ, Da Silva Lima N, et al
    The L-alpha-lysophosphatidylinositol/GPR55 system induces the development of non-alcoholic steatosis and steatohepatitis.
    Hepatology. 2020 Apr 23. doi: 10.1002/hep.31290.
    >> Share

  743. CHOI J, Jo C, Lim YS
    Tenofovir vs. Entecavir on Recurrence of Hepatitis B Virus-Related Hepatocellular Carcinoma after Surgical Resection.
    Hepatology. 2020 Apr 23. doi: 10.1002/hep.31289.
    >> Share

  744. MCGLYNN KA, Petrick JL, El-Serag HB
    Epidemiology of Hepatocellular Carcinoma.
    Hepatology. 2020 Apr 22. doi: 10.1002/hep.31288.
    >> Share

  745. KUMAR A
    Letter to the Editor: Role of Sorafenib in Liver Transplantation Outcomes of Patients with Hepatocellular Carcinoma Presenting Beyond Milan Criteria?
    Hepatology. 2020 Apr 22. doi: 10.1002/hep.31285.
    >> Share

  746. KARDASHIAN A, Agopian V
    Reply to: "Role of Sorafenib in Liver Transplantation Outcomes of Patients with Hepatocellular Carcinoma Presenting Beyond Milan Criteria?"
    Hepatology. 2020 Apr 20. doi: 10.1002/hep.31283.
    >> Share

  747. MAHMUD N, Asrani SK
    Defining (and refining) the role of the Model for End Stage Liver Disease-Lactate (MELD-LA) score in cirrhosis.
    Hepatology. 2020 Apr 20. doi: 10.1002/hep.31287.
    >> Share

  748. LU L, Jiang J, Zhan M, Zhang H, et al
    Targeting Neoantigens in Hepatocellular Carcinoma for Immunotherapy: A Futile Strategy?
    Hepatology. 2020 Apr 16. doi: 10.1002/hep.31279.
    >> Share

  749. FIX OK, Hameed B, Fontana RJ, Kwok RM, et al
    Clinical Best Practice Advice for Hepatology and Liver Transplant Providers During the COVID-19 Pandemic: AASLD Expert Panel Consensus Statement.
    Hepatology. 2020 Apr 16. doi: 10.1002/hep.31281.
    >> Share

  750. ZHANG L, Tian R, Yao X, Zhang XJ, et al
    Milk Fat Globule-EGF Factor 8 improves Hepatic Steatosis and Inflammation.
    Hepatology. 2020 Apr 15. doi: 10.1002/hep.31277.
    >> Share

  751. MONTALVO-GORDON I, Chi-Cervera LA, Garcia-Tsao G
    Sodium-glucose cotransporter 2 inhibitors (SGLT2-I) ameliorate ascites and peripheral edema in patients with cirrhosis and diabetes.
    Hepatology. 2020 Apr 15. doi: 10.1002/hep.31270.
    >> Share

  752. DAVE S, Park S, Murad MH, Barnard A, et al
    Comparative Effectiveness of Entecavir vs Tenofovir for Preventing Hepatocellular Carcinoma in Patients with Chronic Hepatitis B: a Systematic Review and Meta-analysis.
    Hepatology. 2020 Apr 10. doi: 10.1002/hep.31267.
    >> Share

  753. SERPER M, Weinberg EM, Cohen JB, Reese PP, et al
    Mortality and hepatic decompensation in patients with cirrhosis and atrial fibrillation treated with anticoagulation.
    Hepatology. 2020 Apr 8. doi: 10.1002/hep.31264.
    >> Share

  754. PRIMIGNANI M, Tosetti G, Tripodi A
    Thromboelastography guided blood product transfusion in cirrhosis with coagulopathy: real saving or just less waste?
    Hepatology. 2020 Apr 8. doi: 10.1002/hep.31263.
    >> Share

  755. KUMAR A, Sharma P, Arora A
    A new prognostic algorithm based on stage of cirrhosis and HVPG to improve risk-stratification after variceal bleeding.
    Hepatology. 2020 Apr 4. doi: 10.1002/hep.31254.
    >> Share

  756. LAPUMNUAYPOL K, Danford CJ, Lau DTY, Pisa JF, et al
    Hepatology Highlights.
    Hepatology. 2020;71:1143-1145.
    >> Share

  757. RATZIU V
    Timing Is Everything: Improving NASH Histology in Clinical Trials Should Not Be Rushed.
    Hepatology. 2020;71:1146-1149.
    >> Share

  758. WANG S, Friedman SL
    Taming the Savage Breast From Within: Transcription Factor 21, a Regulator of Stellate Cell Deactivation.
    Hepatology. 2020;71:1150-1153.
    >> Share

  759. HILSCHER MB, Shah VH
    Small but Mighty: Platelets in NASH and Other Chronic Liver Diseases.
    Hepatology. 2020;71:1501-1504.
    >> Share

  760. YKI-JARVINEN H
    Ceramides: A Cause of Insulin Resistance in Nonalcoholic Fatty Liver Disease in Both Murine Models and Humans.
    Hepatology. 2020;71:1499-1501.
    >> Share

  761. HAJIFATHALIAN K, Torabi Sagvand B, McCullough A
    Reply.
    Hepatology. 2020;71:1526.
    >> Share

  762. BRAILLON A
    Letter to the Editor: Modest Alcohol Consumption and Nonalcoholic Fatty Liver Disease: An Oxymoron?
    Hepatology. 2020;71:1525.
    >> Share

  763. CARVAO J, Jasmins L
    Letter to the Editor: Glomerular Filtration Rate Assessment in Liver Disease (GRAIL): Are We There Yet?
    Hepatology. 2020;71:1522-1523.
    >> Share

  764. KHALAF RT, Sokol RJ
    New Insights Into Intestinal Failure-Associated Liver Disease in Children.
    Hepatology. 2020;71:1486-1498.
    >> Share

  765. XIONG X, Kuang H, Liu T, Lin JD, et al
    A Single-Cell Perspective of the Mammalian Liver in Health and Disease.
    Hepatology. 2020;71:1467-1473.
    >> Share

  766. IBRAHIM SH, Jonas MM, Taylor SA, Gutierrez Sanchez LH, et al
    Liver Diseases in the Perinatal Period: Interactions Between Mother and Infant.
    Hepatology. 2020;71:1474-1485.
    >> Share

  767. XIONG J, Liu T, Mi L, Kuang H, et al
    hnRNPU/TrkB Defines a Chromatin Accessibility Checkpoint for Liver Injury and Nonalcoholic Steatohepatitis Pathogenesis.
    Hepatology. 2020;71:1228-1246.
    >> Share

  768. LIU J, Wu Z, Han D, Wei C, et al
    Mesencephalic Astrocyte-Derived Neurotrophic Factor Inhibits Liver Cancer Through Small Ubiquitin-Related Modifier (SUMO)ylation-Related Suppression of NF-kappaB/Snail Signaling Pathway and Epithelial-Mesenchymal Transition.
    Hepatology. 2020;71:1262-1278.
    >> Share

  769. ADAMS JM, Huppert KA, Castro EC, Lopez MF, et al
    Sox9 Is a Modifier of the Liver Disease Severity in a Mouse Model of Alagille Syndrome.
    Hepatology. 2020;71:1331-1349.
    >> Share

  770. CHEN F, Esmaili S, Rogers GB, Bugianesi E, et al
    Lean NAFLD: A Distinct Entity Shaped by Differential Metabolic Adaptation.
    Hepatology. 2020;71:1213-1227.
    >> Share

  771. ZHANG C, Lin R, Li Z, Yang S, et al
    Immune Exhaustion of T Cells in Alveolar Echinococcosis Patients and Its Reversal by Blocking Checkpoint Receptor TIGIT in a Murine Model.
    Hepatology. 2020;71:1297-1315.
    >> Share

  772. SHIGETA K, Datta M, Hato T, Kitahara S, et al
    Dual Programmed Death Receptor-1 and Vascular Endothelial Growth Factor Receptor-2 Blockade Promotes Vascular Normalization and Enhances Antitumor Immune Responses in Hepatocellular Carcinoma.
    Hepatology. 2020;71:1247-1261.
    >> Share

    March 2020
  773. LIU Y, Yang W, VoPham T, Ma Y, et al
    Plant-based and animal-based low-carbohydrate diets and risk of hepatocellular carcinoma among US men and women.
    Hepatology. 2020 Mar 29. doi: 10.1002/hep.31251.
    >> Share

  774. QIN J, Wang H, Qin X, Zhang P, et al
    Perioperative Presentation of COVID-19 Disease in a Liver Transplant Recipient.
    Hepatology. 2020 Mar 27. doi: 10.1002/hep.31257.
    >> Share

  775. SCHWACHA-EIPPER B, Minciuna I, Banz V, Dufour JF, et al
    Immunotherapy as a downstaging therapy for liver transplantation.
    Hepatology. 2020 Mar 14. doi: 10.1002/hep.31234.
    >> Share

  776. ISAACS-TEN A, Echeandia M, Moreno-Gonzalez M, Brion A, et al
    Intestinal microbiome-macrophage crosstalk contributes to cholestatic liver disease by promoting intestinal permeability.
    Hepatology. 2020 Mar 13. doi: 10.1002/hep.31228.
    >> Share

  777. STENDER S, Loomba R
    PNPLA3 Genotype and Risk of Liver and All-Cause Mortality.
    Hepatology. 2020;71:777-779.
    >> Share

  778. TANER T, Heimbach JK
    Something Wicked this Way Comes.
    Hepatology. 2020;71:1119-1121.
    >> Share

  779. WONG GL, Wong VW
    Reply.
    Hepatology. 2020;71:1134.
    >> Share

  780. LO GH
    Letter to the Editor: Could Variceal Screening Stratified by Liver/Spleen Stiffness Replace the Role of Endoscopy?
    Hepatology. 2020;71:1133.
    >> Share

  781. RIZVI S, Gores GJ
    The Two Faces of Relaxin in Cancer: Antitumor or Protumor?
    Hepatology. 2020;71:1117-1119.
    >> Share

  782. SUGIYAMA T
    Letter to the Editor: Bone Health and Denosumab Treatment in Autoimmune Liver Diseases: A Possible Involvement of Physical Activity.
    Hepatology. 2020;71:1131-1132.
    >> Share

  783. ARASE Y, Kagawa T
    Reply.
    Hepatology. 2020;71:1132-1133.
    >> Share

  784. YANG D, Yan J, Weng J
    Reply.
    Hepatology. 2020;71:1129.
    >> Share

  785. LU ZN, Han ZG
    Reply.
    Hepatology. 2020;71:1130-1131.
    >> Share

  786. WANG JB, Bai ZF, Xiao XH
    Letter to the Editor: Is Aristolochic Acid the Major Cause of Liver Cancer in China and Asia?
    Hepatology. 2020;71:1130.
    >> Share

  787. SPANN A, Yasodhara A, Kang J, Watt K, et al
    Applying Machine Learning in Liver Disease and Transplantation: A Comprehensive Review.
    Hepatology. 2020;71:1093-1105.
    >> Share

  788. UNALP-ARIDA A, Ruhl CE
    Patatin-Like Phospholipase Domain-Containing Protein 3 I148M and Liver Fat and Fibrosis Scores Predict Liver Disease Mortality in the U.S. Population.
    Hepatology. 2020;71:820-834.
    >> Share

  789. LU ZN, Luo Q, Zhao LN, Shi Y, et al
    The Mutational Features of Aristolochic Acid-Induced Mouse and Human Liver Cancers.
    Hepatology. 2020;71:929-942.
    >> Share

  790. AJMERA VH, Liu A, Singh S, Yachoa G, et al
    Clinical Utility of an Increase in Magnetic Resonance Elastography in Predicting Fibrosis Progression in Nonalcoholic Fatty Liver Disease.
    Hepatology. 2020;71:849-860.
    >> Share

  791. DE CHIARA F, Thomsen KL, Habtesion A, Jones H, et al
    Ammonia Scavenging Prevents Progression of Fibrosis in Experimental Nonalcoholic Fatty Liver Disease.
    Hepatology. 2020;71:874-892.
    >> Share

  792. CHANG Y, Ryu S, Kim Y, Cho YK, et al
    Low Levels of Alcohol Consumption, Obesity, and Development of Fatty Liver With and Without Evidence of Advanced Fibrosis.
    Hepatology. 2020;71:861-873.
    >> Share

  793. ABERG F, Puukka P, Salomaa V, Mannisto S, et al
    Risks of Light and Moderate Alcohol Use in Fatty Liver Disease: Follow-Up of Population Cohorts.
    Hepatology. 2020;71:835-848.
    >> Share

    February 2020
  794. NAULT JC, Villanueva A
    Biomarkers for hepatobiliary cancers.
    Hepatology. 2020 Feb 11. doi: 10.1002/hep.31175.
    >> Share

  795. DEROO R, Trepo E, Holvoet T, De Pauw M, et al
    Vasomodulators and liver transplantation for portopulmonary hypertension: evidence from a systematic review and meta-analysis.
    Hepatology. 2020 Feb 4. doi: 10.1002/hep.31164.
    >> Share

  796. GUILLOT A, Tacke F
    The Unexpected Role of Neutrophils for Resolving Liver Inflammation by Transmitting MicroRNA-223 to Macrophages.
    Hepatology. 2020;71:749-751.
    >> Share

  797. PANDEY S
    Letter to the Editor: Re: Noninvasive Tests in Advanced Fibrosis Due to Nonalcoholic Steatohepatitis: Critical Insights from STELLAR Trials.
    Hepatology. 2020;71:763-764.
    >> Share

  798. HASSAN S, Sebastian S, Maharjan S, Lesha A, et al
    Liver-on-a-Chip Models of Fatty Liver Disease.
    Hepatology. 2020;71:733-740.
    >> Share

  799. SANDAHL TD, Laursen TL, Munk DE, Vilstrup H, et al
    The Prevalence of Wilson's Disease: An Update.
    Hepatology. 2020;71:722-732.
    >> Share

  800. ARASE Y, Tsuruya K, Hirose S, Ogiwara N, et al
    Efficacy and Safety of 3-Year Denosumab Therapy for Osteoporosis in Patients With Autoimmune Liver Diseases.
    Hepatology. 2020;71:757-759.
    >> Share

  801. PENRICE D, Simonetto DA
    Nodular Regenerative Hyperplasia Associated With Primary Liver Malignancies.
    Hepatology. 2020;71:760-761.
    >> Share

  802. BAIGES A, Turon F, Simon-Talero M, Tasayco S, et al
    Congenital Extrahepatic Portosystemic Shunts (Abernethy Malformation): An International Observational Study.
    Hepatology. 2020;71:658-669.
    >> Share

  803. SCHUMACHER JD, Kong B, Wu J, Rizzolo D, et al
    Direct and Indirect Effects of Fibroblast Growth Factor (FGF) 15 and FGF19 on Liver Fibrosis Development.
    Hepatology. 2020;71:670-685.
    >> Share

  804. ALLEN AM, Shah VH, Therneau TM, Venkatesh SK, et al
    The Role of Three-Dimensional Magnetic Resonance Elastography in the Diagnosis of Nonalcoholic Steatohepatitis in Obese Patients Undergoing Bariatric Surgery.
    Hepatology. 2020;71:510-521.
    >> Share

  805. ARORA V, Maiwall R, Rajan V, Jindal A, et al
    Terlipressin Is Superior to Noradrenaline in the Management of Acute Kidney Injury in Acute on Chronic Liver Failure.
    Hepatology. 2020;71:600-610.
    >> Share

    January 2020
  806. WALLACE D, Cowling T, PcPhail MJ, Brown SE, et al
    Assessing the time-dependent impact of performance status on outcomes after liver transplantation.
    Hepatology. 2020 Jan 22. doi: 10.1002/hep.31124.
    >> Share

  807. NEUSCHWANDER-TETRI BA
    Too Much Sugar-The Not-So-Sweet Reality of Its Impact on Our Health.
    Hepatology. 2020;71:377-379.
    >> Share

  808. THALHEIMER U
    Letter to the Editor: The Obsolescence of Sclerotherapy.
    Hepatology. 2020;71:393.
    >> Share

  809. CHEUNG AC, Walker DI, Juran BD, Miller GW, et al
    Studying the Exposome to Understand the Environmental Determinants of Complex Liver Diseases.
    Hepatology. 2020;71:352-362.
    >> Share

  810. SHANG L, Mashek DG
    The Underpinnings of PNPLA3-Mediated Fatty Liver Emerge.
    Hepatology. 2020;71:375-377.
    >> Share

  811. JANSSON-KNODELL CL, Gawrieh S, McIntyre AD, Liang T, et al
    Apolipoprotein B and PNPLA3 Double Heterozygosity in a Father-Son Pair With Advanced Nonalcoholic Fatty Liver Disease.
    Hepatology. 2020;71:383-385.
    >> Share

  812. BALOG S, Li Y, Ogawa T, Miki T, et al
    Development of Capsular Fibrosis Beneath the Liver Surface in Humans and Mice.
    Hepatology. 2020;71:291-305.
    >> Share

  813. KWAN SY, Sheel A, Song CQ, Zhang XO, et al
    Depletion of TRRAP Induces p53-Independent Senescence in Liver Cancer by Down-Regulating Mitotic Genes.
    Hepatology. 2020;71:275-290.
    >> Share

  814. LAITINEN TT, Vahtera J, Pahkala K, Magnussen CG, et al
    Childhood Socioeconomic Disadvantage and Risk of Fatty Liver in Adulthood: The Cardiovascular Risk in Young Finns Study.
    Hepatology. 2020;71:67-75.
    >> Share

  815. GELLERT-KRISTENSEN H, Nordestgaard BG, Tybjaerg-Hansen A, Stender S, et al
    High Risk of Fatty Liver Disease Amplifies the Alanine Transaminase-Lowering Effect of a HSD17B13 Variant.
    Hepatology. 2020;71:56-66.
    >> Share

    December 2019
  816. GAO E, Cheema H, Waheed N, Mushtaq I, et al
    OSTalpha deficiency: A disorder with cholestasis, liver fibrosis and congenital diarrhea.
    Hepatology. 2019 Dec 21. doi: 10.1002/hep.31087.
    >> Share

    November 2019
  817. GYORI GP, Pereyra D, Rumpf B, Hackl H, et al
    Von Willebrand factor facilitates MELD-independent risk stratification on the waiting list for liver transplantation.
    Hepatology. 2019 Nov 27. doi: 10.1002/hep.31047.
    >> Share

  818. LEE BP, Vittinghoff E, Pletcher MJ, Dodge JL, et al
    Medicaid Policy and Liver Transplant for Alcohol-Related Liver Disease.
    Hepatology. 2019 Nov 8. doi: 10.1002/hep.31027.
    >> Share

  819. KUTKUT I, Rachwan RJ, Timsina LR, Ghabril MS, et al
    Pre-Liver Transplant Cardiac Catheterization is Associated with Low Rate of Myocardial Infarction and Cardiac Mortality.
    Hepatology. 2019 Nov 7. doi: 10.1002/hep.31023.
    >> Share

  820. EATON JE, Vuppalanchi R, Reddy R, Sathapathy S, et al
    Liver Injury in Patients with Cholestatic Liver Disease Treated with Obeticholic Acid.
    Hepatology. 2019 Nov 4. doi: 10.1002/hep.31017.
    >> Share

    October 2019
  821. POLI E, Kounis I, Guettier C, Verstuyft C, et al
    Post-Liver Transplantation Sinusoidal Obstruction Syndrome With Refractory Ascites Induced by Mycophenolate Mofetil.
    Hepatology. 2019 Oct 9. doi: 10.1002/hep.30984.
    >> Share

  822. SHAHEEN R, Alsahli S, Ewida N, Alzahrani F, et al
    Biallelic mutations in TTC26 (IFT56) cause severe biliary ciliopathy in humans.
    Hepatology. 2019 Oct 8. doi: 10.1002/hep.30982.
    >> Share

    September 2019
  823. KIM YC, Jung H, Seok S, Zhang Y, et al
    MicroRNA-210 promotes bile acid-induced cholestatic liver injury by targeting mixed-lineage leukemia-4 methyltransferase in mice.
    Hepatology. 2019 Sep 24. doi: 10.1002/hep.30966.
    >> Share

  824. DUSZYNSKI CC, Avati V, Lapointe AP, Scholkmann F, et al
    Near infrared spectroscopy reveals brain hypoxia and cerebrovascular dysregulation in primary biliary cholangitis.
    Hepatology. 2019 Sep 19. doi: 10.1002/hep.30920.
    >> Share

  825. ASRANI SK, Jennings LW, Kim WR, Kamath P, et al
    MELD-GRAIL-Na: Glomerular filtration rate and mortality on Liver-Transplant Waiting List.
    Hepatology. 2019 Sep 16. doi: 10.1002/hep.30932.
    >> Share

  826. BI X, Deising A, Frenette C
    Acute Liver Failure from Exertional Heatstroke Can Result in Excellent Long-term Survival with Liver Transplantation.
    Hepatology. 2019 Sep 11. doi: 10.1002/hep.30938.
    >> Share

  827. TARDELLI M, Bruschi FV, Fuchs CD, Claudel T, et al
    Monoacylglycerol lipase inhibition protects from liver injury in mouse models of sclerosing cholangitis.
    Hepatology. 2019 Sep 10. doi: 10.1002/hep.30929.
    >> Share

    August 2019
  828. KWON HM, Moon YJ, Jung KW, Park YS, et al
    Appraisal of cardiac ejection fraction with liver disease severity: Implication in post-liver transplantation mortality.
    Hepatology. 2019 Aug 28. doi: 10.1002/hep.30913.
    >> Share

  829. BEUERS U, Hohenester S
    Fatigue in Primary Biliary Cholangitis: no Place for Rituximab.
    Hepatology. 2019 Aug 23. doi: 10.1002/hep.30906.
    >> Share

  830. MOHANTY SK, Lobeck I, Donnelly B, Dupree P, et al
    Rotavirus reassortant induced murine model of liver fibrosis parallels human biliary atresia.
    Hepatology. 2019 Aug 23. doi: 10.1002/hep.30907.
    >> Share

    July 2019
  831. KYRITSI K, Chen L, O'Brien A, Francis H, et al
    Modulation of the TPH1/MAO-A/5HT/5HTR2A/2B/2C Axis Regulates Biliary Proliferation and Liver Fibrosis During Cholestasis.
    Hepatology. 2019 Jul 25. doi: 10.1002/hep.30880.
    >> Share

  832. CHOUDHARY NS, Saigal S, Soin AS
    Liver transplantation for Acute Liver Failure due to Dengue fever: first successful reported case worldwide.
    Hepatology. 2019 Jul 22. doi: 10.1002/hep.30869.
    >> Share

  833. MARRERO JA
    Obesity and Liver Disease: The New Era of Liver Transplantation.
    Hepatology. 2019 Jul 13. doi: 10.1002/hep.30854.
    >> Share

    June 2019
  834. FIRL DJ, Sasaki K, Agopian VG, Gorgen A, et al
    Charting the Path Forward for Risk Prediction in Liver Transplant for HCC: International Validation of HALTHCC amongst 4,089 patients.
    Hepatology. 2019 Jun 27. doi: 10.1002/hep.30838.
    >> Share

  835. CAREY EJ, Lai JC, Sonnenday C, Tapper EB, et al
    A North American Expert Opinion Statement on Sarcopenia in Liver Transplantation.
    Hepatology. 2019 Jun 20. doi: 10.1002/hep.30828.
    >> Share

  836. GALANTE A, Adeyi O, Lau L, Humar A, et al
    Liver transplantation for Acute Liver Failure due to Dengue fever: first successful reported case worldwide.
    Hepatology. 2019 Jun 4. doi: 10.1002/hep.30803.
    >> Share

    May 2019
  837. TERZIROLI BERETTA-PICCOLI B, Thompson R, Foskett P, Cerny A, et al
    A novel heterozygous ABCB4, RUNDC3B and ABCB1 deletion associated with severe cholestatic liver disease in adulthood.
    Hepatology. 2019 May 24. doi: 10.1002/hep.30783.
    >> Share

  838. SIEW SM, Cunningham SC, Zhu E, Tay SS, et al
    Prevention of cholestatic liver disease and reduced tumorigenicity in a murine model of PFIC type 3 using hybrid AAV-piggyBac gene therapy.
    Hepatology. 2019 May 17. doi: 10.1002/hep.30773.
    >> Share

  839. XIAO Y, Liu R, Li X, Gurley EC, et al
    Long non-coding RNA H19 contributes to cholangiocyte proliferation and cholestatic liver fibrosis in biliary atresia.
    Hepatology. 2019 May 7. doi: 10.1002/hep.30698.
    >> Share

    April 2019
  840. LEVITSKY J, Asrani SK, Abecassis M, Ruiz R, et al
    External Validation of a Pre-Transplant Biomarker Model (REVERSE) Predictive of Renal Recovery after Liver Transplantation.
    Hepatology. 2019 Apr 19. doi: 10.1002/hep.30667.
    >> Share

    March 2019
  841. WANG C, Zheng X, Jiang P, Tang R, et al
    Genome Wide Association Studies of Specific Antinuclear Autoantibody Sub-phenotypes in Primary Biliary Cholangitis.
    Hepatology. 2019 Mar 10. doi: 10.1002/hep.30604.
    >> Share

    February 2019
  842. SINHA J, Mehta N, Dodge JL, Poltavskiy E, et al
    Are There Upper Limits in Tumor Burden for Down-staging of HCC to Liver Transplant? Analysis of the All-comers Protocol.
    Hepatology. 2019 Feb 19. doi: 10.1002/hep.30570.
    >> Share

    January 2019
  843. HEERKENS M, Dedden S, Scheepers H, Van Paassen P, et al
    Effect of plasmapheresis on cholestatic pruritus and autotaxin activity during pregnancy.
    Hepatology. 2019 Jan 7. doi: 10.1002/hep.30496.
    >> Share

    December 2018
  844. FUNKE K, Rockey DC
    Cholestatic drug induced liver injury caused by mifepristone.
    Hepatology. 2018 Dec 18. doi: 10.1002/hep.30465.
    >> Share

  845. GONG S, Yan Z, Liu Z, Niu M, et al
    Intestinal microbiota mediates the susceptibility to polymicrobial sepsis-induced liver injury by granisetron generation in mice.
    Hepatology. 2018 Dec 1. doi: 10.1002/hep.30361.
    >> Share

    November 2018
  846. SANTAMARIA E, Rodriguez-Ortigosa CM, Uriarte I, Latasa MU, et al
    The epidermal growth factor receptor ligand amphiregulin protects from cholestatic liver injury and regulates bile acids synthesis.
    Hepatology. 2018 Nov 8. doi: 10.1002/hep.30348.
    >> Share

    September 2018
  847. SONG ATW, Abdala E, de Martino RB, Malbouisson LMS, et al
    Liver transplantation for fulminant hepatitis due to yellow fever.
    Hepatology. 2018 Sep 15. doi: 10.1002/hep.30273.
    >> Share

    August 2018
  848. GORGIS NM, Kennedy C, Lam F, Thompson K, et al
    Clinical Consequences of Cardiomyopathy in Children with Biliary Atresia Requiring Liver Transplantation.
    Hepatology. 2018 Aug 3. doi: 10.1002/hep.30204.
    >> Share

  849. LINDOR KD, Bowlus CL, Boyer J, Levy C, et al
    Primary Biliary Cholangitis: 2018 Practice Guidance from the American Association for the Study of Liver Diseases.
    Hepatology. 2018 Aug 2. doi: 10.1002/hep.30145.
    >> Share

    July 2018
  850. LOOMES KM, Spino C, Goodrich NP, Hangartner TN, et al
    Bone Density in Children with Chronic Liver Disease Correlates with Growth and Cholestasis.
    Hepatology. 2018 Jul 31. doi: 10.1002/hep.30196.
    >> Share

  851. SAYINER M, Golabi P, Stepanova M, Younossi I, et al
    Primary Biliary Cholangitis in Medicare Population: The Impact on Mortality and Resource Utilization.
    Hepatology. 2018 Jul 17. doi: 10.1002/hep.30174.
    >> Share

    May 2018
  852. KHANNA A, Jopson L, Howel D, Bryant A, et al
    Rituximab is Ineffective for Treatment of Fatigue in Primary Biliary Cholangitis: A phase-2 Randomised Controlled Trial.
    Hepatology. 2018 May 23. doi: 10.1002/hep.30099.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016